<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>053 Pharmacology Ini-Cet 2021 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQ / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">35</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x21a98a=_0x3bbb;(function(_0x30a2fa,_0x519060){const _0x489523=_0x3bbb,_0x3e3e09=_0x30a2fa();while(!![]){try{const _0xb99049=parseInt(_0x489523(0x382))/0x1*(parseInt(_0x489523(0x152))/0x2)+parseInt(_0x489523(0x174))/0x3*(-parseInt(_0x489523(0x337))/0x4)+-parseInt(_0x489523(0x12f))/0x5+-parseInt(_0x489523(0x28b))/0x6*(-parseInt(_0x489523(0x33b))/0x7)+parseInt(_0x489523(0x268))/0x8+parseInt(_0x489523(0x22c))/0x9*(-parseInt(_0x489523(0x288))/0xa)+-parseInt(_0x489523(0x2a0))/0xb*(-parseInt(_0x489523(0x1b4))/0xc);if(_0xb99049===_0x519060)break;else _0x3e3e09['push'](_0x3e3e09['shift']());}catch(_0x5d0ee7){_0x3e3e09['push'](_0x3e3e09['shift']());}}}(_0x13ef,0x97c71));const _0x3e26df=(function(){const _0x353111=_0x3bbb,_0x54f0ce={'qTkQZ':'open','Oedyf':function(_0x29e889,_0x3a7a5c){return _0x29e889===_0x3a7a5c;},'yAzUL':_0x353111(0x3bf),'Xuafy':function(_0x5df198,_0x10bae3){return _0x5df198===_0x10bae3;},'ffeOe':_0x353111(0x18f)};let _0xc6ddde=!![];return function(_0x9baf54,_0xa85517){const _0x3c0e31=_0x353111,_0xed0600={'FoLGH':function(_0x272e51,_0x5169a2){const _0x454a22=_0x3bbb;return _0x54f0ce[_0x454a22(0x1cd)](_0x272e51,_0x5169a2);},'ELocU':_0x3c0e31(0x320),'mgWuN':_0x54f0ce[_0x3c0e31(0x11e)]};if(_0x54f0ce[_0x3c0e31(0x17b)](_0x3c0e31(0x370),_0x54f0ce[_0x3c0e31(0x24d)]))_0x48e475[_0x3c0e31(0x137)](_0x3c0e31(0x1d3))[_0x3c0e31(0x364)][_0x3c0e31(0x196)](_0x54f0ce[_0x3c0e31(0x23f)]);else{const _0x27b2ec=_0xc6ddde?function(){const _0x36b6ad=_0x3c0e31,_0xbc0cf3={'TwrYH':function(_0x492b29,_0x2ac487){const _0x2573cc=_0x3bbb;return _0xed0600[_0x2573cc(0x1e1)](_0x492b29,_0x2ac487);},'CBdJf':_0xed0600[_0x36b6ad(0x3db)],'DVrTU':_0xed0600['mgWuN']};if(_0xed0600['FoLGH'](_0x36b6ad(0x1a9),_0x36b6ad(0x1a9))){if(_0xa85517){const _0xd08370=_0xa85517[_0x36b6ad(0x2d2)](_0x9baf54,arguments);return _0xa85517=null,_0xd08370;}}else _0xbc0cf3[_0x36b6ad(0x210)](_0x3aa383['choices'][_0x59f8a6['selectedAnswer']]['id'],_0x56656d['correct_choice_id'])?(_0x51a3f6++,_0x41b110[_0x36b6ad(0x116)]=_0xbc0cf3[_0x36b6ad(0x2c0)]):(_0x38470e++,_0x422904[_0x36b6ad(0x116)]=_0xbc0cf3[_0x36b6ad(0x36d)]);}:function(){};return _0xc6ddde=![],_0x27b2ec;}};}()),_0x5766e2=_0x3e26df(this,function(){const _0x2616de=_0x3bbb,_0x65fc8c={'fSEUx':'(((.+)+)+)+$'};return _0x5766e2[_0x2616de(0x13b)]()[_0x2616de(0x2cb)]('(((.+)+)+)+$')[_0x2616de(0x13b)]()[_0x2616de(0x2f3)](_0x5766e2)[_0x2616de(0x2cb)](_0x65fc8c[_0x2616de(0x198)]);});_0x5766e2();const _0x31a9e0=(function(){const _0x3c72d0=_0x3bbb,_0x57940f={'aUbQA':function(_0x3cc84e,_0x5842c6){return _0x3cc84e-_0x5842c6;},'trAkk':_0x3c72d0(0x182),'ofLnM':function(_0x1eee40,_0x15cda0){return _0x1eee40===_0x15cda0;},'BMYPF':'imKyB','iiYty':_0x3c72d0(0x3bb)};let _0x420f08=!![];return function(_0x26d38c,_0x1b9ff8){const _0x36a82a=_0x3c72d0,_0x1bac94={'HRome':function(_0x231d0a,_0x31d243){const _0x35c1ca=_0x3bbb;return _0x57940f[_0x35c1ca(0x25b)](_0x231d0a,_0x31d243);},'FQBOQ':_0x57940f['trAkk'],'AMJbo':function(_0x74fb88,_0x13f48d){const _0x2fb17d=_0x3bbb;return _0x57940f[_0x2fb17d(0x1c6)](_0x74fb88,_0x13f48d);},'JLOnY':_0x57940f[_0x36a82a(0x2a3)],'jdHEW':function(_0x4ed1a6,_0x239d2a){const _0x1d17a2=_0x36a82a;return _0x57940f[_0x1d17a2(0x1c6)](_0x4ed1a6,_0x239d2a);},'styZn':_0x57940f[_0x36a82a(0x118)]},_0x22c336=_0x420f08?function(){const _0x447c7e=_0x36a82a,_0x208494={'ycjYx':_0x1bac94[_0x447c7e(0x304)],'bQglA':function(_0x293f74){return _0x293f74();}};if(_0x1bac94[_0x447c7e(0x2f5)](_0x1bac94[_0x447c7e(0x178)],_0x447c7e(0x342))){if(_0x1b9ff8){if(_0x1bac94[_0x447c7e(0x366)](_0x1bac94[_0x447c7e(0x150)],_0x1bac94[_0x447c7e(0x150)])){const _0x38fa1b=_0x1b9ff8[_0x447c7e(0x2d2)](_0x26d38c,arguments);return _0x1b9ff8=null,_0x38fa1b;}else _0x58cc47[_0xdae247][_0x447c7e(0x24e)]+=_0x1bac94[_0x447c7e(0x2bd)](_0x3a5433[_0x447c7e(0x2c5)](),_0x276d15),_0x495c0f=_0x28711f[_0x447c7e(0x2c5)]();}}else _0x41cdb9[_0x447c7e(0x307)][_0x447c7e(0x27c)]['endsWith'](_0x208494['ycjYx'])&&_0x491558[_0x447c7e(0x3e1)](_0x447c7e(0x29b)),_0x208494[_0x447c7e(0x199)](_0x3e3652),_0x4e3cf0['reload']();}:function(){};return _0x420f08=![],_0x22c336;};}()),_0x4d4cf1=_0x31a9e0(this,function(){const _0xa09bad=_0x3bbb,_0x385881={'scmxL':function(_0x3beea6,_0x4df9e5){return _0x3beea6+_0x4df9e5;},'ExePq':_0xa09bad(0x23b),'qYdPS':_0xa09bad(0x22a),'UPmHA':_0xa09bad(0x3a3),'LZVyh':_0xa09bad(0x148),'NaDlV':_0xa09bad(0x192)};let _0x53bd8a;try{const _0x54ed69=Function(_0x385881['scmxL'](_0x385881[_0xa09bad(0x3a6)](_0x385881[_0xa09bad(0x181)],_0xa09bad(0x396)),');'));_0x53bd8a=_0x54ed69();}catch(_0x4b3cda){_0x53bd8a=window;}const _0x4e126a=_0x53bd8a['console']=_0x53bd8a[_0xa09bad(0x1f1)]||{},_0x2e4e6d=[_0xa09bad(0x1f0),_0x385881[_0xa09bad(0x32a)],_0xa09bad(0x21f),_0x385881[_0xa09bad(0x1dd)],_0x385881[_0xa09bad(0x1ae)],_0x385881[_0xa09bad(0x2d6)],'trace'];for(let _0x13f04b=0x0;_0x13f04b<_0x2e4e6d[_0xa09bad(0x376)];_0x13f04b++){const _0x2f3a54=_0x31a9e0[_0xa09bad(0x2f3)][_0xa09bad(0x3c0)][_0xa09bad(0x3d1)](_0x31a9e0),_0x311fb3=_0x2e4e6d[_0x13f04b],_0x2865e1=_0x4e126a[_0x311fb3]||_0x2f3a54;_0x2f3a54[_0xa09bad(0x213)]=_0x31a9e0[_0xa09bad(0x3d1)](_0x31a9e0),_0x2f3a54[_0xa09bad(0x13b)]=_0x2865e1[_0xa09bad(0x13b)][_0xa09bad(0x3d1)](_0x2865e1),_0x4e126a[_0x311fb3]=_0x2f3a54;}});_0x4d4cf1();let questionsData=[{'text':_0x21a98a(0x2d9),'choices':[{'id':0x1,'text':_0x21a98a(0x2b4)},{'id':0x2,'text':_0x21a98a(0x36b)},{'id':0x3,'text':_0x21a98a(0x1e7)},{'id':0x4,'text':_0x21a98a(0x399)}],'correct_choice_id':0x3,'solution':'<p><strong>Fixed\x20drug\x20combinations\x20</strong>are<strong>\x20not\x20preferred</strong>\x20over\x20single\x20drugs\x20while\x20selecting\x20essential\x20drugs.</p>\x0a<p>Criteria\x20for\x20selection\x20of\x20essential\x20medicines\x20as\x20per\x20WHO:</p>\x0a<ul>\x0a<li>There\x20should\x20be\x20<strong>adequate\x20data</strong>\x20on\x20the\x20<strong>safety\x20and\x20efficacy</strong>\x20of\x20the\x20drug.</li>\x0a<li>The\x20drug\x20should\x20be\x20available\x20in\x20a\x20form\x20where\x20its\x20quality\x20including\x20bioavailability\x20and\x20stability\x20on\x20storage\x20is\x20assured.</li>\x0a<li>The\x20choice\x20of\x20the\x20drug\x20depends\x20on\x20the\x20<strong>pattern\x20of\x20prevalent\x20disease</strong>s,\x20financial\x20resources,\x20availability\x20of\x20trained\x20personnel\x20and\x20facilities,\x20genetic,\x20demographic,\x20and\x20environmental\x20factors.</li>\x0a<li>The\x20<strong>cost-benefit\x20ratio</strong>\x20is\x20an\x20important\x20factor.</li>\x0a<li>Pharmacokinetic\x20properties\x20of\x20the\x20drug\x20and\x20the\x20local\x20manufacture\x20and\x20storage\x20facilities\x20are\x20also\x20considered.</li>\x0a<li>Essential\x20drugs\x20<strong>should\x20preferably\x20be\x20single\x20compounds.</strong></li>\x0a<li>Fixed\x20combinations\x20are\x20used\x20only\x20when\x20the\x20dosage\x20of\x20each\x20component\x20meets\x20the\x20requirement\x20of\x20the\x20population\x20in\x20which\x20it\x20is\x20used.\x20It\x20should\x20also\x20have\x20the\x20advantage\x20in\x20safety,\x20therapeutic\x20effect,\x20adherence,\x20and\x20prevention\x20of\x20drug\x20resistance\x20when\x20compared\x20to\x20single\x20compounds.</li>\x0a<li>The\x20selection\x20of\x20essential\x20drugs\x20is\x20a\x20continuous\x20process\x20and\x20changes\x20are\x20to\x20be\x20made\x20with\x20developments\x20in\x20public\x20health\x20and\x20the\x20availability\x20of\x20better\x20drugs.</li>\x0a<li>The\x20selection\x20should\x20be\x20based\x20on\x20rationally\x20developed\x20treatment\x20guidelines.</li>\x0a</ul>\x0a<p>Note:</p>\x0a<p>In\x201977\x20WHO\x20brought\x20the\x20first\x20\x22Model\x20List\x20of\x20Essential\x20Drugs\x22.\x20India\x20made\x20its\x20\x22National\x20Essential\x20Drug\x20List\x22\x20in\x201996\x20and\x20revised\x20the\x20list\x20in\x202011\x20and\x20renamed\x20it\x20as\x20\x22<strong>National\x20List\x20of\x20Essential\x20Medicines</strong>\x22.\x20The\x20latest\x20edition\x20of\x20WHO\x20Model\x20List\x20of\x20Essential\x20Drugs\x20is\x20the\x2021st\x20edition\x20published\x20in\x202019.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x27d),'choices':[{'id':0x1,'text':_0x21a98a(0x3a2)},{'id':0x2,'text':_0x21a98a(0x2e0)},{'id':0x3,'text':_0x21a98a(0x25e)},{'id':0x4,'text':_0x21a98a(0x2e8)}],'correct_choice_id':0x3,'solution':_0x21a98a(0x20b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x11f),'choices':[{'id':0x1,'text':'Increase\x20the\x20dose'},{'id':0x2,'text':'Decrease\x20the\x20dose'},{'id':0x3,'text':_0x21a98a(0x261)},{'id':0x4,'text':_0x21a98a(0x2cf)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x397),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x2fc),'choices':[{'id':0x1,'text':_0x21a98a(0x341)},{'id':0x2,'text':_0x21a98a(0x2f9)},{'id':0x3,'text':_0x21a98a(0x1ab)},{'id':0x4,'text':_0x21a98a(0x275)}],'correct_choice_id':0x1,'solution':'<p><strong>Downregulation\x20of\x20CYP2C19</strong>\x20is\x20responsible\x20for\x20the\x20failure\x20of\x20clopidogrel\x20in\x20this\x20patient.</p>\x0a<p>Clopidogrel\x20is\x20a\x20<strong>prodrug</strong>\x20and\x20its\x20metabolic\x20activation\x20occurs\x20in\x20the\x20liver.\x20It\x20is\x20<strong>bioactivated\x20by\x20the\x20CYP2C19</strong>\x20enzyme.\x20If\x20there\x20is\x20downregulation\x20of\x20this\x20enzyme\x20it\x20will\x20cause\x20a\x20decrease\x20in\x20the\x20efficacy\x20of\x20clopidogrel\x20and\x20can\x20lead\x20to\x20thrombotic\x20events\x20like\x20stroke.\x20Drugs\x20that\x20inhibit\x20CYP2C19\x20can\x20also\x20decrease\x20the\x20antiplatelet\x20effect\x20of\x20clopidogrel.\x20<strong>Proton-pump\x20inhibitors</strong>\x20may\x20cause\x20<strong>inhibition\x20of\x20CYP2C19</strong>\x20and\x20when\x20they\x20are\x20given\x20in\x20combination\x20there\x20would\x20be\x20a\x20decrease\x20in\x20the\x20efficacy\x20of\x20clopidogrel.&nbsp;</p>\x0a<p><strong>Therapeutic\x20uses</strong>:\x20Clopidogrel\x20is\x20used\x20to\x20reduce\x20the\x20rate\x20of\x20stroke\x20and\x20myocardial\x20infarction.\x20It\x20also\x20decreases\x20the\x20rate\x20of\x20deaths\x20in\x20patients\x20with\x20recent\x20myocardial\x20infarction\x20or\x20stroke.\x20Other\x20uses\x20are\x20acute\x20coronary\x20syndrome\x20and\x20peripheral\x20arterial\x20disease.</p>\x0a<p><strong>Adverse\x20effects</strong>:\x20Increased\x20<strong>risk\x20of\x20bleeding</strong>\x20especially\x20when\x20given\x20with\x20an\x20anticoagulant\x20or\x20aspirin.\x20Rarely\x20thrombotic\x20thrombocytopenic\x20purpura\x20can\x20occur.</p>\x0a<p><strong>CYP2C19</strong>:\x20Common\x20drugs\x20that\x20are\x20metabolized\x20include\x20omeprazole,\x20phenytoin,\x20diazepam,\x20and\x20propanolol.\x20Inducers\x20of\x20the\x20CYP2C\x20subfamily\x20are\x20rifampicin\x20and\x20carbamazepine.\x20Omeprazole\x20is\x20an\x20inhibitor.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>CYP2D6</strong>:\x20Drugs\x20metabolized\x20include\x20SSRIs,&nbsp;\x20tricyclic\x20antidepressants,\x20antiarrhythmic\x20drugs,\x20beta-blockers,\x20and\x20opiates.\x20It\x20is\x20<strong>inhibited\x20by\x20quinidine</strong>\x20and\x20it\x20will\x20prevent\x20the\x20formation\x20of\x20morphine\x20from\x20codeine.\x20Hence\x20quinidine\x20decreases\x20the\x20analgesic\x20effect\x20of\x20codeine.</p>\x0a<p><strong>CYP1A1/2</strong>:\x20It\x20metabolizes\x20few\x20drugs\x20like\x20theophylline,\x20paracetamol,\x20caffeine\x20and\x20carbamazepine.\x20It\x20plays\x20an\x20important\x20role\x20in\x20the\x20<strong>activation\x20of\x20procarcinogens.</strong>\x20Inducers\x20are\x20rifampicin,\x20carbamazepine,\x20polycyclic\x20hydrocarbons,\x20charbroiled\x20meat,\x20and\x20cigarette\x20smoke.</p>\x0a<p><strong>CYP2E1</strong>:\x20It\x20is\x20involved\x20in\x20the\x20oxidation\x20of\x20alcohol,\x20halothane,\x20and\x20minor\x20metabolism\x20of\x20other\x20drugs.\x20It\x20is\x20important\x20to\x20note\x20that\x20it\x20is\x20involved\x20in\x20the\x20formation\x20of\x20hepatotoxic<strong>&nbsp;N-acetyl\x20benzoquinone\x20imine</strong>\x20from\x20<strong>paracetamol.</strong>\x20Chronic\x20alcoholism\x20is\x20responsible\x20for\x20the\x20induction\x20of\x20this\x20enzyme.</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x327),'choices':[{'id':0x1,'text':_0x21a98a(0x2f8)},{'id':0x2,'text':_0x21a98a(0x2fb)},{'id':0x3,'text':_0x21a98a(0x350)},{'id':0x4,'text':_0x21a98a(0x18e)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x3d9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x128),'choices':[{'id':0x1,'text':'Atherosclerosis'},{'id':0x2,'text':_0x21a98a(0x3ec)},{'id':0x3,'text':'Polyradicular\x20neuropathy'},{'id':0x4,'text':_0x21a98a(0x2f7)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x187),'explanation_video':'','question_images':[_0x21a98a(0x293)],'explanation_images':[]},{'text':_0x21a98a(0x2e6),'choices':[{'id':0x1,'text':'Treatment\x20of\x20migrane'},{'id':0x2,'text':_0x21a98a(0x392)},{'id':0x3,'text':_0x21a98a(0x1aa)},{'id':0x4,'text':_0x21a98a(0x1e9)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x211),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x2c9),'choices':[{'id':0x1,'text':'Andexanet\x20alfa:\x20Edoxaban'},{'id':0x2,'text':_0x21a98a(0x353)},{'id':0x3,'text':'Idarucizumab\x20:\x20Dabigatran'},{'id':0x4,'text':_0x21a98a(0x36a)}],'correct_choice_id':0x4,'solution':_0x21a98a(0x185),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x1e2),'choices':[{'id':0x1,'text':_0x21a98a(0x130)},{'id':0x2,'text':_0x21a98a(0x19e)},{'id':0x3,'text':_0x21a98a(0x15a)},{'id':0x4,'text':_0x21a98a(0x2be)}],'correct_choice_id':0x2,'solution':'<p><strong>Inhaled\x20nitric\x20oxide</strong>\x20(NO)\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>pulmonary\x20hypertension.</strong></p>\x0a<p>The\x20only<strong>\x20FDA-approved\x20therapeutic\x20indication</strong>\x20of\x20inhaled\x20nitric\x20oxide\x20is\x20in\x20<strong>persistent\x20pulmonary\x20hypertension\x20</strong>of\x20the\x20<strong>newborn</strong>.\x20It\x20has\x20the\x20ability\x20to\x20selectively\x20dilate\x20pulmonary\x20vasculature.\x20Hence\x20it\x20can\x20be\x20used\x20in\x20conditions\x20with\x20increased\x20pulmonary\x20vascular\x20resistance.</p>\x0a<p>It\x20is\x20proposed\x20for\x20the:</p>\x0a<ul>\x0a<li>Long-term\x20management\x20of\x20pulmonary\x20artery\x20hypertension(PAH)\x20and\x20other\x20forms\x20of\x20pulmonary\x20hypertension</li>\x0a<li>Rescue\x20therapy\x20for\x20severely\x20hypoxemic\x20patients\x20with\x20or\x20without\x20pulmonary\x20hypertension</li>\x0a</ul>\x0a<p><strong>Diagnostic\x20indications</strong>:</p>\x0a<ul>\x0a<li>In\x20heart\x20failure\x20patients\x20and\x20infants\x20with\x20congenital\x20heart\x20disease\x20during\x20<strong>cardiac\x20catheterizatio</strong>n\x20to\x20evaluate\x20<strong>pulmonary\x20vasoreactivity.</strong></li>\x0a<li>In\x20determining\x20the<strong>&nbsp;diffusion\x20capacity</strong>\x20across\x20the\x20alveolar-capillary\x20unit.\x20It\x20is\x20considered\x20superior\x20to\x20carbon\x20dioxide\x20in\x20this\x20because\x20it\x20has\x20a\x20greater\x20affinity\x20for\x20hemoglobin\x20and\x20higher\x20water\x20solubility\x20at\x20body\x20temperature.</li>\x0a</ul>\x0a<p><strong>Mechanism\x20of\x20action</strong>:</p>\x0a<p>It\x20activates\x20soluble\x20guanylyl\x20cyclase\x20and\x20produces\x20cGMP,\x20which\x20then\x20activates\x20cGMP-dependent\x20protein\x20kinase.\x20This\x20leads\x20to\x20the\x20activation\x20of\x20multiple\x20regulatory\x20mechanisms\x20that\x20decrease\x20intracellular\x20calcium\x20and\x20cause\x20vasodilation\x20in\x20precapillary\x20resistance\x20arterioles.</p>\x0a<p><strong>Adverse\x20effects</strong>:</p>\x0a<ul>\x0a<li><strong>Methemoglobinemia</strong>\x20at\x20higher\x20concentrations.</li>\x0a<li>It\x20can\x20worsen\x20left\x20ventricular\x20performance\x20in\x20patients\x20with\x20an\x20already\x20impaired\x20left\x20ventricular\x20function.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Nivolumab\x20is\x20used\x20as\x20a\x20checkpoint\x20inhibitor\x20in','choices':[{'id':0x1,'text':_0x21a98a(0x356)},{'id':0x2,'text':_0x21a98a(0x23c)},{'id':0x3,'text':_0x21a98a(0x231)},{'id':0x4,'text':_0x21a98a(0x3c7)}],'correct_choice_id':0x4,'solution':'<p>Nivolumab\x20is\x20used\x20as\x20a\x20checkpoint\x20inhibitor\x20in\x20<strong>Hodgkin\x27s\x20lymphoma</strong>.</p>\x0a<p>FDA\x20approved\x20uses\x20of\x20nivolumab:</p>\x0a<ul>\x0a<li>Advanced\x20<strong>melanoma</strong></li>\x0a<li>Advanced\x20non-small\x20cell\x20lung\x20cancer(<strong>NSCLC</strong>)\x20that\x20are\x20previously\x20treated</li>\x0a<li>Renal\x20cell\x20carcinoma</li>\x0a<li>Advanced\x20head\x20and\x20neck\x20cancers</li>\x0a<li>Refractory/relapsed\x20classical\x20<strong>Hodgkin\x27s\x20lymphoma</strong></li>\x0a</ul>\x0a<p>Nivolumab\x20is\x20a\x20<strong>checkpoint\x20inhibitor</strong>\x20that\x20blocks\x20the\x20interaction\x20between\x20<strong>PD-1\x20and\x20its\x20ligand</strong>s.\x20It\x20is\x20a\x20fully\x20human\x20monoclonal\x20IgG4\x20antibody.\x20It\x20has\x20a\x20good\x20response\x20rate\x20in\x20patients\x20with\x20pretreated\x20solid\x20tumors\x20and\x20hematological\x20malignancies.\x20Similar\x20effectiveness\x20is\x20also\x20seen\x20with<strong>\x20pembrolizumab</strong>\x20which\x20is\x20also\x20an\x20anti-PD-1\x20monoclonal\x20antibody.</p>\x0a<p>Adverse\x20effects:</p>\x0a<ul>\x0a<li>In\x20melanoma\x20patients\x20<strong>rash</strong>\x20is\x20a\x20commonly\x20seen\x20side\x20effect&nbsp;</li>\x0a<li>fatigue,\x20dyspnea,\x20musculoskeletal\x20pain,\x20cough,&nbsp;\x20decreased\x20appetite,\x20and\x20constipation\x20can\x20be\x20seen\x20in\x20advanced\x20squamous\x20NSCLC\x20patients</li>\x0a<li>Pneumonitis,\x20colitis,\x20nephritis,\x20hepatitis,\x20and\x20renal\x20dysfunction\x20are\x20also\x20seen</li>\x0a</ul>\x0a<p>Important\x20note:</p>\x0a<p>The\x20FDA\x20on\x20<strong>May\x202021</strong>\x20has\x20approved\x20the\x20use\x20of\x20<strong>nivolumab</strong>\x20in\x20patients\x20having\x20c<strong>ompletely\x20resected\x20esophageal\x20or\x20gastroesophageal\x20junction\x20cancers</strong>\x20with\x20residual\x20pathologic\x20disease\x20who\x20have\x20received\x20neoadjuvant\x20chemoradiotherapy.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x170),'choices':[{'id':0x1,'text':_0x21a98a(0x12e)},{'id':0x2,'text':_0x21a98a(0x2f4)},{'id':0x3,'text':'Benzalkonium\x20chloride'},{'id':0x4,'text':_0x21a98a(0x21b)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x32d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Antimicrobial\x20combinations\x20are\x20used\x20in\x20all\x20except','choices':[{'id':0x1,'text':_0x21a98a(0x2a7)},{'id':0x2,'text':_0x21a98a(0x39f)},{'id':0x3,'text':'Intra\x20abdominal\x20infections'},{'id':0x4,'text':_0x21a98a(0x31a)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x163),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x33c),'choices':[{'id':0x1,'text':'1'},{'id':0x2,'text':'2'},{'id':0x3,'text':'3'},{'id':0x4,'text':'4'}],'correct_choice_id':0x4,'solution':_0x21a98a(0x285),'explanation_video':'','question_images':[_0x21a98a(0x2ed)],'explanation_images':[]},{'text':_0x21a98a(0x232),'choices':[{'id':0x1,'text':_0x21a98a(0x394)},{'id':0x2,'text':_0x21a98a(0x3d6)},{'id':0x3,'text':_0x21a98a(0x172)},{'id':0x4,'text':_0x21a98a(0x2e9)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x31e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x283),'choices':[{'id':0x1,'text':_0x21a98a(0x11d)},{'id':0x2,'text':_0x21a98a(0x2f0)},{'id':0x3,'text':_0x21a98a(0x1bc)},{'id':0x4,'text':_0x21a98a(0x247)}],'correct_choice_id':0x4,'solution':'<p>Risperidone\x20is\x20<strong>FDA</strong>\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>bipolar\x20affective\x20disorders</strong>.</p>\x0a<p>Uses\x20of\x20risperidone:</p>\x0a<ul>\x0a<li>Long-term\x20management\x20of\x20<strong>psychosis</strong>\x20and\x20<strong>schizophrenia.</strong></li>\x0a<li>Maintenance\x20therapy\x20in\x20mania\x20<strong>bipolar\x20disorders.</strong></li>\x0a<li>Management\x20of\x20irritability\x20associated\x20with\x20<strong>autism</strong>.</li>\x0a</ul>\x0a<p>Off-label\x20uses\x20of\x20risperidone:</p>\x0a<ul>\x0a<li>Management\x20of&nbsp;<strong>psychotic\x20symptoms</strong>&nbsp;in&nbsp;<strong>delirium</strong>\x20and\x20<strong>dementia</strong>.</li>\x0a<li><strong>Obsessive-compulsive\x20disorders.</strong></li>\x0a<li><strong>Post-traumatic\x20stress\x20disorders.</strong></li>\x0a</ul>\x0a<p>Risperidone\x20is\x20an\x20<strong>atypical\x20antipsychotic</strong>\x20that\x20shows\x20both\x20D2\x20and\x205\x20HT2\x20receptor\x20blockade.\x20It\x20also\x20has\x20an\x20affinity\x20for\x20alpha\x201,\x20alpha\x202,\x20and\x20H1\x20receptors.\x20It\x20produces\x20a\x20more\x20potent\x20D2\x20blockade\x20than\x20clozapine.\x20<strong>Hyperprolactinemia</strong>\x20is\x20an\x20important\x20adverse\x20effect.\x20It\x20is\x20also\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20stroke\x20in\x20elderly\x20patients.\x20At\x20low\x20doses,\x20extrapyramidal\x20side\x20effects\x20are\x20less.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x294),'choices':[{'id':0x1,'text':_0x21a98a(0x38b)},{'id':0x2,'text':_0x21a98a(0x3a8)},{'id':0x3,'text':_0x21a98a(0x314)},{'id':0x4,'text':_0x21a98a(0x164)}],'correct_choice_id':0x3,'solution':_0x21a98a(0x32b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x273),'choices':[{'id':0x1,'text':_0x21a98a(0x132)},{'id':0x2,'text':_0x21a98a(0x1b2)},{'id':0x3,'text':_0x21a98a(0x1f7)},{'id':0x4,'text':'120\x20minutes'}],'correct_choice_id':0x4,'solution':'<p>The\x20<strong>minimum\x20duration</strong>&nbsp;of\x20time\x20between\x20the\x20consumption\x20of<strong>\x20phenytoin</strong>\x20and\x20<strong>sucralfate</strong>\x20should\x20be\x20<strong>120\x20minutes</strong>.</p>\x0a<p>Sucralfate,\x20in\x20an\x20<strong>acidic\x20environment</strong>\x20(<strong>pH\x20&lt;\x204</strong>)\x20acts\x20by\x20producing\x20a\x20<strong>viscous</strong>,<strong>\x20sticky\x20polymer</strong>\x20that\x20adheres\x20to\x20ulcer\x20craters\x20and\x20epithelial\x20cells\x20for\x20up\x20to<strong>&nbsp;6\x20hours</strong>\x20after\x20a\x20single\x20dose.\x20This\x20<strong>viscous\x20layer\x20produced</strong>\x20in\x20the\x20stomach\x20leads\x20to\x20<strong>inhibition\x20</strong>of<strong>\x20absorption</strong>\x20of\x20other\x20drugs,\x20like\x20<strong>phenytoin</strong>,\x20digoxin,\x20cimetidine,\x20ketoconazole,\x20and\x20fluoroquinolone\x20antibiotics.\x20Therefore,\x20sucralfate\x20should\x20be\x20taken\x20after\x20a\x20gap\x20of\x20at\x20least\x202\x20hours\x20/<strong>\x20120\x20minutes</strong>&nbsp;after\x20the\x20administration\x20of\x20phenytoin.&nbsp;</p>\x0a<p><strong>Constipation</strong>\x20is\x20the\x20most\x20common\x20side\x20effect\x20of\x20sucralfate.\x20It\x20should\x20be\x20<strong>avoided</strong>\x20in\x20patients\x20with\x20<strong>renal\x20failure</strong>\x20who\x20are\x20at\x20risk\x20of\x20<strong>aluminium\x20overload.</strong>&nbsp;Aluminum-containing\x20antacids\x20should\x20not\x20be\x20combined\x20with\x20sucralfate\x20in\x20these\x20patients.\x20&nbsp;As\x20the\x20viscous\x20gel\x20produced\x20by\x20sucralfate\x20is\x20sticky,\x20it\x20may\x20eventually\x20lead\x20to\x20<strong>bezoar</strong>\x20formation.</p>\x0a<p>It\x20is\x20generally\x20used\x20for\x20<strong>prophylaxis</strong>\x20of\x20peptic\x20ulcers,\x20but\x20<strong>rarely</strong>\x20so\x20because\x20of\x20its\x20side\x20effects\x20and\x20its\x20risks\x20outweigh\x20its\x20benefits.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x2ec),'choices':[{'id':0x1,'text':_0x21a98a(0x310)},{'id':0x2,'text':'Dose\x20adjustment\x20in\x20renal\x20failure'},{'id':0x3,'text':_0x21a98a(0x30a)},{'id':0x4,'text':'As\x20per\x20safety\x20or\x20therapeutic\x20index'}],'correct_choice_id':0x1,'solution':_0x21a98a(0x29c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x3dc),'choices':[{'id':0x1,'text':_0x21a98a(0x1e0)},{'id':0x2,'text':_0x21a98a(0x216)},{'id':0x3,'text':_0x21a98a(0x226)},{'id':0x4,'text':_0x21a98a(0x3c5)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x3f0),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20dose\x20at\x20which\x20dopamine\x20acts\x20on\x20beta\x201\x20receptors\x20is\x20____.','choices':[{'id':0x1,'text':_0x21a98a(0x154)},{'id':0x2,'text':_0x21a98a(0x159)},{'id':0x3,'text':'10-20\x20mcg/kg/min'},{'id':0x4,'text':_0x21a98a(0x2f2)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x3da),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20the\x20incorrect\x20statement\x20regarding\x20clomiphene\x20citrate?','choices':[{'id':0x1,'text':'Causes\x20monofollicular\x20development'},{'id':0x2,'text':_0x21a98a(0x349)},{'id':0x3,'text':_0x21a98a(0x1b9)},{'id':0x4,'text':_0x21a98a(0x223)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x17d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x112),'choices':[{'id':0x1,'text':_0x21a98a(0x2c7)},{'id':0x2,'text':_0x21a98a(0x3ab)},{'id':0x3,'text':_0x21a98a(0x3ea)},{'id':0x4,'text':_0x21a98a(0x144)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x395),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x14b),'choices':[{'id':0x1,'text':_0x21a98a(0x2e1)},{'id':0x2,'text':_0x21a98a(0x20e)},{'id':0x3,'text':_0x21a98a(0x2bb)},{'id':0x4,'text':_0x21a98a(0x17f)}],'correct_choice_id':0x1,'solution':'<p>Administration\x20of\x20<strong>ritonavir</strong>\x20would\x20increase\x20the\x20bioavailability\x20of\x20<strong>saquinavir</strong>.</p>\x0a<p>Saquinavir\x20is\x20an\x20<strong>HIV\x20protease\x20inhibitor</strong>\x20that\x20inhibits\x20replication\x20of\x20both\x20HIV-1\x20and\x20HIV-2.\x20It\x20is\x20metabolized\x20predominantly\x20by\x20the\x20hepatic\x20enzyme\x20<strong>CYP3A4</strong>.\x20Inhibition\x20of\x20CYP3A4\x20results\x20in\x20an\x20increase\x20or\x20a\x20boost\x20in\x20the\x20concentration\x20of\x20saquinavir.&nbsp;\x20Ritonavir\x20is\x20one\x20such\x20drug\x20that\x20inhibits\x20CYP3A4.\x20Therefore\x20combining\x20it\x20with\x20a\x20protease\x20inhibitor\x20like\x20saquinavir\x20results\x20in:</p>\x0a<ul>\x0a<li>Enhanced\x20bioavailability</li>\x0a<li>Inhibition\x20of\x20systemic\x20clearance</li>\x0a<li>Inhibition\x20of\x20first-pass\x20metabolism,\x20and</li>\x0a<li>Longer\x20half-life\x20of\x20the\x20co-administered\x20HIV\x20protease\x20inhibitor.</li>\x0a</ul>\x0a<p>This\x20allows\x20for\x20a\x20<strong>reduction</strong>\x20of\x20drug\x20dose\x20and\x20dosing\x20frequency\x20of\x20saquinavir.</p>\x0a<p>All\x20protease\x20inhibitors\x20except\x20for\x20nelfinavir\x20are\x20predominantly\x20metabolized\x20by\x20CYP3A4.\x20Therefore,\x20the\x20administration\x20of\x20CYP3A4\x20inhibitors\x20like\x20ritonavir\x20or\x20<strong>cobicistat</strong>\x20can\x20increase\x20the\x20bioavailability\x20of\x20these\x20protease\x20inhibitors.\x20This\x20phenomenon\x20is\x20known\x20as\x20<strong>boosting</strong>&nbsp;protease\x20inhibitors\x20by\x20CYP\x20inhibitors.\x20The\x20dosage\x20of\x20ritonavir,\x20when\x20given\x20as\x20a\x20booster\x20drug,\x20is\x20100\x20to\x20200mg\x20once\x20or\x20twice\x20daily.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20B:<strong>&nbsp;Vitamin\x20C</strong>\x20/\x20<strong>Ascorbic\x20acid</strong>\x20is\x20a\x20water-soluble\x20vitamin\x20that\x20can\x20actually\x20reduce\x20the\x20steady-state\x20concentration\x20of\x20protease\x20inhibitors.\x20It\x20<strong>increases</strong>\x20the\x20absorption\x20of\x20dietary\x20<strong>iron</strong>.</p>\x0a<p>Option\x20C:&nbsp;<strong>Cimetidine</strong>\x20is\x20a\x20histamine\x202\x20receptor\x20antagonist\x20which\x20is\x20used\x20to\x20promote\x20gastric\x20and\x20duodenal\x20ulcer\x20healing.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20gastroesophageal\x20reflux\x20disease.\x20It\x20also\x20inhibits\x20CYPs,\x20but\x20only\x20ritonavir\x20and\x20<strong>cobicistat</strong>\x20are\x20used\x20for\x20boosting\x20protease\x20inhibitors.</p>\x0a<p>Option\x20D:<strong>&nbsp;Ganciclovir</strong>\x20is\x20a\x20guanine\x20nucleoside\x20analogue\x20which\x20has\x20inhibitory\x20activity\x20against\x20all\x20herpes\x20viruses,\x20especially\x20cytomegalovirus\x20(CMV).</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x149),'choices':[{'id':0x1,'text':'Drug\x20A\x20decreases\x20intestinal\x20absorption\x20of\x20Drug\x20B'},{'id':0x2,'text':_0x21a98a(0x38f)},{'id':0x3,'text':_0x21a98a(0x34b)},{'id':0x4,'text':_0x21a98a(0x117)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x1d1),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x2c3),'choices':[{'id':0x1,'text':_0x21a98a(0x383)},{'id':0x2,'text':_0x21a98a(0x32e)},{'id':0x3,'text':_0x21a98a(0x260)},{'id':0x4,'text':_0x21a98a(0x20c)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x156),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x344),'choices':[{'id':0x1,'text':'Albumin'},{'id':0x2,'text':_0x21a98a(0x3aa)},{'id':0x3,'text':'Lipoprotein'},{'id':0x4,'text':_0x21a98a(0x1fc)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x3e8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x289),'choices':[{'id':0x1,'text':_0x21a98a(0x3e0)},{'id':0x2,'text':_0x21a98a(0x23a)},{'id':0x3,'text':_0x21a98a(0x17e)},{'id':0x4,'text':_0x21a98a(0x1bb)}],'correct_choice_id':0x4,'solution':_0x21a98a(0x35f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x136),'choices':[{'id':0x1,'text':'Triamterene'},{'id':0x2,'text':_0x21a98a(0x1bd)},{'id':0x3,'text':_0x21a98a(0x2e0)},{'id':0x4,'text':'Furosemide'}],'correct_choice_id':0x2,'solution':_0x21a98a(0x26c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x14f),'choices':[{'id':0x1,'text':_0x21a98a(0x315)},{'id':0x2,'text':_0x21a98a(0x2c1)},{'id':0x3,'text':_0x21a98a(0x33f)},{'id':0x4,'text':_0x21a98a(0x3ba)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x11a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x2c4),'choices':[{'id':0x1,'text':_0x21a98a(0x162)},{'id':0x2,'text':_0x21a98a(0x358)},{'id':0x3,'text':_0x21a98a(0x2e5)},{'id':0x4,'text':_0x21a98a(0x1ee)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x158),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x254),'choices':[{'id':0x1,'text':_0x21a98a(0x362)},{'id':0x2,'text':_0x21a98a(0x387)},{'id':0x3,'text':_0x21a98a(0x38e)},{'id':0x4,'text':_0x21a98a(0x3ef)}],'correct_choice_id':0x2,'solution':'<p><strong>Vilazodone</strong>\x20is\x20the&nbsp;novel\x20antidepressant.</p>\x0a<p\x20id=\x22__p9\x22>The\x20antidepressant\x20effect\x20of\x20vilazodone\x20is\x20due\x20to\x20its\x20<strong>enhancement</strong>\x20of\x20<strong>serotonergic\x20activity</strong>\x20in\x20the\x20CNS\x20through\x20selective\x20inhibition\x20of\x20serotonin\x20reuptake.\x20It\x20binds\x20with\x20<strong>high\x20affinity</strong>\x20to\x20the\x20serotonin\x20reuptake\x20site\x20<strong>but\x20not</strong>\x20to\x20the\x20norepinephrine\x20or\x20dopamine\x20reuptake\x20site.\x20As\x20a\x20result,\x20vilazodone\x20<strong>potently</strong>\x20and\x20<strong>selectively\x20inhibits</strong>\x20the\x20reuptake\x20of\x20serotonin.</p>\x0a<p>Vilazodone\x20is\x20also\x20a\x20<strong>partial\x20agonist</strong>\x20at\x20serotonergic\x20<strong>5-HT<sub>1A</sub></strong>&nbsp;receptors;\x20the\x20result\x20of\x20this\x20activity\x20on\x20serotonergic\x20transmission\x20also\x20plays\x20a\x20role\x20in\x20its\x20antidepressant\x20effect.</p>\x0a<p>Thus\x20it\x20offers\x20a\x20<strong>novel</strong>\x20combination\x20of\x20<strong>selective\x20serotonin\x20reuptake\x20inhibition\x20(SSRI)</strong>\x20and\x20serotonergic\x20(<strong>5-HT<sub>1A</sub></strong>)\x20receptor\x20<strong>partial\x20agonist</strong>\x20activity.&nbsp;Because\x20of\x20these\x20characteristics,\x20vilazodone\x20has\x20been\x20termed\x20a\x20serotonin\x20partial\x20agonist&ndash;reuptake\x20inhibitor\x20(<strong>SPARI</strong>).</p>\x0a<p>Vilazodone\x20is\x20never\x20combined\x20with\x20a\x20<strong>monoamine\x20oxidase</strong>\x20(<strong>MAO</strong>)\x20inhibitor\x20or\x20given\x20within\x20<strong>14\x20days</strong>\x20of\x20discontinuing\x20or\x20initiating\x20MAO\x20inhibitor\x20therapy\x20due\x20to\x20the\x20serious\x20risk\x20of\x20<strong>serotonin\x20toxicity</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Lurasidone&nbsp;</strong>is\x20a\x20second-generation\x20antipsychotic\x20that\x20is\x20a&nbsp;<strong>5-HT<sub>2A&nbsp;</sub></strong>and\x20<strong>D</strong><sub><strong>2</strong>&nbsp;</sub>receptor\x20antagonist.\x20it\x20is\x20used\x20in\x20the\x20treatment\x20of\x20schizophrenia\x20and\x20bipolar\x20depression\x20(as\x20monotherapy\x20or\x20as\x20an\x20adjunct).</p>\x0a<p>Option\x20C:<strong>\x20Asenapine&nbsp;</strong>is\x20a\x20second-generation\x20antipsychotic\x20which\x20is\x20also\x20a&nbsp;<strong>5-HT<sub>2A&nbsp;</sub></strong>and\x20<strong>D</strong><sub><strong>2</strong>&nbsp;</sub>receptor\x20antagonist,\x20used\x20in\x20the\x20management\x20of\x20schizophrenia\x20and\x20acute\x20mania.</p>\x0a<p>Option\x20D:\x20<strong>Blonanserin</strong>\x20is\x20a\x20second-generation\x20antipsychotic,\x20which\x20acts\x20as\x20an\x20antagonist\x20at\x20<strong>D<sub>2</sub></strong>,\x20<strong>D<sub>3</sub></strong>,\x20and\x20<strong>5-HT<sub>2A</sub></strong>&nbsp;receptors.\x20Blonanserin\x20has\x20a\x20low\x20affinity\x20for\x205-HT<sub>2C</sub>,\x20adrenergic\x20&alpha;<sub>1</sub>,\x20histamine\x20H<sub>1</sub>,\x20and\x20muscarinic\x20M<sub>1</sub>&nbsp;receptors,\x20but\x20displays\x20a\x20relatively\x20high\x20affinity\x20for\x205-HT<sub>6</sub>&nbsp;receptors.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20schizophrenia.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x377),'choices':[{'id':0x1,'text':_0x21a98a(0x323)},{'id':0x2,'text':_0x21a98a(0x155)},{'id':0x3,'text':_0x21a98a(0x263)},{'id':0x4,'text':_0x21a98a(0x3a5)}],'correct_choice_id':0x1,'solution':_0x21a98a(0x145),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/37758943b0974770b61e968d337fcac4.JPEG'],'explanation_images':[]},{'text':_0x21a98a(0x219),'choices':[{'id':0x1,'text':'Ambroxol'},{'id':0x2,'text':'Diphenoxylate'},{'id':0x3,'text':'Levopropoxyphene'},{'id':0x4,'text':'Levorphanol'}],'correct_choice_id':0x3,'solution':_0x21a98a(0x365),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x21a98a(0x3e7),'choices':[{'id':0x1,'text':_0x21a98a(0x2c6)},{'id':0x2,'text':'1,\x202\x20and\x204'},{'id':0x3,'text':'1,\x203\x20and\x204'},{'id':0x4,'text':_0x21a98a(0x121)}],'correct_choice_id':0x2,'solution':_0x21a98a(0x28d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20breast\x20cancer\x20patient\x20post-chemotherapy\x20developed\x20a\x20low-grade\x20fever\x20with\x20anemia\x20and\x20leukocytopenia\x20(<4000/cm3;\x20DNC:\x2030).\x20Which\x20of\x20the\x20following\x20antibiotics\x20will\x20not\x20be\x20used\x20in\x20the\x20empirical\x20management\x20of\x20this\x20patient?','choices':[{'id':0x1,'text':'Cefepime'},{'id':0x2,'text':_0x21a98a(0x1b0)},{'id':0x3,'text':_0x21a98a(0x205)},{'id':0x4,'text':_0x21a98a(0x1ba)}],'correct_choice_id':0x3,'solution':'<p><strong>Linezolid</strong>\x20cannot\x20be\x20used\x20in\x20this\x20patient\x20as\x20<strong>bone\x20marrow\x20suppressio</strong>n\x20is\x20a\x20side\x20effect\x20of\x20this\x20drug\x20and\x20hence\x20it\x20can\x20worsen\x20the\x20post-chemotherapy\x20bone\x20marrow\x20suppression\x20in\x20this\x20patient.</p>\x0a<p>Linezolid\x20can\x20cause\x20<strong>myelosuppression</strong>\x20which\x20can\x20present\x20as\x20anemia,\x20thrombocytopenia,\x20leukopenia,\x20and\x20pancytopenia.\x20It\x20is\x20<strong>commonly</strong>\x20associated\x20with\x20<strong>thrombocytopenia</strong>\x20and\x20is\x20seen\x207-10\x20days\x20following\x20administration.\x20This\x20is\x20usually\x20reversed\x20on\x20discontinuation\x20of\x20the\x20drug.&nbsp;</p>\x0a<p>Other\x20adverse\x20effects\x20of\x20linezolid:</p>\x0a<ul>\x0a<li>It\x20inhibits\x20mitochondrial\x20protein\x20synthesis\x20and\x20may\x20lead\x20to\x20peripheral\x20neuropathy,\x20optic\x20neuritis,\x20and\x20lactic\x20acidosis\x20in\x20patients\x20receiving\x20the\x20drug\x20for\x20longer\x20durations.</li>\x0a<li>It\x20can\x20cause\x20<strong>serotonin\x20syndrome</strong>\x20when\x20coadministered\x20with\x20adrenergic\x20or\x20serotonergic\x20drugs\x20like\x20SSRIs\x20due\x20to\x20its\x20nonspecific\x20MAO\x20inhibition.</li>\x0a</ul>\x0a<p>It\x20is\x20a\x20protein\x20synthesis\x20inhibitor\x20of\x20the\x20class\x20<strong>oxazolidinone</strong>s.\x20It\x20mainly\x20acts\x20against\x20<strong>gram-positive</strong>\x20organisms.\x20It\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20the\x20following\x20conditions:</p>\x0a<ul>\x0a<li><strong>Skin</strong>\x20and\x20<strong>skin\x20structure\x20infection</strong>s\x20by\x20staphylococcus(Both\x20MRSA\x20and\x20MSSA)\x20and\x20streptococcus.</li>\x0a<li>Community-acquired\x20pneumonia\x20due\x20to\x20streptococcus\x20pneumoniae.</li>\x0a<li>Nosocomial\x20pneumonia\x20due\x20to\x20staphylococcus\x20aureus.&nbsp;</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p><strong>Cefepime</strong>:\x20It\x20is\x20a\x20fourth-generation\x20antipseudomonal\x20cephalosporin.\x20It\x20is\x20useful\x20in\x20enterobacter\x20and\x20pseudomonas\x20infections\x20that\x20are\x20resistant\x20to\x20other\x20cephalosporins.</p>\x0a<p><strong>Piperacillin-Tazobactam</strong>-\x20It\x20is\x20a\x20combination\x20of\x20piperacillin\x20which\x20is\x20a\x20ureidopenicillin\x20and\x20tazobactam\x20which\x20is\x20a\x20beta-lactamase\x20inhibitor.\x20It\x20is\x20useful\x20in\x20various\x20infections\x20including\x20nosocomial\x20infections,\x20intraabdominal\x20infections,\x20pneumonia,\x20and\x20UTI.\x20It\x20is\x20highly\x20effective\x20against\x20<strong>E\x20Coli\x20and\x20Klebsiella</strong>.</p>\x0a<p><strong>Meropenem</strong>:\x20It\x20belongs\x20to\x20the\x20carbapenem\x20group\x20of\x20beta-lactam\x20antibiotics.\x20They\x20are\x20more\x20active\x20against\x20gram-negative\x20organisms.\x20Coadministration\x20of\x20<strong>cilastatin\x20is\x20not\x20required</strong>\x20with\x20this\x20drug.\x20(Cilastation\x20should\x20be\x20coadministered\x20with\x20imipenem\x20as\x20imipenem\x20is\x20sensitive\x20to\x20renal\x20peptidase\x20degradation)</p>','explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x21a98a(0x139);const quizFilename=_0x21a98a(0x18a);let hierarchy=['Marrow',_0x21a98a(0x240),_0x21a98a(0x3a1)];if(window[_0x21a98a(0x307)]['pathname'][_0x21a98a(0x27a)]('custom_quiz.html')){const customData=JSON[_0x21a98a(0x3e6)](localStorage['getItem'](_0x21a98a(0x29b)));customData&&(questionsData=customData[_0x21a98a(0x355)],quizName=customData[_0x21a98a(0x22e)],hierarchy=customData[_0x21a98a(0x122)],document['title']=quizName+'\x20-\x20Brain\x20And\x20Scalpel',document['getElementById']('totalQuestions')[_0x21a98a(0x1a0)]=questionsData[_0x21a98a(0x376)],document[_0x21a98a(0x137)]('quizHierarchy')[_0x21a98a(0x1a0)]=hierarchy[_0x21a98a(0x27f)]('\x20>\x20'));}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x21a98a(0x1a1),timer=null,timeRemaining=0x0,questionStartTime=Date['now'](),quizStartTime=Date['now'](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x21a98a(0x376)])['fill'](null)[_0x21a98a(0x173)](()=>({'status':_0x21a98a(0x1c2),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData['length']};function saveProgress(){const _0x55cd52=_0x21a98a,_0x4c93ba={'Sqhch':_0x55cd52(0x2cd),'xOBwB':'userHistory'};if(isQuizCompleted)return;const _0x571b31=JSON['parse'](localStorage[_0x55cd52(0x1be)]('userHistory'))||{};_0x571b31[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x4c93ba[_0x55cd52(0x16c)],'lastSeen':new Date()[_0x55cd52(0x253)]()},localStorage[_0x55cd52(0x1e4)](_0x4c93ba[_0x55cd52(0x1c4)],JSON['stringify'](_0x571b31));}function loadProgress(){const _0x42575e=_0x21a98a,_0x36e580={'Chwyq':_0x42575e(0x249),'efSMl':_0x42575e(0x235)},_0x1e8471=JSON[_0x42575e(0x3e6)](localStorage[_0x42575e(0x1be)](_0x36e580[_0x42575e(0x384)]))||{},_0xb9f7f7=_0x1e8471[quizFilename];if(_0xb9f7f7)return questionStates=_0xb9f7f7[_0x42575e(0x1de)],stats=_0xb9f7f7['stats'],currentQuestionIndex=_0xb9f7f7['currentQuestionIndex'],currentMode=_0xb9f7f7[_0x42575e(0x169)],console['log'](_0x36e580[_0x42575e(0x23d)]),!![];return![];}function clearProgress(){const _0x21bc89=_0x21a98a,_0x8cd2a3={'xTMPQ':'userHistory','tKbcU':_0x21bc89(0x222)},_0x34a0b8=JSON[_0x21bc89(0x3e6)](localStorage[_0x21bc89(0x1be)](_0x8cd2a3[_0x21bc89(0x35d)]))||{};_0x34a0b8[quizFilename]&&(delete _0x34a0b8[quizFilename],localStorage['setItem'](_0x8cd2a3['xTMPQ'],JSON[_0x21bc89(0x262)](_0x34a0b8)),console[_0x21bc89(0x1f0)](_0x8cd2a3[_0x21bc89(0x3af)]));}function markQuizAsCompleted(){const _0x817e44=_0x21a98a,_0x5bf50d=JSON[_0x817e44(0x3e6)](localStorage[_0x817e44(0x1be)]('userHistory'))||{},_0x17ed20=questionsData['length'],_0x350b54=stats[_0x817e44(0x1af)]||0x0;_0x5bf50d[quizFilename]={'score':_0x350b54,'total':_0x17ed20,'status':_0x817e44(0x204),'completedOn':new Date()[_0x817e44(0x253)]()},localStorage['setItem'](_0x817e44(0x249),JSON[_0x817e44(0x262)](_0x5bf50d));}const urlParams=new URLSearchParams(window['location'][_0x21a98a(0x2cb)]),startAt=parseInt(urlParams[_0x21a98a(0x333)]('startAt')),resume=urlParams['get'](_0x21a98a(0x14c))===_0x21a98a(0x348);function goBack(){const _0x3bde38=_0x21a98a;if(!isQuizCompleted)saveProgress();window[_0x3bde38(0x307)][_0x3bde38(0x224)]=document['referrer']||_0x3bde38(0x2ce);}function selectMode(_0x90b814){const _0x571ee9=_0x21a98a,_0x12ca64={'BNxBj':'modeModal','brXpm':_0x571ee9(0x252)};currentMode=_0x90b814,document[_0x571ee9(0x137)](_0x12ca64[_0x571ee9(0x188)])['style'][_0x571ee9(0x2a4)]=_0x12ca64[_0x571ee9(0x1f2)],initializeQuiz();}function _0x3bbb(_0x280126,_0x293ee4){const _0x588da6=_0x13ef();return _0x3bbb=function(_0x4d4cf1,_0x31a9e0){_0x4d4cf1=_0x4d4cf1-0x112;let _0x2e9428=_0x588da6[_0x4d4cf1];return _0x2e9428;},_0x3bbb(_0x280126,_0x293ee4);}function initializeQuiz(){const _0x530f77=_0x21a98a,_0x247c5f={'xGmFX':_0x530f77(0x2de),'tgdcw':_0x530f77(0x15b),'qdAUL':function(_0x3a1d50,_0x27dedc){return _0x3a1d50===_0x27dedc;},'vOVQd':_0x530f77(0x3e2),'UfzJO':_0x530f77(0x2d3),'jbSaU':'none','efKPJ':'block','XXHRP':_0x530f77(0x3d8),'ePZVP':_0x530f77(0x35c),'HplWi':_0x530f77(0x227),'zNSXX':_0x530f77(0x151),'Ckvwv':_0x530f77(0x38c),'eYjZf':'hidden','ssrkJ':function(_0x2ab99a,_0x5973f6){return _0x2ab99a(_0x5973f6);},'BtkSy':function(_0x5660e9){return _0x5660e9();},'jABgD':function(_0x17f42d){return _0x17f42d();},'bzilC':function(_0x39ff88){return _0x39ff88();}};quizStartTime=Date[_0x530f77(0x2c5)]();const _0x222017=document[_0x530f77(0x137)](_0x247c5f[_0x530f77(0x243)]),_0x1700f2=document['getElementById']('markReviewBtn'),_0x5924e6=document[_0x530f77(0x137)](_0x247c5f[_0x530f77(0x19f)]),_0x3d48e9=_0x247c5f[_0x530f77(0x3c2)](currentMode,_0x247c5f[_0x530f77(0x3c9)])||_0x247c5f['qdAUL'](currentMode,_0x247c5f[_0x530f77(0x297)]);document['getElementById'](_0x530f77(0x30b))['style'][_0x530f77(0x2a4)]=_0x3d48e9?_0x247c5f['jbSaU']:_0x247c5f[_0x530f77(0x3a4)],document[_0x530f77(0x137)]('studyModeLegend')[_0x530f77(0x13d)][_0x530f77(0x2a4)]=_0x3d48e9?_0x247c5f['jbSaU']:_0x247c5f[_0x530f77(0x3a4)],document[_0x530f77(0x137)](_0x247c5f[_0x530f77(0x157)])[_0x530f77(0x13d)][_0x530f77(0x2a4)]=_0x3d48e9?_0x530f77(0x325):_0x247c5f['jbSaU'],document[_0x530f77(0x137)](_0x247c5f['ePZVP'])[_0x530f77(0x13d)][_0x530f77(0x2a4)]=_0x3d48e9?_0x530f77(0x325):_0x247c5f['jbSaU'],_0x222017[_0x530f77(0x13d)]['display']=_0x3d48e9?_0x247c5f['jbSaU']:_0x247c5f['HplWi'],_0x1700f2[_0x530f77(0x13d)][_0x530f77(0x2a4)]=_0x3d48e9?'flex':'none',_0x5924e6[_0x530f77(0x13d)]['display']=_0x3d48e9?_0x247c5f[_0x530f77(0x311)]:_0x247c5f[_0x530f77(0x282)],(_0x247c5f[_0x530f77(0x3c2)](currentMode,_0x247c5f[_0x530f77(0x272)])||currentMode===_0x247c5f[_0x530f77(0x297)])&&document['getElementById'](_0x247c5f[_0x530f77(0x27e)])[_0x530f77(0x364)][_0x530f77(0x12b)](_0x247c5f[_0x530f77(0x140)]),!_0x247c5f[_0x530f77(0x133)](isNaN,startAt)&&startAt>=0x0&&startAt<questionsData[_0x530f77(0x376)]&&(currentQuestionIndex=startAt),_0x247c5f[_0x530f77(0x3b8)](loadBookmarkedQuestions),_0x247c5f[_0x530f77(0x37a)](generateQuestionNav),_0x247c5f[_0x530f77(0x3a7)](updateStats),_0x247c5f[_0x530f77(0x37a)](displayQuestion);}function generateQuestionNav(){const _0x3885ec=_0x21a98a,_0x3c4558={'hiGYb':function(_0x44374f,_0x421a65){return _0x44374f<_0x421a65;},'QdtAt':_0x3885ec(0x284),'CYPrU':function(_0x14facf,_0x54b705){return _0x14facf+_0x54b705;},'qZFVw':_0x3885ec(0x233),'PLVOH':function(_0xd63b45){return _0xd63b45();}},_0x4ebe55=document['getElementById'](_0x3885ec(0x12d));_0x4ebe55[_0x3885ec(0x2a9)]='';for(let _0x4b14ab=0x0;_0x3c4558[_0x3885ec(0x142)](_0x4b14ab,questionsData[_0x3885ec(0x376)]);_0x4b14ab++){const _0x18f57e=document[_0x3885ec(0x1c3)](_0x3c4558['QdtAt']);_0x18f57e[_0x3885ec(0x1a0)]=_0x3c4558['CYPrU'](_0x4b14ab,0x1),_0x18f57e[_0x3885ec(0x270)]=_0x3c4558['qZFVw'],_0x18f57e['onclick']=()=>jumpToQuestion(_0x4b14ab),_0x18f57e['id']=_0x3885ec(0x30e)+_0x4b14ab,_0x4ebe55[_0x3885ec(0x229)](_0x18f57e);}_0x3c4558[_0x3885ec(0x274)](updateQuestionNav);}function updateQuestionNav(){const _0x228ca0=_0x21a98a,_0x36bda7={'ADHnW':_0x228ca0(0x3bf),'VHQUX':_0x228ca0(0x193),'hSIyE':function(_0x897061,_0x2b7b99){return _0x897061<_0x2b7b99;},'eKYIx':function(_0x558528,_0x3e69c1){return _0x558528!==_0x3e69c1;},'IQxMY':_0x228ca0(0x31c),'bKJYB':function(_0x3dd382,_0x42e30b){return _0x3dd382===_0x42e30b;},'Nefnd':_0x228ca0(0x3dd),'azLRF':function(_0x18aaa0,_0x301979){return _0x18aaa0!==_0x301979;},'EwMTj':_0x228ca0(0x3d0),'SkbqA':'PFAbB','FRyZW':_0x228ca0(0x2ab),'cduKu':_0x228ca0(0x320),'ZPwGX':_0x228ca0(0x114),'cVfZc':function(_0x53f10c,_0x1e3cc9){return _0x53f10c===_0x1e3cc9;},'WnRTi':_0x228ca0(0x3f1),'yRjOH':function(_0x3bce7f,_0x2f33c3){return _0x3bce7f!==_0x2f33c3;},'AlWrq':'nav-btn-answered','imlWi':_0x228ca0(0x39d)};for(let _0x39a89e=0x0;_0x36bda7[_0x228ca0(0x236)](_0x39a89e,questionsData[_0x228ca0(0x376)]);_0x39a89e++){if(_0x36bda7[_0x228ca0(0x37d)](_0x228ca0(0x16f),_0x36bda7[_0x228ca0(0x317)])){const _0x2dfda4=document[_0x228ca0(0x137)]('navBtn_'+_0x39a89e),_0xb7c538=questionStates[_0x39a89e];let _0x40537d='';if(_0x36bda7[_0x228ca0(0x1bf)](_0x39a89e,currentQuestionIndex))_0x40537d=_0x228ca0(0x24b);else{if(_0xb7c538[_0x228ca0(0x1ac)])_0x40537d=_0x36bda7[_0x228ca0(0x347)];else{if(_0xb7c538['markedForReview'])_0x36bda7[_0x228ca0(0x3bc)](_0x36bda7[_0x228ca0(0x26d)],_0x36bda7[_0x228ca0(0x14e)])?_0x40537d=_0x36bda7['FRyZW']:(_0x6a14b9=_0x36bda7[_0x228ca0(0x1df)],_0x156a94='Incorrect');else{if(currentMode==='study'||_0x36bda7[_0x228ca0(0x1bf)](currentMode,_0x228ca0(0x151))){if(_0x36bda7[_0x228ca0(0x1bf)](_0xb7c538[_0x228ca0(0x116)],_0x36bda7[_0x228ca0(0x2ff)]))_0x40537d=_0x228ca0(0x1d8);else{if(_0xb7c538['status']===_0x228ca0(0x3bf))_0x40537d=_0x36bda7[_0x228ca0(0x316)];else _0x40537d='nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20';}}else{if(_0x36bda7[_0x228ca0(0x299)](_0x36bda7['WnRTi'],_0x36bda7[_0x228ca0(0x153)])){if(_0x36bda7[_0x228ca0(0x30c)](_0xb7c538[_0x228ca0(0x3f5)],null))_0x40537d=_0x36bda7[_0x228ca0(0x206)];else _0x40537d=_0x36bda7['imlWi'];}else _0x4bf9d9['classList']['toggle'](_0x36bda7['VHQUX'],_0x43f536===_0x22e608);}}}}_0x2dfda4['className']=_0x228ca0(0x248)+_0x40537d;}else _0x5ed2a[_0x228ca0(0x125)]=_0x2c4cd0;}}function jumpToQuestion(_0x53dfac){const _0x5dd038=_0x21a98a,_0x13735a={'aQXIZ':function(_0x3f509a,_0x24da2d){return _0x3f509a!==_0x24da2d;},'yJLWD':_0x5dd038(0x208),'KSiFp':function(_0x4942fa,_0x26148d){return _0x4942fa-_0x26148d;},'Imecm':function(_0x5de438){return _0x5de438();},'QBWPC':function(_0x5873d0){return _0x5873d0();}};if(_0x53dfac>=0x0&&_0x53dfac<questionsData[_0x5dd038(0x376)]){if(_0x13735a[_0x5dd038(0x313)](_0x13735a[_0x5dd038(0x2b8)],_0x5dd038(0x359)))questionStartTime&&(questionStates[currentQuestionIndex]['timeSpent']+=_0x13735a[_0x5dd038(0x3cd)](Date[_0x5dd038(0x2c5)](),questionStartTime)),currentQuestionIndex=_0x53dfac,_0x13735a[_0x5dd038(0x2db)](displayQuestion),_0x13735a['QBWPC'](saveProgress);else{_0x38cb49['totalAttempted']++,_0x4e2cf3[_0x5dd038(0x322)]--;if(_0xa1f47)_0x12f956[_0x5dd038(0x1af)]++;else _0x547832[_0x5dd038(0x2d4)]++;}}}function updateStats(){const _0x3b9705=_0x21a98a,_0x5c3e4b={'tgRPD':_0x3b9705(0x1a1),'PJdGV':_0x3b9705(0x151),'oBZUc':_0x3b9705(0x39b),'hQPct':'incorrectCount','aFQzK':_0x3b9705(0x265),'erSKX':function(_0x2208f6,_0x13d3b2){return _0x2208f6>_0x13d3b2;},'zHeGS':'accuracy','AfQbD':function(_0x48c8d3,_0x49ea92){return _0x48c8d3/_0x49ea92;},'bbfMh':function(_0x51c1e1,_0x9187ea){return _0x51c1e1+_0x9187ea;},'QcwEU':function(_0x538b36,_0x1d164b){return _0x538b36+_0x1d164b;}};if(currentMode===_0x5c3e4b['tgRPD']||currentMode===_0x5c3e4b[_0x3b9705(0x2c2)]){document['getElementById'](_0x5c3e4b['oBZUc'])[_0x3b9705(0x1a0)]=stats[_0x3b9705(0x1af)],document[_0x3b9705(0x137)](_0x5c3e4b[_0x3b9705(0x209)])[_0x3b9705(0x1a0)]=stats['incorrectAnswers'],document[_0x3b9705(0x137)](_0x5c3e4b['aFQzK'])[_0x3b9705(0x1a0)]=stats[_0x3b9705(0x265)];const _0x2fd6ea=_0x5c3e4b[_0x3b9705(0x1b5)](stats[_0x3b9705(0x265)],0x0)?Math['round'](stats[_0x3b9705(0x1af)]/stats['totalAttempted']*0x64):0x0;document[_0x3b9705(0x137)](_0x5c3e4b[_0x3b9705(0x13e)])[_0x3b9705(0x1a0)]=_0x2fd6ea+'%',stats[_0x3b9705(0x2b7)]=questionStates[_0x3b9705(0x281)]((_0x1e2b10,_0xb630f9)=>_0x1e2b10+_0xb630f9[_0x3b9705(0x24e)],0x0);const _0x2c27c9=Math[_0x3b9705(0x237)](stats[_0x3b9705(0x2b7)]/0x3e8),_0x4676fc=Math[_0x3b9705(0x237)](_0x5c3e4b[_0x3b9705(0x351)](_0x2c27c9,0x3c)),_0xce705=_0x2c27c9%0x3c;document[_0x3b9705(0x137)](_0x3b9705(0x24e))[_0x3b9705(0x1a0)]=_0x5c3e4b[_0x3b9705(0x3ce)](_0x5c3e4b['QcwEU'](_0x4676fc,':'),_0xce705[_0x3b9705(0x13b)]()[_0x3b9705(0x1d9)](0x2,'0'));}}function setupVideo(_0x299c7f,_0x2c583c){const _0x1f1312=_0x21a98a,_0x5622e8={'ccEiq':'correctCount','BcJcr':_0x1f1312(0x276),'KVmEz':_0x1f1312(0x265),'MYdOS':function(_0x2b23e9,_0x1d19a1){return _0x2b23e9*_0x1d19a1;},'oAEXy':function(_0x26962e,_0x5c79c6){return _0x26962e/_0x5c79c6;},'DpIvy':_0x1f1312(0x31b),'JbRyq':function(_0x5631f1,_0x4b9764){return _0x5631f1+_0x4b9764;},'nIlJy':function(_0x453f81,_0x321e8d){return _0x453f81%_0x321e8d;},'aYQXG':function(_0x4303ba,_0x3c66de){return _0x4303ba+_0x3c66de;},'lzWBK':'vXIXc','AzvTq':'application/vnd.apple.mpegurl'};if(Hls['isSupported']()){if(_0x1f1312(0x335)!==_0x5622e8[_0x1f1312(0x2fd)]){_0x278feb[_0x1f1312(0x137)](_0x5622e8['ccEiq'])['textContent']=_0x1014b2[_0x1f1312(0x1af)],_0x457b2b[_0x1f1312(0x137)](_0x5622e8[_0x1f1312(0x25d)])[_0x1f1312(0x1a0)]=_0x3d4169[_0x1f1312(0x2d4)],_0x19186b['getElementById'](_0x5622e8['KVmEz'])[_0x1f1312(0x1a0)]=_0x348bfd[_0x1f1312(0x265)];const _0x2a4ecf=_0x57dfdd[_0x1f1312(0x265)]>0x0?_0x2ee526[_0x1f1312(0x3b7)](_0x5622e8[_0x1f1312(0x368)](_0x5622e8[_0x1f1312(0x2a6)](_0x1d90ca[_0x1f1312(0x1af)],_0x3b969f[_0x1f1312(0x265)]),0x64)):0x0;_0x2d8535[_0x1f1312(0x137)](_0x5622e8[_0x1f1312(0x1e8)])[_0x1f1312(0x1a0)]=_0x5622e8[_0x1f1312(0x16e)](_0x2a4ecf,'%'),_0xb5975e[_0x1f1312(0x2b7)]=_0x540b7f[_0x1f1312(0x281)]((_0x39e73,_0x3eb137)=>_0x39e73+_0x3eb137[_0x1f1312(0x24e)],0x0);const _0x26c892=_0x578d94[_0x1f1312(0x237)](_0x5622e8[_0x1f1312(0x2a6)](_0x371626[_0x1f1312(0x2b7)],0x3e8)),_0xeb98f1=_0x279c6c[_0x1f1312(0x237)](_0x5622e8['oAEXy'](_0x26c892,0x3c)),_0x46ac50=_0x5622e8[_0x1f1312(0x1fd)](_0x26c892,0x3c);_0x3c8972['getElementById']('timeSpent')['textContent']=_0x5622e8['JbRyq'](_0x5622e8[_0x1f1312(0x3ae)](_0xeb98f1,':'),_0x46ac50[_0x1f1312(0x13b)]()['padStart'](0x2,'0'));}else{const _0x3b902f=new Hls();_0x3b902f[_0x1f1312(0x15c)](_0x2c583c),_0x3b902f[_0x1f1312(0x21c)](_0x299c7f);}}else _0x299c7f[_0x1f1312(0x22d)](_0x5622e8[_0x1f1312(0x168)])&&(_0x299c7f[_0x1f1312(0x125)]=_0x2c583c);}function displayQuestion(){const _0x49e313=_0x21a98a,_0x2897bb={'sSoej':_0x49e313(0x3d4),'GRMhd':function(_0x48c4a2,_0x5d0a58){return _0x48c4a2===_0x5d0a58;},'LtkUS':_0x49e313(0x234),'CgarH':function(_0x5c3958,_0x2d3cda){return _0x5c3958(_0x2d3cda);},'oGIOF':function(_0x18e1b3,_0x525682){return _0x18e1b3!==_0x525682;},'sJtIi':_0x49e313(0x124),'evfbU':function(_0x4e7b0f,_0x4e3b43){return _0x4e7b0f+_0x4e3b43;},'JCcdh':_0x49e313(0x2d1),'zfvkX':'Option\x20','GdJyF':function(_0x436807,_0x4baa54){return _0x436807+_0x4baa54;},'PHfpi':_0x49e313(0x16a),'bBFLf':function(_0x36bfc0,_0x25b2fd){return _0x36bfc0(_0x25b2fd);},'cqNmj':_0x49e313(0x329),'fJVHY':_0x49e313(0x135),'IJkGs':function(_0x5bfc87,_0x30d8d7){return _0x5bfc87*_0x30d8d7;},'ALnaP':_0x49e313(0x1ea),'IdLTu':function(_0x475fc9,_0x4cd374){return _0x475fc9+_0x4cd374;},'sxdmO':_0x49e313(0x15e),'VYxWD':'prevBtn','ZFlGp':_0x49e313(0x141),'DadkQ':_0x49e313(0x13a),'nSIxq':_0x49e313(0x26a),'GkpEq':_0x49e313(0x3f3),'QEbzq':'optionsContainer','xbHoj':_0x49e313(0x147),'tnIVs':function(_0x2a82e6){return _0x2a82e6();},'mFelv':function(_0x11e87d){return _0x11e87d();},'NFhzu':function(_0x27f0e7,_0x2cf3e3){return _0x27f0e7===_0x2cf3e3;},'qDigP':function(_0x2e289b){return _0x2e289b();}};if(!questionsData||_0x2897bb[_0x49e313(0x29f)](questionsData[_0x49e313(0x376)],0x0)){if(_0x2897bb[_0x49e313(0x207)](_0x2897bb[_0x49e313(0x375)],_0x49e313(0x203))){document[_0x49e313(0x137)](_0x49e313(0x13a))[_0x49e313(0x2a9)]=_0x49e313(0x120);return;}else _0x499617[_0x49e313(0x364)]['add'](_0x2897bb[_0x49e313(0x161)]);};const _0x2a9330=questionsData[currentQuestionIndex];questionStartTime=Date['now'](),selectedOption=questionStates[currentQuestionIndex][_0x49e313(0x3f5)];const _0x52a4d0=_0x2897bb['IJkGs'](_0x2897bb['evfbU'](currentQuestionIndex,0x1)/questionsData['length'],0x64);document['getElementById'](_0x2897bb[_0x49e313(0x26f)])[_0x49e313(0x13d)][_0x49e313(0x1b6)]=_0x2897bb[_0x49e313(0x1f4)](_0x52a4d0,'%'),document[_0x49e313(0x137)](_0x2897bb[_0x49e313(0x305)])['textContent']=currentQuestionIndex+0x1,updateQuestionNav(),document[_0x49e313(0x137)](_0x2897bb[_0x49e313(0x2da)])['disabled']=currentQuestionIndex===0x0,document[_0x49e313(0x137)](_0x2897bb[_0x49e313(0x3c1)])[_0x49e313(0x364)][_0x49e313(0x338)](_0x2897bb[_0x49e313(0x161)]),document[_0x49e313(0x137)](_0x2897bb[_0x49e313(0x2ba)])[_0x49e313(0x2a9)]=_0x2a9330[_0x49e313(0x388)]||_0x2897bb['nSIxq'];let _0x587e4f='';if(_0x2a9330[_0x49e313(0x331)])_0x587e4f+=_0x49e313(0x1fa)+_0x2a9330[_0x49e313(0x331)]+_0x49e313(0x36c);if(_0x2a9330[_0x49e313(0x1a2)])_0x587e4f+=_0x49e313(0x2d8)+_0x2a9330['question_video']+_0x49e313(0x3b2);_0x2a9330[_0x49e313(0x367)]&&_0x2a9330['question_images']['forEach'](_0x450092=>{const _0x70c317=_0x49e313;if(_0x2897bb['GRMhd'](_0x2897bb[_0x70c317(0x39c)],_0x2897bb[_0x70c317(0x39c)])){if(_0x450092)_0x587e4f+=_0x70c317(0x1cb)+_0x450092+_0x70c317(0x25a);}else _0x8427fa();});document[_0x49e313(0x137)](_0x2897bb[_0x49e313(0x3b6)])[_0x49e313(0x2a9)]=_0x587e4f;const _0x58a9b5=document[_0x49e313(0x137)](_0x2897bb[_0x49e313(0x238)]);_0x58a9b5['innerHTML']='',_0x58a9b5[_0x49e313(0x364)][_0x49e313(0x12b)](_0x49e313(0x20a)),_0x2a9330['choices']&&Array[_0x49e313(0x2ad)](_0x2a9330[_0x49e313(0x126)])&&(_0x2a9330[_0x49e313(0x126)][_0x49e313(0x301)]((_0x1661ca,_0x4559a0)=>{const _0x238256=_0x49e313,_0x56b0e4={'cdZyN':function(_0x28c404,_0x994311){return _0x2897bb['CgarH'](_0x28c404,_0x994311);},'nGAnc':function(_0x2faf4d){return _0x2faf4d();},'NjdRz':function(_0x456dae){return _0x456dae();}};if(_0x2897bb[_0x238256(0x207)](_0x2897bb['sJtIi'],_0x238256(0x124)))_0x56b0e4['cdZyN'](_0x48bd3a,_0x238256(0x3b0))&&(_0x1c2b07=0x0,_0x56b0e4[_0x238256(0x28a)](_0xdb28f7),_0x56b0e4[_0x238256(0x290)](_0x5ed023));else{const _0x4b9d35=String[_0x238256(0x312)](_0x2897bb[_0x238256(0x2af)](0x41,_0x4559a0)),_0x4ce954=selectedOption===_0x4559a0,_0xa9f8c2=document[_0x238256(0x1c3)](_0x2897bb[_0x238256(0x214)]);_0xa9f8c2[_0x238256(0x2a9)]=_0x238256(0x371)+(_0x4ce954?_0x238256(0x193):'')+'\x22\x20data-option-index=\x22'+_0x4559a0+_0x238256(0x32c)+_0x4b9d35+_0x238256(0x278)+(_0x1661ca[_0x238256(0x388)]||_0x2897bb[_0x238256(0x2af)](_0x2897bb[_0x238256(0x2ef)],_0x2897bb['GdJyF'](_0x4559a0,0x1)))+_0x238256(0x202),_0x58a9b5[_0x238256(0x229)](_0xa9f8c2);}}),_0x58a9b5[_0x49e313(0x18b)](_0x2897bb[_0x49e313(0x393)],function(_0x1b054d){const _0x117ec4=_0x49e313,_0x261783=_0x1b054d[_0x117ec4(0x1d7)]['closest'](_0x2897bb[_0x117ec4(0x298)]);if(_0x261783){const _0x47f688=_0x2897bb[_0x117ec4(0x319)](parseInt,_0x261783[_0x117ec4(0x256)](_0x2897bb[_0x117ec4(0x15f)]));selectOption(_0x47f688);}})),_0x2897bb[_0x49e313(0x328)](updateBookmarkButton),_0x2897bb[_0x49e313(0x245)](updateMarkReviewButton),(_0x2897bb[_0x49e313(0x143)](currentMode,_0x49e313(0x151))||_0x2897bb[_0x49e313(0x29f)](currentMode,_0x49e313(0x2d3)))&&!isQuizCompleted&&_0x2897bb[_0x49e313(0x292)](startTimer);}function selectOption(_0x2de475){const _0x23982a=_0x21a98a,_0x5dca7a={'VRQTz':_0x23982a(0x193),'GGLbr':'optionsContainer','BlZzU':function(_0x495b62,_0x4da1ab){return _0x495b62===_0x4da1ab;},'hkJfQ':_0x23982a(0x1a1),'vCoxV':_0x23982a(0x1c2),'uSFxX':_0x23982a(0x20a),'PClSY':function(_0x1fb8fb){return _0x1fb8fb();}},_0x330521=document[_0x23982a(0x137)](_0x5dca7a[_0x23982a(0x258)]);if(_0x330521[_0x23982a(0x364)][_0x23982a(0x2c8)](_0x23982a(0x20a)))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x23982a(0x24e)]+=Date[_0x23982a(0x2c5)]()-questionStartTime,questionStartTime=Date[_0x23982a(0x2c5)]()),selectedOption=_0x2de475,questionStates[currentQuestionIndex][_0x23982a(0x3f5)]=_0x2de475,document['querySelectorAll'](_0x23982a(0x16a))[_0x23982a(0x301)]((_0x10c90b,_0x36a43b)=>{const _0x44a8c3=_0x23982a;_0x10c90b[_0x44a8c3(0x364)][_0x44a8c3(0x196)](_0x5dca7a[_0x44a8c3(0x398)],_0x36a43b===_0x2de475);}),_0x5dca7a[_0x23982a(0x18d)](currentMode,_0x5dca7a[_0x23982a(0x12a)])||currentMode===_0x23982a(0x151)?processAnswer():(questionStates[currentQuestionIndex][_0x23982a(0x116)]===_0x5dca7a[_0x23982a(0x242)]&&(questionStates[currentQuestionIndex]['status']=_0x5dca7a[_0x23982a(0x13f)],stats[_0x23982a(0x265)]++,stats[_0x23982a(0x322)]--),updateQuestionNav()),_0x5dca7a[_0x23982a(0x19a)](saveProgress);}function processAnswer(){const _0x2bbb65=_0x21a98a,_0x4702a5={'lTQSd':function(_0x18129f,_0x37d3f7){return _0x18129f===_0x37d3f7;},'mQZif':'not_attempted','Oltru':_0x2bbb65(0x320),'GSkFQ':_0x2bbb65(0x3bf),'PAxcS':function(_0x4b7744){return _0x4b7744();},'JONOn':function(_0x415473,_0x4b8871){return _0x415473(_0x4b8871);}},_0x2dcc9a=questionsData[currentQuestionIndex],_0x3ef45f=_0x2dcc9a[_0x2bbb65(0x2e7)];if(selectedOption===null)return;const _0x54dc08=_0x2dcc9a[_0x2bbb65(0x126)][selectedOption],_0x544834=_0x54dc08['id']===_0x3ef45f;if(_0x4702a5[_0x2bbb65(0x184)](questionStates[currentQuestionIndex][_0x2bbb65(0x116)],_0x4702a5['mQZif'])){stats[_0x2bbb65(0x265)]++,stats[_0x2bbb65(0x322)]--;if(_0x544834)stats[_0x2bbb65(0x1af)]++;else stats[_0x2bbb65(0x2d4)]++;}questionStates[currentQuestionIndex][_0x2bbb65(0x116)]=_0x544834?_0x4702a5['Oltru']:_0x4702a5[_0x2bbb65(0x306)],_0x4702a5[_0x2bbb65(0x37f)](updateStats),_0x4702a5['JONOn'](showInlineFeedback,_0x544834),updateQuestionNav();}function showInlineFeedback(_0x46eef7){const _0x288e90=_0x21a98a,_0x372c2d={'ndztz':_0x288e90(0x193),'qrLeg':function(_0x536862,_0x37365e){return _0x536862===_0x37365e;},'oYwno':_0x288e90(0x320),'vLMzi':function(_0x1e7e10,_0x401477){return _0x1e7e10===_0x401477;},'ZuJBW':'incorrect','EbUTj':function(_0x219e5c,_0x2d92f1){return _0x219e5c!==_0x2d92f1;},'bfnHx':_0x288e90(0x151),'nMttM':_0x288e90(0x16d),'ZszHe':_0x288e90(0x16a),'knJZV':function(_0x2611bc){return _0x2611bc();}};if(_0x372c2d[_0x288e90(0x390)](currentMode,'study')&&_0x372c2d[_0x288e90(0x390)](currentMode,_0x372c2d[_0x288e90(0x24c)]))return;const _0x246d1c=document[_0x288e90(0x137)](_0x372c2d['nMttM']),_0x318978=_0x246d1c[_0x288e90(0x113)](_0x372c2d[_0x288e90(0x1d0)]),_0x102a09=questionsData[currentQuestionIndex],_0x397ce0=_0x102a09[_0x288e90(0x2e7)];let _0x486aae=_0x102a09['choices'][_0x288e90(0x175)](_0x3ca28d=>_0x3ca28d['id']===_0x397ce0);_0x246d1c['classList'][_0x288e90(0x338)](_0x288e90(0x20a)),_0x318978[_0x288e90(0x301)]((_0xeedbcb,_0x55e051)=>{const _0x5d258b=_0x288e90;_0xeedbcb['classList'][_0x5d258b(0x12b)](_0x372c2d[_0x5d258b(0x37c)]);if(_0x372c2d['qrLeg'](_0x55e051,_0x486aae))_0xeedbcb[_0x5d258b(0x364)][_0x5d258b(0x338)](_0x372c2d[_0x5d258b(0x228)]);else{if(_0x372c2d['vLMzi'](_0x55e051,selectedOption)&&!_0x46eef7)_0xeedbcb['classList']['add'](_0x372c2d['ZuJBW']);}}),_0x372c2d[_0x288e90(0x191)](showSolution);}function showSolution(){const _0x18fec9=_0x21a98a,_0x15e0b5={'RbuEd':_0x18fec9(0x2ab),'EwTsp':'gEdIU','cSZIp':'study','PWvAB':'timed_study','MJMKp':_0x18fec9(0x357),'DRWsl':_0x18fec9(0x1b8),'IWDjW':'explanationVideoPlayer','Mmbmc':_0x18fec9(0x3d4),'yJCBB':_0x18fec9(0x26b),'yWTIp':function(_0x5f4ab9,_0x2e5c6d,_0xd7b368){return _0x5f4ab9(_0x2e5c6d,_0xd7b368);},'HEkqi':_0x18fec9(0x138),'MagoC':_0x18fec9(0x141)};if(currentMode!==_0x15e0b5[_0x18fec9(0x1d6)]&&currentMode!==_0x15e0b5[_0x18fec9(0x30f)])return;const _0x3956eb=questionsData[currentQuestionIndex];document[_0x18fec9(0x137)](_0x15e0b5[_0x18fec9(0x2b1)])[_0x18fec9(0x2a9)]=_0x3956eb['solution']||'No\x20solution\x20provided';const _0x418cc1=document[_0x18fec9(0x137)](_0x15e0b5[_0x18fec9(0x1dc)]),_0x5316be=document[_0x18fec9(0x137)](_0x15e0b5[_0x18fec9(0x361)]),_0xc2b42e=_0x3956eb[_0x18fec9(0x343)];if(_0xc2b42e){_0x418cc1['classList'][_0x18fec9(0x12b)](_0x15e0b5[_0x18fec9(0x3b9)]);if(_0xc2b42e[_0x18fec9(0x190)](_0x15e0b5[_0x18fec9(0x39a)]))_0x15e0b5[_0x18fec9(0x2dc)](setupVideo,_0x5316be,_0xc2b42e);else _0x5316be[_0x18fec9(0x125)]=_0xc2b42e;}else _0x418cc1[_0x18fec9(0x364)]['add'](_0x15e0b5['Mmbmc']);const _0x44c882=document[_0x18fec9(0x137)]('solutionAudio');_0x44c882[_0x18fec9(0x2a9)]='';_0x3956eb[_0x18fec9(0x3a9)]&&(_0x44c882[_0x18fec9(0x2a9)]+=_0x18fec9(0x34d)+_0x3956eb[_0x18fec9(0x3a9)]+_0x18fec9(0x36c));_0x3956eb[_0x18fec9(0x389)]&&(_0x44c882[_0x18fec9(0x2a9)]+=_0x18fec9(0x146)+_0x3956eb[_0x18fec9(0x389)]+_0x18fec9(0x36c));const _0x16fbf3=document[_0x18fec9(0x137)](_0x15e0b5[_0x18fec9(0x3b3)]);_0x16fbf3[_0x18fec9(0x2a9)]='',_0x3956eb['explanation_images']&&_0x3956eb[_0x18fec9(0x352)]['forEach'](_0x58e8c2=>{const _0xb4c4b5=_0x18fec9;if(_0x15e0b5[_0xb4c4b5(0x300)]===_0x15e0b5[_0xb4c4b5(0x300)]){if(_0x58e8c2)_0x16fbf3[_0xb4c4b5(0x2a9)]+=_0xb4c4b5(0x230)+_0x58e8c2+_0xb4c4b5(0x251);}else _0xc8ef6c=_0x15e0b5[_0xb4c4b5(0x3cc)];}),document[_0x18fec9(0x137)](_0x15e0b5[_0x18fec9(0x2e2)])[_0x18fec9(0x364)][_0x18fec9(0x12b)](_0x18fec9(0x3d4));}function submitQuiz(){const _0x114afa=_0x21a98a,_0x8ea5f8={'FxPXc':_0x114afa(0x249),'bfLIB':function(_0x513bd4,_0x170000){return _0x513bd4!==_0x170000;},'AYdqX':function(_0x43921d,_0x533d69){return _0x43921d!==_0x533d69;},'ZhrIP':_0x114afa(0x3c8),'bHwmh':'incorrect','tdQYj':function(_0x1df560,_0x3cc248){return _0x1df560(_0x3cc248);},'pcEFF':function(_0x14c622,_0x56b20){return _0x14c622(_0x56b20);},'RdqHx':_0x114afa(0x336),'dBeZq':function(_0x5d39dd,_0x325904){return _0x5d39dd-_0x325904;},'oWepH':_0x114afa(0x2dd),'MZtwT':function(_0x41bb24,_0x10adb8){return _0x41bb24-_0x10adb8;},'DpjPr':function(_0x35ef00,_0x5f10f9){return _0x35ef00+_0x5f10f9;},'NxlXF':function(_0x4f6839){return _0x4f6839();},'erWXm':function(_0x368cd5,_0x2aab6c,_0x3bd016,_0xbdf090,_0x52cc96){return _0x368cd5(_0x2aab6c,_0x3bd016,_0xbdf090,_0x52cc96);}};if(timer)_0x8ea5f8['tdQYj'](clearInterval,timer);if(!_0x8ea5f8['pcEFF'](confirm,_0x8ea5f8[_0x114afa(0x287)]))return;isQuizCompleted=!![];let _0x387063=0x0,_0x5b61b7=0x0;const _0x37f5e4=_0x8ea5f8[_0x114afa(0x326)](Date['now'](),quizStartTime);questionsData[_0x114afa(0x301)]((_0x3de041,_0x175221)=>{const _0x32fe7=_0x114afa,_0x5e33d4=questionStates[_0x175221];if(_0x8ea5f8[_0x32fe7(0x3ad)](_0x5e33d4[_0x32fe7(0x3f5)],null)){if(_0x8ea5f8['AYdqX'](_0x8ea5f8[_0x32fe7(0x33a)],_0x8ea5f8[_0x32fe7(0x33a)])){const _0x266689=_0x3fdf79[_0x32fe7(0x3e6)](_0x4c6daf['getItem'](_0x32fe7(0x249)))||{},_0xd02c10=_0x3a25de[_0x32fe7(0x376)],_0x593029=_0x184fcf[_0x32fe7(0x1af)]||0x0;_0x266689[_0x5ee22b]={'score':_0x593029,'total':_0xd02c10,'status':_0x32fe7(0x204),'completedOn':new _0x406a0a()[_0x32fe7(0x253)]()},_0x3e38d9['setItem'](_0x8ea5f8[_0x32fe7(0x31d)],_0x523439[_0x32fe7(0x262)](_0x266689));}else _0x3de041[_0x32fe7(0x126)][_0x5e33d4[_0x32fe7(0x3f5)]]['id']===_0x3de041[_0x32fe7(0x2e7)]?(_0x387063++,_0x5e33d4[_0x32fe7(0x116)]=_0x32fe7(0x320)):(_0x5b61b7++,_0x5e33d4['status']=_0x8ea5f8[_0x32fe7(0x239)]);}});const _0xb2a17e=JSON[_0x114afa(0x3e6)](localStorage[_0x114afa(0x1be)](_0x8ea5f8['oWepH']))||[];_0xb2a17e[_0x114afa(0x176)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x114afa(0x2c5)](),'totalTime':_0x37f5e4,'stats':{'correct':_0x387063,'incorrect':_0x5b61b7,'notAttempted':_0x8ea5f8['MZtwT'](questionsData[_0x114afa(0x376)],_0x8ea5f8['DpjPr'](_0x387063,_0x5b61b7))}}),localStorage[_0x114afa(0x1e4)](_0x114afa(0x2dd),JSON[_0x114afa(0x262)](_0xb2a17e)),stats['correctAnswers']=_0x387063,stats[_0x114afa(0x2d4)]=_0x5b61b7,_0x8ea5f8[_0x114afa(0x255)](markQuizAsCompleted),_0x8ea5f8[_0x114afa(0x215)](showPerformanceAnalysis,_0x387063,_0x5b61b7,questionsData[_0x114afa(0x376)]-_0x8ea5f8['DpjPr'](_0x387063,_0x5b61b7),_0x37f5e4);}function showPerformanceAnalysis(_0x35ce75,_0x47d2f1,_0x37079a,_0x34212d){const _0x5819cf=_0x21a98a,_0x22972e={'jfHXc':_0x5819cf(0x16b),'TYtKZ':function(_0x3d73bf,_0x2e337b){return _0x3d73bf>_0x2e337b;},'Ykuid':function(_0x21bc00,_0x2a51b7){return _0x21bc00+_0x2a51b7;},'DVsQG':function(_0x284e8c,_0x33174d){return _0x284e8c/_0x33174d;},'waqVk':function(_0x24d493,_0x3f3822){return _0x24d493*_0x3f3822;},'mDwJp':function(_0x4a4aee,_0x2c14ad){return _0x4a4aee-_0x2c14ad;},'nPHju':_0x5819cf(0x1ce),'OkLlo':_0x5819cf(0x26e),'aXiHL':_0x5819cf(0x2eb),'LOpvM':_0x5819cf(0x15d),'XZGiG':_0x5819cf(0x280),'zAHHl':function(_0x50d086,_0x442319){return _0x50d086/_0x442319;},'opyPe':function(_0x391e9c,_0x584f24){return _0x391e9c%_0x584f24;},'RFqkC':_0x5819cf(0x346),'Zqfze':function(_0x1e0df1,_0x14b213){return _0x1e0df1/_0x14b213;},'sWKxQ':function(_0x2da6c6,_0x50f524){return _0x2da6c6/_0x50f524;},'fIiwd':'hidden'},_0x1ae331=document[_0x5819cf(0x137)](_0x22972e[_0x5819cf(0x2b0)]),_0x582352=_0x22972e[_0x5819cf(0x14d)](_0x22972e[_0x5819cf(0x302)](_0x35ce75,_0x47d2f1),0x0)?Math[_0x5819cf(0x3b7)](_0x22972e[_0x5819cf(0x3b4)](_0x35ce75,_0x22972e[_0x5819cf(0x302)](_0x35ce75,_0x47d2f1))*0x64):0x0,_0x59075c=_0x22972e[_0x5819cf(0x2e4)](0x2*Math['PI'],0x41),_0x1b37da=document[_0x5819cf(0x137)](_0x5819cf(0x3ca));_0x1b37da[_0x5819cf(0x13d)][_0x5819cf(0x2a1)]=_0x59075c+'\x20'+_0x59075c,_0x1b37da[_0x5819cf(0x13d)]['strokeDashoffset']=_0x22972e[_0x5819cf(0x1ff)](_0x59075c,_0x22972e['waqVk'](_0x22972e['DVsQG'](_0x582352,0x64),_0x59075c)),document[_0x5819cf(0x137)](_0x22972e[_0x5819cf(0x23e)])[_0x5819cf(0x1a0)]=_0x582352+'%',document['getElementById'](_0x22972e[_0x5819cf(0x380)])['textContent']=questionsData['length'],document[_0x5819cf(0x137)](_0x22972e[_0x5819cf(0x38d)])[_0x5819cf(0x1a0)]=_0x35ce75,document[_0x5819cf(0x137)](_0x22972e[_0x5819cf(0x31f)])[_0x5819cf(0x1a0)]=_0x47d2f1,document['getElementById'](_0x22972e[_0x5819cf(0x2f6)])[_0x5819cf(0x1a0)]=_0x37079a;const _0x5b730f=Math[_0x5819cf(0x237)](_0x22972e['zAHHl'](_0x34212d,0xea60)),_0x5f5994=Math['floor'](_0x22972e['opyPe'](_0x34212d,0xea60)/0x3e8);document['getElementById'](_0x22972e[_0x5819cf(0x1fb)])[_0x5819cf(0x1a0)]=_0x5b730f+':'+_0x5f5994['toString']()['padStart'](0x2,'0');const _0x265485=_0x22972e['DVsQG'](_0x34212d,questionsData[_0x5819cf(0x376)]),_0xf3c10=Math[_0x5819cf(0x237)](_0x22972e['Zqfze'](_0x265485,0xea60)),_0x5c0515=Math[_0x5819cf(0x237)](_0x22972e[_0x5819cf(0x3bd)](_0x22972e[_0x5819cf(0x221)](_0x265485,0xea60),0x3e8));document[_0x5819cf(0x137)](_0x5819cf(0x119))['textContent']=_0xf3c10+':'+_0x5c0515[_0x5819cf(0x13b)]()[_0x5819cf(0x1d9)](0x2,'0'),_0x1ae331[_0x5819cf(0x364)][_0x5819cf(0x12b)](_0x22972e[_0x5819cf(0x1f6)]);}function closePerformanceModal(){const _0x43a4e8=_0x21a98a,_0x165e64={'KKFCQ':_0x43a4e8(0x3d4)};document[_0x43a4e8(0x137)]('performanceModal')[_0x43a4e8(0x364)][_0x43a4e8(0x338)](_0x165e64[_0x43a4e8(0x381)]);}function reviewQuestions(){const _0x417e0c=_0x21a98a,_0x264d08={'grtXh':_0x417e0c(0x24a),'CceaL':_0x417e0c(0x252),'nyaOA':function(_0x34702c){return _0x34702c();},'IsZdL':_0x417e0c(0x227),'TToEw':function(_0x250e2b,_0x4824af){return _0x250e2b===_0x4824af;},'DMlBI':_0x417e0c(0x2b2),'juHqi':_0x417e0c(0x286),'kkxAV':function(_0x1a4c79,_0x46733b){return _0x1a4c79===_0x46733b;},'ArFoh':_0x417e0c(0x372),'UtxRG':'not-attempted','GtwSl':function(_0x31a67c,_0x5b9a6a){return _0x31a67c!==_0x5b9a6a;},'ooTFB':_0x417e0c(0x320),'HhEmb':'Correct','nERcF':_0x417e0c(0x21a),'XNKkj':'div','XawnO':function(_0x259ef9,_0x53513d){return _0x259ef9+_0x53513d;},'IIveB':'green','hcDyN':function(_0x3c19d6,_0x19a627){return _0x3c19d6===_0x19a627;},'TRhQB':_0x417e0c(0x3bf),'PdwJv':_0x417e0c(0x11c),'cZuVj':_0x417e0c(0x1f9),'lCyVr':_0x417e0c(0x3d4),'zbIMs':_0x417e0c(0x37b),'gLngG':function(_0x22a5bb){return _0x22a5bb();}};document[_0x417e0c(0x137)](_0x417e0c(0x127))[_0x417e0c(0x364)][_0x417e0c(0x12b)](_0x264d08[_0x417e0c(0x123)]);const _0x42b382=document[_0x417e0c(0x137)](_0x264d08[_0x417e0c(0x28c)]);_0x42b382[_0x417e0c(0x2a9)]='',questionsData[_0x417e0c(0x301)]((_0x2d1761,_0x286254)=>{const _0x529b16=_0x417e0c,_0x4972ac={'bxBBm':_0x264d08[_0x529b16(0x1fe)],'yXfqS':_0x264d08[_0x529b16(0x379)],'iaVxK':function(_0x3a9019){const _0x5266e4=_0x529b16;return _0x264d08[_0x5266e4(0x29d)](_0x3a9019);},'FjlIl':_0x264d08[_0x529b16(0x1f3)],'apNmC':function(_0x593bef,_0x10b4c7){const _0x371eec=_0x529b16;return _0x264d08[_0x371eec(0x160)](_0x593bef,_0x10b4c7);},'VsEgR':function(_0x35eead,_0x1d3a72){const _0x4f24a0=_0x529b16;return _0x264d08[_0x4f24a0(0x160)](_0x35eead,_0x1d3a72);},'ICHiq':_0x264d08[_0x529b16(0x3c3)],'fFyov':_0x264d08[_0x529b16(0x1e3)],'fUlGR':function(_0x54a697,_0x30f8c4){return _0x54a697+_0x30f8c4;}};if(_0x264d08[_0x529b16(0x3e5)](_0x264d08['ArFoh'],_0x529b16(0x2fe)))_0x508614()?(_0x5bf1e6['getElementById'](_0x4972ac[_0x529b16(0x3c6)])[_0x529b16(0x13d)][_0x529b16(0x2a4)]=_0x4972ac[_0x529b16(0x360)],_0x4c40e1()):(_0x4972ac['iaVxK'](_0x39000d),_0x313ff6[_0x529b16(0x137)](_0x4972ac['bxBBm'])['style'][_0x529b16(0x2a4)]=_0x4972ac[_0x529b16(0x1c1)]);else{const _0x2e374b=questionStates[_0x286254],_0x576e57=_0x2d1761['correct_choice_id'];let _0x1439d1=_0x264d08[_0x529b16(0x1ca)],_0x4c7f0e=_0x529b16(0x1ad);if(_0x264d08[_0x529b16(0x339)](_0x2e374b[_0x529b16(0x3f5)],null)){const _0x441205=_0x2d1761[_0x529b16(0x126)][_0x2e374b[_0x529b16(0x3f5)]];_0x441205['id']===_0x576e57?(_0x1439d1=_0x264d08[_0x529b16(0x369)],_0x4c7f0e=_0x264d08[_0x529b16(0x1d5)]):(_0x1439d1=_0x529b16(0x3bf),_0x4c7f0e=_0x264d08['nERcF']);}const _0x295a36=document['createElement'](_0x264d08['XNKkj']);_0x295a36[_0x529b16(0x270)]=_0x529b16(0x3a0)+_0x1439d1;let _0x578c28=(_0x2d1761[_0x529b16(0x126)]||[])[_0x529b16(0x173)]((_0xeb0608,_0x572000)=>{const _0x3b106c=_0x529b16,_0x6117a3=_0x4972ac['apNmC'](_0x2e374b[_0x3b106c(0x3f5)],_0x572000),_0x413710=_0x4972ac['VsEgR'](_0xeb0608['id'],_0x576e57);let _0x3f1d45=_0x4972ac[_0x3b106c(0x171)];if(_0x413710)_0x3f1d45=_0x3b106c(0x264);else{if(_0x6117a3)_0x3f1d45=_0x4972ac[_0x3b106c(0x34c)];}return _0x3b106c(0x22f)+_0x3f1d45+_0x3b106c(0x3e4)+String[_0x3b106c(0x312)](_0x4972ac['fUlGR'](0x41,_0x572000))+_0x3b106c(0x183)+_0xeb0608[_0x3b106c(0x388)]+'</span></div>';})[_0x529b16(0x27f)]('');const _0x21430b=_0x2d1761[_0x529b16(0x343)]?'<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-'+_0x286254+_0x529b16(0x1db)+_0x2d1761[_0x529b16(0x343)]+_0x529b16(0x18c):'';let _0x2c1218='';if(_0x2d1761[_0x529b16(0x3a9)])_0x2c1218+=_0x529b16(0x1a7)+_0x2d1761['explanation_audio_eng']+_0x529b16(0x36c);if(_0x2d1761[_0x529b16(0x389)])_0x2c1218+=_0x529b16(0x291)+_0x2d1761[_0x529b16(0x389)]+_0x529b16(0x36c);let _0x1ac4eb=(_0x2d1761['explanation_images']||[])['map'](_0x6b5661=>_0x6b5661?_0x529b16(0x230)+_0x6b5661+_0x529b16(0x251):'')[_0x529b16(0x27f)]('');_0x295a36['innerHTML']='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20'+_0x264d08[_0x529b16(0x12c)](_0x286254,0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x1439d1===_0x264d08[_0x529b16(0x369)]?_0x264d08['IIveB']:_0x264d08['hcDyN'](_0x1439d1,_0x264d08[_0x529b16(0x1c5)])?_0x264d08[_0x529b16(0x3d2)]:_0x529b16(0x3d7))+_0x529b16(0x241)+_0x4c7f0e+_0x529b16(0x1ed)+_0x2d1761[_0x529b16(0x388)]+_0x529b16(0x1c7)+_0x578c28+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>'+(_0x2d1761[_0x529b16(0x3e9)]||_0x264d08[_0x529b16(0x271)])+_0x529b16(0x1a8)+_0x21430b+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x2c1218+_0x529b16(0x14a)+_0x1ac4eb+_0x529b16(0x3f4),_0x42b382[_0x529b16(0x229)](_0x295a36);}}),_0x264d08[_0x417e0c(0x246)](initializeReviewVideos);}function initializeReviewVideos(){const _0x826220=_0x21a98a,_0x52977a={'zjNra':_0x826220(0x26b),'nXcnT':function(_0x1cb5e6,_0x1160ee,_0x5b80f0){return _0x1cb5e6(_0x1160ee,_0x5b80f0);},'JxJMc':_0x826220(0x1f5)};document[_0x826220(0x113)](_0x52977a['JxJMc'])[_0x826220(0x301)](_0x5bd245=>{const _0x3b1c2d=_0x826220,_0x3832ed=_0x5bd245[_0x3b1c2d(0x2f1)]['src'];if(_0x3832ed&&_0x3832ed[_0x3b1c2d(0x190)](_0x52977a[_0x3b1c2d(0x36e)]))_0x52977a[_0x3b1c2d(0x2ee)](setupVideo,_0x5bd245,_0x3832ed);else _0x3832ed&&(_0x5bd245[_0x3b1c2d(0x125)]=_0x3832ed);});}function retakeQuiz(){const _0xa536e6=_0x21a98a,_0x1b308b={'JvWxW':_0xa536e6(0x13a),'MnqxW':_0xa536e6(0x120),'eZKlT':_0xa536e6(0x16a),'dIiBa':function(_0x71ea7c,_0x4eb794){return _0x71ea7c(_0x4eb794);},'mfnBg':function(_0x13a1da,_0x1a2b50){return _0x13a1da(_0x1a2b50);},'AYveW':function(_0x3825d0,_0x52af2e){return _0x3825d0+_0x52af2e;},'RRLlN':_0xa536e6(0x193),'iEgqZ':_0xa536e6(0x179),'iEflC':function(_0x8748d8,_0x51a41e){return _0x8748d8+_0x51a41e;},'qwFkJ':_0xa536e6(0x147),'ZtuJy':function(_0x544283,_0x498c5b){return _0x544283===_0x498c5b;},'IjuiV':'ctALT','tMzUh':_0xa536e6(0x182),'vYtep':function(_0x1654b2,_0x258d79){return _0x1654b2!==_0x258d79;},'qQnxV':_0xa536e6(0x1c9),'xwDLp':_0xa536e6(0x29b),'WwDaS':function(_0x105323){return _0x105323();}};if(_0x1b308b[_0xa536e6(0x25c)](confirm,'Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.')){if(_0x1b308b['ZtuJy'](_0x1b308b[_0xa536e6(0x217)],_0x1b308b[_0xa536e6(0x217)])){if(window['location'][_0xa536e6(0x27c)]['endsWith'](_0x1b308b['tMzUh'])){if(_0x1b308b['vYtep'](_0x1b308b['qQnxV'],_0x1b308b[_0xa536e6(0x17a)])){_0x469cb1[_0xa536e6(0x137)](_0x1b308b[_0xa536e6(0x3be)])[_0xa536e6(0x2a9)]=_0x1b308b[_0xa536e6(0x212)];return;}else localStorage['removeItem'](_0x1b308b['xwDLp']);}_0x1b308b[_0xa536e6(0x1ef)](clearProgress),location[_0xa536e6(0x2a8)]();}else{const _0x39011a={'OMgSh':function(_0x38eb20,_0x1f92f3){const _0x48ef09=_0xa536e6;return _0x1b308b[_0x48ef09(0x3ee)](_0x38eb20,_0x1f92f3);},'YQlXg':function(_0x1a86d3,_0xc6836e){return _0x1a86d3===_0xc6836e;},'sagUU':_0x1b308b[_0xa536e6(0x1a6)],'XCxNj':_0x1b308b[_0xa536e6(0x220)],'nlCOO':function(_0x6ece4f,_0x3f91f0){const _0x45b214=_0xa536e6;return _0x1b308b[_0x45b214(0x303)](_0x6ece4f,_0x3f91f0);}};_0x333c87[_0xa536e6(0x126)]['forEach']((_0x11a446,_0x433677)=>{const _0x2ba561=_0xa536e6,_0x568b92=_0x385185[_0x2ba561(0x312)](_0x39011a[_0x2ba561(0x257)](0x41,_0x433677)),_0x15d3e6=_0x39011a[_0x2ba561(0x195)](_0x508c97,_0x433677),_0x6d2482=_0x252016[_0x2ba561(0x1c3)](_0x2ba561(0x2d1));_0x6d2482[_0x2ba561(0x2a9)]='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20'+(_0x15d3e6?_0x39011a[_0x2ba561(0x3f2)]:'')+'\x22\x20data-option-index=\x22'+_0x433677+_0x2ba561(0x32c)+_0x568b92+_0x2ba561(0x278)+(_0x11a446[_0x2ba561(0x388)]||_0x39011a['OMgSh'](_0x39011a[_0x2ba561(0x29e)],_0x39011a[_0x2ba561(0x28f)](_0x433677,0x1)))+_0x2ba561(0x202),_0x42f92a[_0x2ba561(0x229)](_0x6d2482);}),_0x549879['addEventListener'](_0x1b308b[_0xa536e6(0x3cb)],function(_0x4038e0){const _0x428a25=_0xa536e6,_0x4be046=_0x4038e0[_0x428a25(0x1d7)][_0x428a25(0x308)](_0x1b308b[_0x428a25(0x2bc)]);if(_0x4be046){const _0x18c1b1=_0x1b308b[_0x428a25(0x25c)](_0x366b52,_0x4be046['getAttribute']('data-option-index'));_0x1b308b[_0x428a25(0x3eb)](_0x525b01,_0x18c1b1);}});}}}function loadBookmarkedQuestions(){const _0x202f22=_0x21a98a,_0x1055e6={'AbXmF':function(_0x5c0a36){return _0x5c0a36();},'qqZmf':function(_0x350af4,_0x2f8012){return _0x350af4===_0x2f8012;},'YAeks':_0x202f22(0x21e),'nHuQP':'JeYZx','cLERp':function(_0x12775d,_0x2b5618){return _0x12775d!==_0x2b5618;},'VGcXa':_0x202f22(0x34f),'BQrwa':function(_0x30ee6c,_0x1c07ca){return _0x30ee6c<_0x1c07ca;},'SusCa':_0x202f22(0x3c4)},_0x59eacc=JSON[_0x202f22(0x3e6)](localStorage['getItem'](_0x1055e6['SusCa']))||[];_0x59eacc[_0x202f22(0x301)](_0xec1082=>{const _0x322cad=_0x202f22,_0x23aaa5={'tjsGv':function(_0x14c808){return _0x1055e6['AbXmF'](_0x14c808);}};_0x1055e6[_0x322cad(0x30d)](_0x1055e6[_0x322cad(0x244)],_0x1055e6[_0x322cad(0x134)])?_0x4347aa=_0x470c7b['filter'](_0x298ec0=>!(_0x298ec0[_0x322cad(0x2b3)]['includes'](_0x11a9ab[_0x322cad(0x27b)]()[_0x322cad(0x131)](/ /g,'-'))&&_0x298ec0[_0x322cad(0x186)]===_0xba00bb)):_0xec1082[_0x322cad(0x2b3)]['includes'](quizName['toLowerCase']()['replace'](/ /g,'-'))&&(_0x1055e6[_0x322cad(0x115)]('sUHPT',_0x1055e6[_0x322cad(0x332)])?_0x1055e6[_0x322cad(0x33d)](_0xec1082[_0x322cad(0x186)],questionsData[_0x322cad(0x376)])&&(questionStates[_0xec1082[_0x322cad(0x186)]]['bookmarked']=!![]):_0x23aaa5[_0x322cad(0x2df)](_0x50e135));});}function toggleBookmark(){const _0x45821a=_0x21a98a,_0x3eff92={'yVrxw':function(_0x54f923,_0xb12e34){return _0x54f923<_0xb12e34;},'PXqBx':_0x45821a(0x3c4),'DpDMc':function(_0x44f8f3,_0x3d5dba){return _0x44f8f3===_0x3d5dba;},'edrWP':_0x45821a(0x2fa),'ZbPMn':function(_0xb97722){return _0xb97722();}},_0x13140b=!questionStates[currentQuestionIndex][_0x45821a(0x1ac)];questionStates[currentQuestionIndex]['bookmarked']=_0x13140b;let _0x29aff7=JSON[_0x45821a(0x3e6)](localStorage[_0x45821a(0x1be)](_0x3eff92['PXqBx']))||[];if(_0x13140b){if(_0x3eff92[_0x45821a(0x32f)](_0x3eff92['edrWP'],_0x3eff92[_0x45821a(0x165)])){const _0x520f03={'quizName':quizName,'quizFile':window[_0x45821a(0x307)][_0x45821a(0x27c)][_0x45821a(0x2b5)]('/')[_0x45821a(0x34a)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x45821a(0x2c5)]()};_0x29aff7['push'](_0x520f03);}else{const _0x4e2835=_0x25d45c[_0x45821a(0x3e6)](_0x398735[_0x45821a(0x1be)](_0x3eff92[_0x45821a(0x2a2)]))||[];_0x4e2835[_0x45821a(0x301)](_0x3a9149=>{const _0x17856d=_0x45821a;_0x3a9149[_0x17856d(0x2b3)][_0x17856d(0x190)](_0x2978d2[_0x17856d(0x27b)]()[_0x17856d(0x131)](/ /g,'-'))&&(_0x3eff92['yVrxw'](_0x3a9149[_0x17856d(0x186)],_0x58f2b8['length'])&&(_0x46fb0b[_0x3a9149[_0x17856d(0x186)]][_0x17856d(0x1ac)]=!![]));});}}else _0x29aff7=_0x29aff7[_0x45821a(0x2b6)](_0x303987=>!(_0x303987[_0x45821a(0x2b3)]['includes'](quizName[_0x45821a(0x27b)]()[_0x45821a(0x131)](/ /g,'-'))&&_0x303987['questionIndex']===currentQuestionIndex));localStorage[_0x45821a(0x1e4)](_0x3eff92[_0x45821a(0x2a2)],JSON[_0x45821a(0x262)](_0x29aff7)),_0x3eff92['ZbPMn'](updateBookmarkButton),updateQuestionNav();}function updateBookmarkButton(){const _0x11cbc6=_0x21a98a,_0x1aaa52={'PrnXI':'bookmarkText','MKYYz':_0x11cbc6(0x22b),'KiIXQ':_0x11cbc6(0x39e),'PUePM':'Bookmark'},_0x351953=document[_0x11cbc6(0x137)]('bookmarkBtn'),_0x2a3273=document[_0x11cbc6(0x137)](_0x1aaa52[_0x11cbc6(0x194)]),_0x4b8459=questionStates[currentQuestionIndex][_0x11cbc6(0x1ac)];_0x351953['className']=_0x4b8459?'gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center':_0x1aaa52['MKYYz'],_0x2a3273[_0x11cbc6(0x1a0)]=_0x4b8459?_0x1aaa52['KiIXQ']:_0x1aaa52[_0x11cbc6(0x386)];}function toggleMarkForReview(){const _0x444651=_0x21a98a,_0x251252={'tUNfU':function(_0x4bf87a){return _0x4bf87a();}};questionStates[currentQuestionIndex][_0x444651(0x28e)]=!questionStates[currentQuestionIndex][_0x444651(0x28e)],updateMarkReviewButton(),_0x251252[_0x444651(0x3ed)](updateQuestionNav);}function _0x13ef(){const _0x9dccc3=['PHfpi','cVfZc','oKJys','customQuizData','<p>Category\x20A,\x20B,\x20C,\x20D,\x20X\x20in\x20drug\x20classification\x20are\x20indicative\x20of\x20their\x20safety\x20in\x20pregnancy.</p>\x0a<p>The\x20united\x20states\x20food\x20and\x20drug\x20administration\x20(FDA)\x20system\x20for\x20teratogenic\x20potential\x20attempts\x20to\x20quantify\x20teratogenic\x20risk\x20from\x20category\x20A\x20(safe)\x20to\x20category\x20X\x20(definite\x20human\x20teratogenic\x20risk).</p>\x0a<p><strong>Category\x20A</strong>:\x20The\x20possibility\x20of\x20fetal\x20<strong>harm</strong>\x20is\x20<strong>remote</strong>\x20and\x20studies\x20in\x20women\x20have\x20failed\x20to\x20demonstrate\x20any\x20evidence\x20of\x20risk\x20to\x20the\x20fetus.\x20Examples:\x20doxylamine,\x20folic\x20acid,\x20levothyroxine.</p>\x0a<p><strong>Category\x20B</strong>:&nbsp;Either\x20animal-reproduction\x20studies\x20have\x20not\x20demonstrated\x20a\x20fetal\x20risk,\x20but\x20there\x20are\x20no\x20controlled\x20studies\x20in\x20pregnant\x20women,\x20or\x20animal-reproduction\x20studies\x20have\x20shown\x20an\x20adverse\x20effect\x20that\x20was\x20not\x20confirmed\x20in\x20controlled\x20studies\x20in\x20pregnant\x20women.\x20Example:\x20Amoxicillin,\x20loratadine,\x20ondansetron.</p>\x0a<p><strong>Category\x20C</strong>:&nbsp;Either\x20studies\x20in\x20animals\x20have\x20revealed\x20adverse\x20effects\x20on\x20the\x20fetus,\x20that\x20is,\x20teratogenic\x20or\x20embryocidal\x20but\x20there\x20are\x20no\x20controlled\x20studies\x20in\x20women,\x20or\x20studies\x20in\x20women\x20and\x20animals\x20are\x20not\x20available.\x20These\x20drugs\x20should\x20be\x20given\x20only\x20if\x20the\x20potential\x20benefit\x20justifies\x20the\x20potential\x20risk\x20to\x20the\x20fetus.\x20Example:\x20fluconazole,\x20metoprolol,\x20sertraline.</p>\x0a<p><strong>Category\x20D</strong>:&nbsp;Though\x20there\x20is\x20evidence\x20of\x20human\x20fetal\x20risk,\x20the\x20benefits\x20from\x20use\x20in\x20pregnant\x20women\x20may\x20be\x20acceptable\x20despite\x20the\x20risk,\x20for\x20example,\x20if\x20the\x20drug\x20is\x20needed\x20in\x20a\x20life-threatening\x20situation\x20or\x20for\x20a\x20disease\x20for\x20which\x20safer\x20drugs\x20cannot\x20be\x20used\x20or\x20are\x20ineffective.\x20Example:\x20lisinopril,\x20lithium,\x20phenytoin.</p>\x0a<p><strong>Category\x20X</strong>:\x20There\x20is\x20evidence\x20of\x20fetal\x20risk\x20based\x20on\x20human\x20or\x20animal\x20experience\x20and\x20the\x20risk\x20of\x20the\x20use\x20of\x20the\x20drug\x20in\x20pregnant\x20women\x20clearly\x20outweighs\x20any\x20possible\x20benefit.\x20The\x20<strong>drug</strong>\x20is\x20<strong>contraindicated</strong>\x20in\x20women\x20who\x20are\x20or\x20may\x20become\x20pregnant.\x20Example:\x20methotrexate,\x20simvastatin,\x20warfarin.</p>\x0a<p>&nbsp;</p>','nyaOA','XCxNj','GRMhd','2073753MuZbTF','strokeDasharray','PXqBx','BMYPF','display','FQnqU','oAEXy','Gonorrhea','reload','innerHTML','fmWAm','nav-btn-marked-review','qnLje','isArray','cCuid','evfbU','jfHXc','MJMKp','border-gray-600','quizFile','Adequate\x20safety\x20profile\x20needs\x20to\x20be\x20established','split','filter','totalTime','yJLWD','xqsFY','DadkQ','Cimetidine','eZKlT','HRome','Resistant\x20Parkinson\x27s\x20disease','HRLFC','CBdJf','Buspirone\x20SR','PJdGV','What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20cyclosporine?','A\x20patient\x20who\x20was\x20on\x20warfarin\x20therapy\x20for\x20atrial\x20fibrillation\x20is\x20prescribed\x20a\x20cephalosporin\x20antibiotic\x20for\x20the\x20treatment\x20of\x20a\x20lower\x20respiratory\x20tract\x20infection.\x20He\x20reports\x20back\x20to\x20the\x20hospital\x20after\x20having\x20developed\x20hemarthrosis.\x20Which\x20of\x20the\x20following\x20cephalosporins\x20is\x20likely\x20to\x20have\x20caused\x20this?','now','1,\x202\x20and\x203','RNA-dependent\x20DNA\x20polymerase\x20inhibition','contains','Which\x20of\x20the\x20following\x20is\x20incorrectly\x20matched?','eMtZy','search','OsAFV','incomplete','index.html','Stop\x20retigabine\x20and\x20start\x20on\x20carbamazepine','AxONV','div','apply','timed_exam','incorrectAnswers','SxFcI','NaDlV','itJjM','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','Which\x20of\x20the\x20following\x20is\x20false\x20about\x20the\x20selection\x20of\x20essential\x20drugs?','VYxWD','Imecm','yWTIp','quizPerformanceData','bookmarkBtn','tjsGv','Chlorthalidone','Ritonavir','MagoC','XgGKD','waqVk','Ceftobiprole','Topiramate\x20is\x20used\x20for','correct_choice_id','Hydrochlorothiazide','Half\x20life\x20and\x20plasma\x20concentration\x20doubles','CrwsZ','correctResult','Category\x20A,\x20B,\x20C,\x20D,\x20X\x20in\x20drug\x20classification\x20are\x20indicative\x20of\x20which\x20of\x20the\x20following?','https://cdn1.dailyrounds.org/uploads/941c257ca30f4a91994ba614ee06e0f8.JPEG','nXcnT','zfvkX','Dementia','dataset','>20\x20mcg/kg/min','constructor','EDTA','AMJbo','XZGiG','Herniated\x20disc','Liraglutide','Downregulation\x20of\x20CYP2D6','hCtwI','Metformin','A\x20patient\x20with\x20history\x20of\x20ischemic\x20stroke\x20was\x20started\x20on\x20clopidogrel.\x20However,\x20she\x20had\x20another\x20attack\x20of\x20stroke\x20after\x206\x20months.\x20Which\x20of\x20the\x20following\x20is\x20likely\x20to\x20be\x20responsible\x20for\x20the\x20failure\x20of\x20clopidogrel\x20in\x20this\x20patient?','lzWBK','qsnQa','cduKu','EwTsp','forEach','Ykuid','iEflC','FQBOQ','sxdmO','GSkFQ','location','closest','VUNVP','Cost\x20ratio\x20from\x20cheap\x20to\x20expensive','statsBar','yRjOH','qqZmf','navBtn_','PWvAB','Safety\x20in\x20pregnancy','HplWi','fromCharCode','aQXIZ','13.8\x20hours','Varenicline','ZPwGX','IQxMY','AfeBh','bBFLf','Malaria','accuracy','zsDKI','FxPXc','<p>In\x20this\x20case,\x20the\x20<strong>half-life\x20remains\x20the\x20same,\x20and\x20the\x20plasma\x20concentration\x20doubles.</strong></p>\x0a<p><strong>Half-life\x20is\x20constant</strong>\x20in\x20drugs\x20following\x20<strong>first-order\x20kinetic</strong>s\x20irrespective\x20of\x20the\x20dose\x20as\x20a\x20constant\x20fraction\x20of\x20the\x20drug\x20is\x20eliminated\x20per\x20unit\x20time.</p>\x0a<p>The\x20plasma\x20concentration\x20of\x20the\x20drug\x20increases\x20when\x20the\x20dose\x20given\x20is\x20increased.\x20In\x20this\x20case,\x20as\x20the\x20drug\x20dose\x20is\x20doubled\x20plasma\x20concentration\x20is\x20also\x20doubled.</p>','LOpvM','correct','CVTcD','notAttempted','Amiodarone','zuPSP','block','dBeZq','Which\x20of\x20the\x20following\x20can\x20be\x20given\x20for\x20long\x20term\x20management\x20of\x20obesity?','tnIVs','data-option-index','qYdPS','<p>The\x20<strong>half-life</strong>\x20of\x20the\x20given\x20drug\x20is\x20<strong>13.8\x20hours</strong>.</p>\x0a<p>The\x20half-life\x20of\x20a\x20drug\x20or&nbsp;<strong>t<sub>1/2</sub></strong>\x20is\x20the\x20time\x20taken\x20for\x20the\x20<strong>plasma\x20concentration</strong>\x20to\x20be\x20<strong>reduced\x20by\x2050%</strong>.\x20The\x20<strong>elimination\x20rate\x20constant</strong>\x20or<strong>&nbsp;k\x20value</strong>\x20of\x20a\x20drug\x20reflects\x20the\x20<strong>fraction\x20of\x20drug\x20removed</strong>\x20from\x20the\x20body\x20compartment\x20per\x20unit\x20of\x20time.</p>\x0a<p\x20style=\x22text-align:\x20left;\x22>The\x20half-life\x20of\x20a\x20drug\x20and\x20its\x20elimination\x20rate\x20constant\x20are\x20inversely\x20proportional\x20to\x20each\x20other.\x20They\x20are\x20represented\x20by\x20the\x20equation:&nbsp;</p>\x0a<p\x20style=\x22text-align:\x20left;\x22><strong>k\x20t<sub>1/2</sub>&nbsp;=&nbsp;\x200.693</strong></p>\x0a<p\x20style=\x22text-align:\x20left;\x22>Therefore,\x20<strong>t<sub>1/2</sub>\x20=\x200.693/\x20k</strong></p>\x0a<p>The\x20given\x20value\x20for\x20elimination\x20rate\x20constant\x20<strong>\x20is\x200.05</strong>,\x20therefore\x20the\x20half-life\x20of\x20the\x20given\x20drug\x20would\x20be:</p>\x0a<p>&nbsp;<strong>0.693/\x200.05\x20=\x2013.8</strong></p>\x0a<p>Therefore,\x20the\x20half-life\x20of\x20the\x20drug\x20would\x20be\x2013.8\x20hours.</p>','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','<p>Paradoxical\x20bronchoconstriction\x20with\x20ipratropium\x20bromide\x20is\x20seen\x20with\x20a\x20<strong>hypotonic\x20nebulizer\x20solution</strong>\x20and\x20not\x20hypertonic\x20saline.</p>\x0a<p>Paradoxical\x20bronchoconstriction\x20with\x20ipratropium\x20bromide\x20is\x20seen\x20especially\x20when\x20<strong>given\x20by\x20a\x20nebulizer</strong>\x20and\x20may\x20be\x20due\x20to\x20the\x20following\x20factors:</p>\x0a<ul>\x0a<li><strong>Hypotonic</strong>\x20nebulizer\x20solution</li>\x0a<li>Antibacterial\x20additives\x20like\x20<strong>benzalkonium\x20chloride</strong>\x20and\x20<strong>EDTA</strong></li>\x0a<li>It\x20may\x20be\x20also\x20due\x20to\x20<strong>prejunctional\x20M2\x20receptor\x20blockade</strong>\x20on\x20the\x20cholinergic\x20nerves\x20present\x20in\x20the\x20airway.\x20These\x20prejunctional\x20M2\x20receptors\x20normally\x20inhibit\x20acetylcholine\x20release\x20into\x20the\x20synapse.\x20So\x20their\x20blockade\x20can\x20cause\x20increased\x20Ach\x20release\x20and\x20bronchoconstriction.</li>\x0a</ul>\x0a<p>Paradoxical\x20bronchoconstriction\x20is\x20<strong>not\x20reported\x20with\x20tiotropium\x20bromide</strong>\x20or\x20any\x20other\x20long-acting\x20muscarinic\x20antagonists.\x20Tiotropium\x20is\x20<strong>selective</strong>\x20for<strong>\x20M3</strong>\x20and\x20<strong>M1</strong>\x20receptors\x20and\x20therefore\x20less\x20likely\x20to\x20produce\x20prejunctional\x20M2\x20receptor\x20blockade.</p>\x0a<p>Other\x20adverse\x20effects\x20of\x20inhaled\x20muscarinic\x20antagonists:</p>\x0a<ul>\x0a<li>A\x20bitter\x20taste\x20is\x20seen\x20with\x20ipratropium</li>\x0a<li>Nebulization\x20with\x20ipratropium\x20bromide\x20may\x20<strong>precipitate\x20glaucoma</strong>\x20in\x20elderly\x20patients.\x20This\x20is\x20due\x20to\x20the\x20direct\x20effect\x20of\x20the\x20drug\x20on\x20the\x20eyes\x20and\x20can\x20be\x20easily\x20prevented\x20by\x20using\x20a\x20mouthpiece\x20instead\x20of\x20a\x20facemask.</li>\x0a<li>Long-acting\x20agents\x20can\x20cause\x20dryness\x20of\x20the\x20mouth.&nbsp;</li>\x0a<li>In\x20elderly\x20patients,\x20<strong>urinary\x20retention</strong>\x20may\x20be\x20seen\x20occasionally.</li>\x0a</ul>','AMP\x20kinase\x20stimulation','DpDMc','RlfLu','question_audio','VGcXa','get','BZDCk','vXIXc','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','12gHiimt','add','GtwSl','ZhrIP','40033cQOFtY','Which\x20of\x20the\x20following\x20steps\x20does\x20Vancomycin\x20act\x20on?','BQrwa','LPKGE','Nicotine\x20gum','FQMub','Downregulation\x20of\x20CYP2C19','imKyB','explanation_video','Anionic\x20and\x20weakly\x20acidic\x20drugs\x20bind\x20to\x20which\x20of\x20the\x20following?','jwnSA','totalTimeResult','Nefnd','true','Inhibits\x20negative\x20feedback\x20on\x20GnRH','pop','Drug\x20A\x20increases\x20the\x20metabolism\x20of\x20Drug\x20B','fFyov','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','SKNin','RcaCi','Sibutramine','AfQbD','explanation_images','Andexanet\x20alfa:\x20Rivaroxaban','Xobre','questions','Retinoblastoma','solutionText','Cefoperazone','GQfyM','LQzYc','zYAUl','submitSection','xTMPQ','fymRM','<p>The\x20probable\x20reason\x20why\x20the\x20drug\x20to\x20be\x20administered\x20was\x20changed\x20from\x20ampicillin\x20to\x20ceftriaxone\x20is\x20because&nbsp;Hemophilus\x20produces\x20<strong>beta-lactamase</strong>\x20and\x20hence,\x20is\x20resistant\x20to\x20ampicillin.</p>\x0a<p>A\x20considerable\x20percentage\x20of\x20isolates\x20of&nbsp;<em>Hemophilus\x20influenzae</em>\x20produce\x20beta-lactamase,\x20rendering\x20them\x20resistant\x20to\x20<strong>ampicillin</strong>,\x20a\x20beta-lactam\x20antibiotic.\x20However,\x20these\x20strains\x20are\x20still\x20sensitive\x20to\x20second\x20and\x20third-generation\x20cephalosporins.</p>\x0a<p>In&nbsp;<em>H.\x20influenzae</em>,\x20the\x20resistance\x20to\x20ampicillin\x20and\x20other\x20&beta;-lactam\x20antibiotics\x20is\x20generally\x20due\x20to\x20the\x20production\x20of\x20a\x20&beta;-lactamase.\x20In\x20the\x20case\x20of\x20&beta;-lactamase-negative\x20ampicillin-resistant\x20strains,\x20resistance\x20is\x20due\x20to\x20the\x20presence\x20of\x20altered\x20penicillin-binding\x20proteins.&nbsp;</p>\x0a<p><strong>Ceftriaxone</strong>\x20is\x20a\x20third-generation\x20cephalosporin\x20that\x20is\x20effective\x20against\x20<em>Hemophilus\x20Influenzae</em>&nbsp;and\x20considerably\x20resistant\x20to\x20beta-lactamase.\x20It\x20has\x20a\x20very\x20long\x20half-life\x20which\x20permits\x20once-daily\x20dosing\x20of\x20the\x20drug.\x20Because\x20of\x20the\x20efficacy\x20of&nbsp;third-generation\x20cephalosporins\x20in\x20the\x20therapy\x20of\x20meningitis\x20caused\x20by&nbsp;<em>Hemophilus\x20Influenzae&nbsp;</em>type\x20b,\x20ceftriaxone\x20administered\x20at\x20the\x20rate\x20of\x2050\x20mg/kg/dose\x20given\x2012th\x20hourly\x20should\x20be\x20a\x20part\x20of\x20the\x20initial\x20empirical\x20therapy.</p>\x0a<p>Vancomycin\x20combined\x20with\x20a&nbsp;third-generation\x20cephalosporin\x20like\x20ceftriaxone\x20is\x20the\x20recommended\x20empirical\x20antibiotic\x20regimen\x20in\x20a\x20suspected\x20case\x20of\x20meningitis,\x20beyond\x20the\x20neonatal\x20period.</p>','yXfqS','IWDjW','Lurasidone','fBAfD','classList','<p><strong>Levopropoxyphene</strong>\x20is\x20a\x20centrally\x20acting\x20opioid\x20antitussive.</p>\x0a<p>Levopropoxyphene\x20is\x20an\x20<strong>opioid\x20derivative</strong>\u00a0that\x20is\x20a\x20strong\x20and\x20partial\x20\x20receptor\x20agonist\x20that\x20helps\x20to\x20<strong>reduce</strong>\x20the\x20<strong>cough\x20reflex</strong>\x20and\x20therefore,\x20is\x20used\x20in\x20the\x20management\x20of\x20acute\x20debilitating\x20cough.\x20The\x20usual\x20antitussive\x20dose\x20is\x2050100\x20mg\x20every\x204\x20hours.\x20It\x20has\x20no\x20analgesic\x20activity.\x20However,\x20it\x20is\x20known\x20to\x20cause\x20some\x20sedation.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Ambroxol</strong>\x20is\x20derived\x20from\x20bromhexine.\x20It\x20is\x20a\x20<strong>mucoactive\x20agent</strong>\x20that\x20helps\x20alter\x20the\x20viscoelastic\x20properties\x20of\x20mucus\x20and\x20increase\x20mucociliary\x20clearance,\x20thereby\x20providing\x20relief\x20in\x20productive\x20cough.\x20It\x20is\x20commonly\x20available\x20as\x20intramuscular\x20or\x20intravenous,\x20lozenges,\x20syrups,\x20or\x20tablets.</p>\x0a<p>Option\x20B:\x20<strong>Diphenoxylate</strong>\x20is\x20an\x20<strong>opioid\x20agonist</strong>\x20that\x20is\x20structurally\x20similar\x20to\x20meperidine.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20acute,\x20chronic,\x20and\x20traveler\x27s\x20diarrhea.\x20Upon\x20administration,\x20it\x20undergoes\x20de-esterification\x20to\x20difenoxin,\x20which\x20is\x20its\x20active\x20metabolite.\x20Its\x20side\x20effects\x20include\x20constipation,\x20toxic\x20megacolon,\x20paralytic\x20ileus\x20and\x20can\x20give\x20rise\x20to\x20CNS\x20depression\x20in\x20children.</p>\x0a<p>Option\x20D:\x20<strong>Levorphanol</strong>\x20is\x20a\x20<strong>synthetic\x20opioid</strong>\x20that\x20is\x20also\x20a\x205HT/Norepinephrine\x20reuptake\x20inhibitor\x20and\x20an\x20NMDA\x20receptor\x20antagonist\x20which\x20is\x20chiefly\x20used\x20in\x20the\x20management\x20of\x20<strong>moderate</strong>\x20to\x20<strong>severe\x20pain</strong>\x20and\x20has\x20a\x20relatively\x20rapid\x20onset\x20of\x20action.\x20Its\x20side\x20effects\x20include\x20delirium\x20and\x20hallucinations.</p>','jdHEW','question_images','MYdOS','ooTFB','Ciraparantag:\x20Fondaparinux','Cost\x20to\x20benefit\x20has\x20to\x20be\x20considered','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','DVrTU','zjNra','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','TCYDb','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','WYRFl','gJzcj','CNOWs','fJVHY','length','A\x2057-year-old\x20man\x20was\x20brought\x20to\x20the\x20hospital\x20with\x20complaints\x20of\x20dizziness\x20and\x20breathlessness.\x20During\x20his\x20physical\x20examination,\x20you\x20notice\x20the\x20following\x20discolouration\x20over\x20his\x20face.\x20He\x20is\x20presently\x20being\x20treated\x20with\x20amiodarone,\x20metoprolol,\x20verapamil,\x20lisinopril,\x20and\x20amlodipine.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20most\x20likely\x20responsible?','MvHpB','CceaL','jABgD','reviewQuestionsContainer','ndztz','eKYIx','nKdzW','PAxcS','OkLlo','KKFCQ','180986ehtOhz','Inhibition\x20of\x20calcineurin','Chwyq','Marked','PUePM','Vilazodone','text','explanation_audio_hin','NOLlx','20.8\x20hours','timerContainer','aXiHL','Asenapine','Drug\x20A\x20reduces\x20first\x20pass\x20metabolism\x20of\x20Drug\x20B','EbUTj','YLJbY','Treatment\x20of\x20Lennox\x20Gastaut\x20syndrome','xbHoj','Half-life\x20doubles\x20and\x20plasma\x20concentration\x20remains\x20the\x20same','<p>The\x20mechanism\x20of\x20action\x20of<strong>&nbsp;remdesivir\x20</strong>is\x20inhibition\x20of\x20the\x20enzyme\x20<strong>RNA-dependent\x20RNA\x20polymerase</strong>.</p>\x0a<p>Remdesivir\x20is\x20an\x20<strong>adenosine\x20nucleotide\x20prodrug.</strong>&nbsp;It\x20distributes\x20into\x20cells\x20where\x20it\x20is\x20metabolized\x20to\x20form\x20<strong>remdesivir\x20triphosphate</strong>\x20(<strong>RDV-TP</strong>).\x20It\x20binds\x20to\x20the\x20viral\x20RNA-dependent\x20RNA\x20polymerase\x20and\x20inhibits\x20viral\x20replication\x20by\x20prematurely\x20terminating\x20RNA\x20transcription.&nbsp;</p>\x0a<p>Remdesivir\x20(under\x20Emergency\x20Use\x20Authorization)\x20is\x20used\x20in\x20the\x20treatment\x20of\x20COVID-19.\x20It\x20may\x20be\x20considered\x20in\x20patients&nbsp;with\x20<strong>moderate\x20to\x20severe\x20disease,</strong>\x20requiring\x20supplemental\x20<strong>oxygen</strong>,<strong>&nbsp;</strong><strong>within\x2010\x20days</strong>\x20of\x20onset\x20of\x20the\x20illness.</p>\x0a<p><strong>Dose</strong>:\x20200\x20mg\x20IV\x20on\x20day\x201\x20followed\x20by\x20100\x20mg\x20IV\x20daily\x20for\x204\x20days\x20(total\x205\x20days).</p>\x0a<p>The\x20following\x20are&nbsp;<strong>contraindications&nbsp;</strong>to\x20the\x20use\x20of\x20remdesivir:</p>\x0a<ul>\x0a<li><strong>Renal</strong>\x20or\x20<strong>hepatic</strong>\x20dysfunction\x20(eGFR\x20&lt;30\x20ml/min/m<sup>2</sup>;\x20AST/ALT\x20&gt;5\x20times\x20upper\x20limit\x20of\x20normal)\x20(Not\x20an\x20absolute\x20contraindication)</li>\x0a<li><strong>Pregnant</strong>\x20or\x20<strong>lactating</strong>\x20females</li>\x0a<li>Patients\x20&lt;12\x20years\x20of\x20age</li>\x0a<li>Patients\x20who\x20are\x20not\x20on\x20oxygen\x20support\x20or\x20in-home\x20settings&nbsp;</li>\x0a</ul>\x0a<p>Remdesivir\x20can\x20cause\x20gastrointestinal\x20symptoms,\x20elevated\x20transaminase\x20levels,\x20increased\x20prothrombin\x20time,\x20and\x20hypersensitivity\x20reactions.\x20Hence,\x20<strong>liver\x20function\x20tests</strong>\x20and\x20<strong>prothrombin\x20time</strong>\x20should\x20be\x20obtained\x20before\x20and\x20during\x20treatment\x20with\x20remdesivir.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A-\x20<strong>RNA-dependent\x20DNA\x20Polymerase</strong>\x20/\x20<strong>reverse\x20transcriptase</strong>\x20<strong>inhibitors</strong>\x20prevent\x20the\x20conversion\x20of\x20viral\x20RNA\x20into\x20proviral\x20DNA.\x20They\x20help\x20to\x20prevent\x20infection\x20of\x20susceptible\x20cells\x20but\x20do\x20not\x20eradicate\x20the\x20virus\x20from\x20cells\x20that\x20are\x20integrated\x20with\x20proviral\x20DNA.\x20Examples:\x20<strong>zidovudine</strong>,\x20<strong>lamivudine</strong>,\x20<strong>stavudine</strong>,\x20<strong>tenofovir</strong>,&nbsp;<strong>didanosine</strong>,<strong>\x20zalcitabine,</strong>&nbsp;and<strong>\x20emtricitabine</strong>.\x20These\x20are\x20drugs\x20used\x20to\x20manage\x20<strong>HIV\x20infection</strong>.</p>\x0a<p>Options\x20C\x20and\x20D-&nbsp;<strong>Entry/fusion\x20inhibitors</strong>&nbsp;include\x20enfuvirtide\x20and\x20maraviroc.\x20<strong>Enfuvirtide</strong>\x20inhibits\x20the\x20fusion\x20of\x20viral\x20and\x20cell\x20membranes\x20mediated\x20by\x20gp41\x20and\x20CD4\x20interactions.\x20<strong>Maraviroc</strong>\x20is\x20a\x20chemokine\x20receptor\x20antagonist\x20and\x20binds\x20to\x20host\x20cell\x20CCR5\x20receptor\x20to\x20block\x20binding\x20of\x20viral\x20gp120.\x20They\x20are\x20also\x20used\x20to\x20manage\x20<strong>HIV\x20infection</strong>.</p>','{}.constructor(\x22return\x20this\x22)(\x20)','<p>The\x20dose\x20of\x20retigabine\x20<strong>should\x20be\x20increased</strong>\x20when\x20phenytoin\x20is\x20added\x20because\x20<strong>phenytoin\x20can\x20decrease\x20the\x20plasma\x20concentration\x20of\x20retigabine</strong>\x20when\x20given\x20together.</p>\x0a<p>Retigabine\x20is\x20also\x20known\x20as\x20<strong>ezogabine</strong>.\x20Metabolism\x20of\x20the\x20drug\x20occurs\x20by\x20glucuronidation\x20and\x20acetylation.\x20Its\x20half-life\x20is\x20about\x207-11\x20hours\x20and\x20hence\x20requires\x20thrice-daily\x20dosing.\x20When\x20it\x20is\x20administered\x20with\x20<strong>phenytoin\x20or\x20carbamazepine</strong>&nbsp;there\x20may\x20be\x20a\x20<strong>reduction\x20in\x20the\x20plasma\x20concentration</strong>\x20of\x20the\x20drug.\x20So\x20the\x20dose\x20of\x20retigabine\x20should\x20be\x20increased\x20when\x20given\x20along\x20with\x20these\x20drugs.</p>\x0a<p>It\x20is\x20a\x20<strong>potassium(K+)\x20channel\x20opener</strong>\x20that\x20enhancer\x20transmembrane\x20potassium\x20currents\x20mediated\x20by\x20the<strong>\x20KNCQ</strong>\x20family\x20of\x20ion\x20channels.\x20It\x20was\x20approved\x20as\x20an\x20adjunctive\x20agent\x20for\x20focal\x20onset\x20seizures\x20of\x20patients\x20above\x2018\x20years.\x20But\x20because\x20of\x20its\x20adverse\x20effects\x20like\x20<strong>retinal\x20abnormalities</strong>\x20and\x20<strong>blue\x20pigmentation</strong>,\x20the\x20production\x20of\x20the\x20drug\x20was\x20discontinued\x20by\x20the\x20manufacturer.</p>\x0a<p>Other\x20drug\x20interactions\x20of\x20phenytoin:</p>\x0a<p>It\x20is\x20an\x20<strong>inducer</strong>\x20of\x20the\x20enzymes\x20<strong>CYP2C8/9,\x20CYP3A4/5</strong>,\x20and\x20other\x20CYPs.\x20It\x20is\x20also\x20an\x20<strong>inhibitor\x20of\x20CYP2C9/19.</strong>&nbsp;</p>\x0a<ul>\x0a<li>Phenobarbitone\x20can\x20inhibit\x20the\x20metabolism\x20of\x20phenytoin.\x20But\x20the\x20overall\x20interaction\x20is\x20unpredictable\x20as\x20both\x20the\x20drug\x20enhance\x20each\x20other\x27s\x20degradation\x20by\x20enzyme\x20induction.</li>\x0a<li>Phenytoin\x20and\x20carbamazepine\x20induce\x20each\x20other\x27s\x20metabolism.</li>\x0a<li><strong>Valproate\x20increases</strong>\x20the\x20level\x20of\x20<strong>unbound\x20phenytoin</strong>\x20by\x20displacing\x20the\x20protein-bound\x20form\x20and\x20decreasing\x20its\x20metabolism.</li>\x0a<li>Phenytoin\x20i<strong>ncreases\x20the\x20metabolism</strong>\x20of\x20steroids,\x20<strong>oral\x20contraceptives</strong>,\x20doxycycline,\x20theophylline,\x20etc\x20by\x20enzyme\x20induction.</li>\x0a<li>It\x20produces\x20competitive\x20<strong>inhibition\x20of\x20warfarin\x20metabolism</strong>.\x20(Increased\x20risk\x20of\x20bleeding\x20when\x20given\x20together)</li>\x0a<li>Drugs\x20like\x20chloramphenicol,\x20warfarin,\x20isoniazid,\x20and\x20cimetidine\x20can\x20inhibit\x20the\x20metabolism\x20of\x20phenytoin\x20and\x20cause\x20its\x20toxicity.</li>\x0a<li>Sucralfate\x20decreases\x20the\x20absorption\x20of\x20phenytoin\x20by\x20binding\x20to\x20it\x20in\x20the\x20gastrointestinal\x20tract.</li>\x0a</ul>','VRQTz','Disease\x20prevalence\x20is\x20considered','yJCBB','correctCount','LtkUS','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','Bookmarked','Tuberculosis','review-question\x20','Pharmacology','Chlorothiazide','error','efKPJ','Verapamil','scmxL','bzilC','6.9\x20hours','explanation_audio_eng','Globulin','RNA-dependent\x20RNA\x20polymerase\x20inhibition','wZfcK','bfLIB','aYQXG','tKbcU','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','AqEVj','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','HEkqi','DVsQG','keydown','GkpEq','round','BtkSy','Mmbmc','Rimonabant','WkQKB','azLRF','sWKxQ','JvWxW','incorrect','prototype','ZFlGp','qdAUL','DMlBI','bookmarkedQuestions','The\x20inhibitor\x20forms\x20a\x20product\x20with\x20the\x20enzyme\x20and\x20the\x20product\x20inhibits\x20it','bxBBm','Hodgkin\x27s\x20lymphoma','pijDK','vOVQd','scoreCircle','qwFkJ','RbuEd','KSiFp','bbfMh','wmlfv','XmaWE','bind','PdwJv','markReviewBtn','hidden','LhEVC','Half-life\x20remains\x20the\x20same\x20and\x20plasma\x20concentration\x20doubles','gray','testModeLegend','<p><strong>Liraglutide</strong>\x20is\x20used\x20in\x20the\x20long-term\x20management\x20of\x20obesity.</p>\x0a<p>Mechanism\x20of\x20action:</p>\x0a<ul>\x0a<li>Increase\x20glucose-mediated\x20insulin\x20release</li>\x0a<li>Lowers\x20the\x20glucagon\x20levels</li>\x0a<li><strong>Delays\x20gastric\x20emptying</strong></li>\x0a<li><strong>Decreases\x20feeding</strong>\x20by\x20stimulating\x20<strong>GLP-1\x20receptors</strong>\x20in\x20the\x20<strong>arcuate</strong>\x20nucleus\x20of\x20the\x20hypothalamus.</li>\x0a</ul>\x0a<p>It\x20is\x20a\x20GLP-1\x20analog\x20used\x20as\x20a\x20<strong>parenteral\x20hypoglycemic\x20agent</strong>\x20and\x20<strong>anti-obesity\x20drug</strong>.\x20It\x20is\x20administered\x20subcutaneously.\x20It\x20is\x20used\x20as\x20an\x20adjuvant\x20in\x20patients\x20who\x20are\x20not\x20achieving\x20glycemic\x20control\x20with\x20oral\x20agents.\x20It\x20can\x20be\x20also\x20added\x20with\x20basal\x20insulin.</p>\x0a<p>It\x20is\x20found\x20to\x20decrease\x20the\x20risk\x20of\x20cardiovascular\x20death,\x20nonfatal\x20myocardial\x20infarction,\x20and\x20stroke\x20in\x20patients\x20with\x20type\x202\x20diabetes\x20and\x20cardiovascular\x20disease.</p>\x0a<p>Adverse\x20effects:\x20Nausea,\x20vomiting,\x20diarrhea,\x20or\x20constipation.\x20It\x20should\x20not\x20be\x20given\x20in\x20patients\x20with\x20a\x20personal\x20or\x20family\x20history\x20of\x20MEN\x20syndrome\x20or\x20medullary\x20carcinoma\x20of\x20the\x20thyroid.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Metformin</strong>:\x20It\x20belongs\x20to\x20the\x20biguanides\x20class\x20of\x20oral\x20hypoglycemic\x20agents.\x20It\x20is\x20used\x20as\x20a\x20first-line\x20agent\x20in\x20the\x20management\x20of\x20type\x202\x20diabetes\x20and\x20it\x20acts\x20by\x20reducing\x20hepatic\x20glucose\x20production.\x20It\x20is\x20also\x20used\x20to\x20treat\x20infertility\x20in\x20PCOD\x20patients.\x20IT\x20is\x20usually\x20not\x20associated\x20with\x20weight\x20gain\x20and\x20in\x20some\x20cases,\x20it\x20may\x20cause\x20mild\x20weight\x20reduction.</p>\x0a<p><strong>Sibutramine</strong>:\x20It\x20has\x20both\x20serotonergic\x20and\x20noradrenergic\x20action.\x20It\x20is\x20also\x20an\x20anorectic\x20agent\x20with\x20a\x20similar\x20mechanism\x20of\x20action\x20to\x20fenfluramine.\x20But\x20due\x20to\x20severe\x20adverse\x20effects,\x20US-FDA\x20has\x20banned\x20its\x20use.</p>\x0a<p><strong>Fenfluramine</strong>:\x20It\x20is\x20a\x20serotonergic\x20anorectic\x20agent.\x20It\x20reduces\x20food-seeking\x20behavior\x20due\x20to\x20increased\x20serotonergic\x20transmission\x20in\x20the\x20hypothalamus.\x20The\x20use\x20of\x20is\x20not\x20recommended\x20now\x20by\x20the\x20US-FDA\x20due\x20to\x20its\x20severe\x20side\x20effects.</p>\x0a<p>&nbsp;</p>','<p>The\x20dose\x20at\x20which\x20<strong>dopamine</strong>\x20acts\x20on\x20<strong>-1</strong>\x20receptors\x20is\x20<strong>2-10\x20mcg/kg/min</strong>.</p>\x0a<p>The\x20<strong>systemic\x20effects</strong>\x20of\x20dopamine\x20<strong>vary</strong>\x20with\x20its\x20<strong>concentration</strong>\x20in\x20the\x20body.</p>\x0a<p>When\x20administered\x20at\x20an\x20infusion\x20rate\x20of\x20<strong>2-5\x20mcg/kg/min</strong>,\x20it\x20directly\x20<strong>stimulates\x20</strong>cardiac\x20<strong></strong><strong>\u00a0receptors.\u00a0</strong>This\u00a0enhances\x20myocardial\x20contractility\x20and\x20is\x20useful\x20in\x20the\x20management\x20of\x20cardiogenic\x20shock.</p>\x0a<p>At\x20doses\x20of\x20<strong>5-15\x20mcg/kg/min</strong>\x20and\x20<strong>above</strong>,\x20it\x20stimulates\u00a0<strong>\u00a0adrenergic\x20receptors</strong>.\x20This\x20causes\x20peripheral\x20arterial\x20and\x20venous\x20<strong>vasoconstriction.</strong></p>\x0a<p>At\x20lower\x20doses\x20of\x20<strong>&lt;2\x20mcg/kg/min</strong>,\x20it\x20directly\x20stimulates\x20both\x20<strong>D1</strong>\x20and\x20<strong>D2\x20receptors</strong>.\x20The\x20D1\x20receptors\x20in\x20renal\x20and\x20mesenteric\x20blood\x20vessels\x20are\x20the\x20most\x20sensitive:\x20i.v.\x20infusion\x20of\x20low\x20dose\x20of\x20DA\x20dilates\x20these\x20vessels\x20subsequently,\x20causing\x20increased\x20renal\x20blood\x20flow\x20and\x20increased\x20urine\x20output.</p>\x0a<p>The\x20clinical\x20indications\x20of\x20dopamine\x20include\x20cardiogenic\x20and\x20vasodilatory\x20<strong>shock</strong>,\x20<strong>congestive\x20cardiac\x20failure</strong>\x20and\x20symptomatic\x20<strong>bradycardia</strong>\x20unresponsive\x20to\x20atropine\x20or\x20pacing.</p>\x0a<p>The\x20major\x20side\x20effects\x20are:\u00a0</p>\x0a<ul>\x0a<li>Severe\x20hypertension\x20(especially\x20when\x20taken\x20with\x20nonselective\x20-blockers)</li>\x0a<li>Ventricular\x20arrhythmias</li>\x0a<li>Cardiac\x20ischemia</li>\x0a<li>Tissue\x20ischemia/gangrene\x20(high\x20doses/extravasation\x20into\x20tissues)</li>\x0a</ul>','ELocU','Identify\x20the\x20false\x20statement\x20regarding\x20suicidal\x20inhibition.','nav-btn-bookmarked','ArrowLeft','gwXDf','Hemophilus\x20alters\x20penicillin\x20binding\x20protein\x20sites,\x20hence\x20resistant\x20to\x20ampicillin','removeItem','test','WFvZn','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','kkxAV','parse','The\x20anti-epileptic\x20drugs\x20which\x20can\x20also\x20be\x20used\x20for\x20the\x20treatment\x20of\x20neuropathic\x20pain\x20are','<p><strong>Anionic</strong>\x20and\x20<strong>weakly\x20acidic</strong>\x20drugs\x20bind\x20to\x20<strong>albumin</strong>.</p>\x0a<p>After\x20being\x20distributed\x20in\x20the\x20circulating\x20blood,\x20drugs\x20bind\x20to\x20<strong>serum\x20proteins</strong>\x20to\x20varying\x20degrees.\x20Among\x20serum\x20proteins,<strong>&nbsp;albumin</strong>&nbsp;and\x20<strong>alpha-1\x20acid\x20glycoprotein</strong>&nbsp;play\x20important\x20roles\x20in\x20protein\x20binding\x20for\x20many\x20drugs,\x20which\x20affects\x20their\x20distribution\x20in\x20the\x20body.</p>\x0a<p><strong>Albumin</strong>\x20is\x20a\x20major\x20carrier\x20of\x20and\x20binds\x20to\x20<strong>acidic\x20drugs</strong>\x20like\x20phenytoin,\x20NSAIDs.&nbsp;Whereas,&nbsp;<strong>&alpha;-1\x20acid\x20glycoprotein</strong>&nbsp;binds\x20<strong>basic\x20drugs</strong>\x20like&nbsp;lignocaine,disopyramide,\x20quinidine\x20and\x20propranolol.</p>\x0a<p>Importance\x20of\x20plasma\x20protein\x20binding:</p>\x0a<p>Conditions\x20resulting\x20in\x20<strong>acute\x20phase\x20reaction</strong>\x20response&nbsp;leading\x20to\x20<strong>elevated</strong>\x20levels\x20of\x20alpha-1\x20acid\x20glycoprotein\x20like\x20Crohn&rsquo;s\x20disease,\x20myocardial\x20infarction,\x20arthritis,\x20cancer,\x20etc.&nbsp;<strong>enhance</strong>&nbsp;binding\x20of\x20basic\x20drugs.\x20Conditions\x20causing&nbsp;<strong>hypoalbuminemia</strong>\x20result\x20in\x20decreased\x20binding\x20sites\x20for\x20acidic\x20drugs.&nbsp;</p>\x0a<p>When\x20a\x20drug\x20is\x20bound\x20to\x20the\x20plasma\x20proteins,\x20it\x20is\x20kept\x20in\x20the\x20blood,\x20while\x20the\x20unbound\x20(free)\x20drug&nbsp;can\x20produce\x20a\x20therapeutic\x20effect,\x20be\x20metabolized,\x20or\x20excreted.&nbsp;In\x20the\x20majority\x20of\x20the\x20drugs,\x20this\x20does\x20not\x20have\x20a\x20significant\x20effect,\x20but\x20in\x20drugs\x20with\x20a\x20<strong>narrow\x20therapeutic\x20index</strong>\x20like\x20<strong>warfarin</strong>,\x20it\x20is\x20clinically\x20relevant\x20as\x20excessive\x20free\x20warfarin\x20can\x20produce\x20toxicity.</p>\x0a<p>Many\x20<strong>drugs\x20displace\x20other\x20drugs</strong>\x20from\x20their\x20protein\x20binding\x20sites.\x20This\x20may\x20cause\x20an\x20increase\x20in\x20the\x20pharmacological\x20effect\x20of\x20the\x20<strong>displaced</strong>\x20drug.&nbsp;</p>\x0a<p>A\x20drug\x20bound\x20to\x20a\x20plasma\x20protein\x20cannot\x20cross\x20membranes\x20and\x20this\x20bound\x20fraction\x20of\x20a\x20drug\x20is\x20also\x20not\x20available\x20for\x20metabolism\x20or\x20glomerular\x20filtration\x20which\x20can\x20make\x20the\x20drug\x20<strong>long-acting.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B-&nbsp;<strong>Globulins</strong>\x20are\x20of\x20three\x20types\x20-\x20&alpha;,&beta;,\x20and\x20&gamma;-globulins.\x20Globulins&nbsp;bind\x20<strong>glucocorticoids</strong>\x20and\x20<strong>progesterone</strong>\x20in\x20the\x20blood.</p>\x0a<p>Option\x20C-\x20<strong>Lipoproteins</strong>\x20like\x20VLDL,\x20LDL\x20can\x20bind\x20<strong>anti-cancer\x20drugs</strong>\x20like&nbsp;5-fluorouracil&nbsp;and\x20doxorubicin.&nbsp;</p>','solution','Fusion\x20inhibition','mfnBg','Ergotism','tUNfU','AYveW','Blonanserin','<p>The\x20false\x20statement\x20regarding\x20suicidal\x20inhibition\x20is\x20the\x20inhibitor\x20can\x20bind\x20with\x20any\x20site\x20resulting\x20in\x20suicidal\x20inhibition.</p>\x0a<p>In\x20suicidal\x20inhibition,\x20the\x20inhibitor\x20can\x20only\x20bind\x20with\x20the\x20<strong>active\x20site</strong>\x20of\x20an\x20enzyme\x20and\x20is\x20<strong>unreactive\x20outside</strong>\x20the\x20confines\x20of\x20the\x20enzyme\x27s\x20active\x20site.&nbsp;</p>\x0a<p>The\x20enzyme\x20inhibition\x20helps\x20to\x20modify\x20the\x20rate\x20of\x20reactions\x20it\x20catalyzes\x20and\x20this\x20inhibition\x20can\x20either\x20be\x20<strong>reversible</strong>\x20or\x20<strong>irreversible</strong>.\x20Reversible\x20inhibitors\x20bind\x20to\x20enzymes\x20through\x20non-covalent\x20bonds.\x20Irreversible\x20inhibitors\x20usually\x20bind\x20to\x20an\x20enzyme\x20through\x20covalent\x20bonds\x20and\x20do\x20so\x20strongly\x20so\x20that\x20it\x20can\x20no\x20longer\x20dissociate.</p>\x0a<p>Suicide\x20inhibitors\x20are\x20a\x20category\x20of\x20irreversible\x20inhibitors\x20also\x20called\x20<strong>mechanism-based\x20inhibitors</strong>.\x20They\x20are\x20specialized\x20substrate\x20analogs\x20that\x20contain\x20a\x20chemical\x20group\x20that\x20reacts\x20with\x20the\x20catalytic\x20machinery\x20of\x20the\x20target\x20enzyme.\x20In\x20these\x20types\x20of\x20inhibitors,\x20the\x20substrate\x20analog\x20<strong>irreversibly</strong>\x20ties\x20up\x20with\x20the\x20binding\x20site\x20of\x20an\x20enzyme,\x20deceiving\x20the\x20enzyme\x20by\x20concealing\x20its\x20functional\x20group\x20resulting\x20in\x20the\x20formation\x20of\x20a\x20<strong>highly\x20reactive\x20molecule</strong>,\x20which\x20brings\x20about\x20<strong>self-inactivation</strong>\x20of\x20the\x20enzyme.</p>\x0a<p>Suicide\x20inhibitors\x20bind\x20to\x20the\x20enzyme\x20by\x20means\x20of\x20<strong>covalent\x20bonds</strong>;\x20they\x20are\x20<strong>enzyme-specific</strong>\x20and\x20unreactive\x20outside\x20the\x20confines\x20of\x20the\x20enzyme&rsquo;s\x20active\x20site.</p>\x0a<p>An\x20example\x20of\x20this\x20would\x20be\x20the\x20binding\x20of\x20<strong>clavulanic\x20acid</strong>\x20to\x20the\x20active\x20site\x20of\x20<strong>beta-lactamases</strong>\x20in\x20bacteria.\x20Clavulanic\x20acid\x20mimics\x20the\x20structure\x20of\x20a\x20beta-lactam\x20antibiotic&nbsp;and\x20forms\x20a\x20covalent\x20adduct\x20with\x20the\x20&beta;-lactamase\x20active\x20site.\x20This\x20leads\x20to\x20a\x20rearrangement\x20that\x20creates\x20a\x20much\x20more\x20reactive\x20derivative,\x20which\x20is\x20subsequently\x20attacked\x20in\x20its\x20active\x20site\x20to\x20irreversibly\x20acylate\x20the\x20enzyme\x20and\x20inactivate\x20it.\x20Thus,\x20amoxicillin\x20and\x20clavulanic\x20acid\x20are\x20combined\x20to\x20overcome\x20bacterial\x20resistance\x20to\x20amoxicillin\x20alone.</p>\x0a<p>The\x20development\x20of\x20clavulanic\x20acid\x20to\x20target\x20beta-lactamase-producing\x20bacteria\x20is\x20also\x20an\x20example\x20of\x20the\x20<strong>rational\x20design</strong>\x20of\x20drugs.\x20Rational\x20design\x20of\x20drugs\x20refers\x20to\x20the\x20ability\x20to\x20predict\x20the\x20appropriate\x20molecular\x20structure\x20of\x20a\x20drug\x20on\x20the\x20basis\x20of\x20information\x20about\x20its\x20biological\x20receptor.</p>','yitIr','sagUU','questionMedia','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','selectedAnswer','What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20remdesivir?','querySelectorAll','nav-btn-incorrect','cLERp','status','Drug\x20A\x20increases\x20renal\x20elimination\x20of\x20Drug\x20B','iiYty','avgTimeResult','<p><strong>Varenicline</strong>\x20is\x20the\x20most\x20effective\x20drug\x20in\x20smoking\x20cessation.</p>\x0a<p><strong>Nicotine</strong>\x20is\x20the\x20principal\x20constituent\x20of\x20tobacco\x20responsible\x20for\x20its\x20addictive\x20behaviour.\x20One\x20of\x20the\x20newest\x20agents\x20introduced\x20to\x20aid\x20in\x20smoking\x20cessation\x20is\x20<strong>varenicline</strong>.</p>\x0a<p>Varenicline\x20works\x20by\x20blocking\x20the\x20effects\x20of\x20nicotine\x20on\x20the\x20brain.\x20It\x20<strong>blocks</strong>\x20&alpha;-4,\x20&beta;-2\x20<strong>nicotinic\x20acetylcholine\x20receptor</strong>\x20subtypes\x20and\x20varenicline\x20<strong>inhibits\x20dopaminergic\x20activation</strong>\x20produced\x20by\x20smoking\x20through\x20their\x20<strong>partial\x20agonism</strong>,\x20and\x20decreases\x20the\x20craving\x20and\x20withdrawal\x20syndrome\x20that\x20occurs\x20with\x20cessation\x20attempts.\x20It\x20prevents\x20nicotine\x20stimulation\x20of\x20the\x20mesolimbic\x20dopamine\x20system\x20associated\x20with\x20nicotine\x20addiction,\x20thus\x20helping\x20to\x20occlude\x20the\x20\x22rewarding\x22\x20effect\x20of\x20smoking.</p>\x0a<p>Varenicline\x20is\x20prescribed\x20only\x20to\x20patients\x2018\x20years\x20or\x20older.\x20Varenicline\x20is\x20taken\x20orally\x20and\x20the\x20dose\x20taken\x20is\x200.5\x20mg\x20once\x20daily\x20on\x20days\x201\x20to\x203,\x20increased\x20to\x200.5\x20mg\x20twice\x20daily\x20on\x20days\x204\x20through\x207\x20and\x201\x20mg\x20twice\x20daily\x20after\x20day\x208\x20for\x2011\x20weeks.\x20Therapy\x20should\x20start\x20one\x20week\x20before\x20the\x20target\x20quit\x20date.\x20It\x20can\x20be\x20continued\x20for\x20another\x2012\x20weeks\x20(1\x20mg\x20BD)\x20to\x20maintain\x20abstinence.</p>\x0a<p>The\x20adverse\x20effects\x20include\x20nausea,\x20which\x20can\x20be\x20mitigated\x20by\x20starting\x20at\x20lower\x20doses\x20and\x20gradually\x20increasing\x20the\x20dose.\x20Other\x20symptoms\x20include\x20disturbed\x20sleep,\x20sleepwalking,\x20agitation,\x20drowsiness,\x20and\x20constipation\x20and&nbsp;may\x20also\x20increase\x20the\x20risk\x20of\x20pancreatitis.\x20Varenicline\x20has\x20also\x20been\x20implicated\x20in\x20specific\x20skin\x20syndromes\x20such\x20as\x20<strong>Stevens-Johnson&nbsp;syndrome</strong>,\x20erythema\x20multiforme,\x20and\x20photosensitivity.\x20Varenicline\x20can\x20cause\x20renal\x20failure\x20and\x20kidney\x20stones,\x20thus\x20renal\x20function\x20must\x20be\x20monitored.</p>\x0a<p>The\x20FDA\x20has\x20issued\x20a\x20warning\x20about\x20<strong>mood</strong>\x20and\x20<strong>behavioral\x20changes</strong>\x20associated\x20with\x20its\x20use,\x20and\x20there\x20is\x20some\x20evidence\x20of\x20<strong>increased\x20cardiovascular\x20risk.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Buspirone\x20</strong>sustained\x20release&nbsp;is\x20a\x20<strong>partial\x20agonist</strong>\x20at<strong>\x205HT</strong>\x20receptors\x20but\x20affinity\x20for\x20D<sub>2</sub>\x20receptors\x20may\x20also\x20be\x20present.\x20Its\x20effects\x20are\x20slow\x20onset,\x20over\x20a\x20couple\x20of\x20weeks\x20and\x20is\x20used\x20in\x20the\x20management\x20of\x20generalised\x20anxiety\x20states.</p>\x0a<p>Option\x20C:\x20<strong>Nicotine</strong>\x20gum\x20has\x20nicotine\x20which\x20is\x20an\x20<strong>agonist</strong>\x20at\x20<strong>N<sub>n</sub>\x20</strong>type\x20nicotinic\x20cholinergic\x20receptors\x20and\x20is\x20also\x20advised\x20for\x20smoking\x20cessation\x20along\x20with\x20psychotherapy.\x20However,\x20varenicline\x20was\x20more\x20effective\x20when\x20compared\x20with\x20singleproduct\x20nicotine\x20replacement\x20therapy\x20(NRT)\x20and\x20was\x20similarly\x20effective\x20compared\x20with\x20combination\x20NRT.</p>\x0a<p>Option\x20D:\x20<strong>Rimonabant</strong>\x20is\x20an\x20<strong>inverse\x20agonist</strong>\x20at\x20cannabinoid\x20receptor\x20CB<sub>1&nbsp;</sub>which\x20decreases\x20neurotransmitter\x20release\x20at\x20GABAergic\x20and\x20glutamatergic\x20synapses;\x20its\x20usage\x20for\x20smoking\x20cessation\x20and\x20treat\x20obesity\x20was\x20stopped\x20after\x20serious\x20side\x20effects\x20notably\x20<strong>severe\x20depression</strong>\x20and\x20<strong>increased\x20risk</strong>\x20of\x20<strong>suicide.</strong>\x20However,\x20it\x20continues\x20to\x20be\x20used\x20off-label\x20for\x20smoking\x20cessation.&nbsp;</p>','FzNOE','red','OCD','yAzUL','A\x20patient\x20who\x20was\x20diagnosed\x20with\x20epilepsy\x20was\x20put\x20on\x20retigabine\x20TDS.\x20Now\x20phenytoin\x20is\x20being\x20added.\x20Which\x20of\x20the\x20following\x20changes\x20should\x20be\x20made\x20to\x20retigabine?','No\x20questions\x20available\x20for\x20this\x20quiz.','2\x20and\x204\x20only','hierarchy','lCyVr','KWWpg','src','choices','questionReviewSection','An\x20HIV-positive\x20woman\x20on\x20ART\x20was\x20prescribed\x20ergotamine\x20for\x20a\x20migraine\x20attack\x204\x20days\x20back.\x20She\x20presented\x20with\x20complaints\x20that\x20she\x20is\x20unable\x20to\x20feel\x20her\x20legs\x20from\x20the\x20mid-thigh\x20to\x20her\x20toes,\x20for\x20the\x20past\x20two\x20days.\x20The\x20angiography\x20image\x20is\x20given\x20below.\x20What\x20is\x20the\x20likely\x20diagnosis?','Opdty','hkJfQ','remove','XawnO','questionNav','Hypertonic\x20saline','4691645mSeQqE','Labile\x20hypertension','replace','30\x20minutes','ssrkJ','nHuQP','DMEbA','A\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20cirrhosis\x20of\x20the\x20liver\x20presents\x20with\x20abdominal\x20distension\x20and\x20swelling\x20of\x20the\x20lower\x20limbs.\x20The\x20preferred\x20diuretic\x20for\x20this\x20patient\x20would\x20be','getElementById','solutionImages','053\x20Pharmacology\x20Ini-Cet\x202021','questionText','toString','sByEe','style','zHeGS','uSFxX','eYjZf','solutionContainer','hiGYb','NFhzu','Entry\x20inhibition','<p>The\x20image\x20shows&nbsp;<strong>grey-blue\x20discoloration</strong>\x20over\x20this\x20patient\x27s\x20face\x20and\x20the\x20drug\x20responsible\x20for\x20this\x20is\x20<strong>amiodarone</strong>.</p>\x0a<p>Long-term\x20treatment\x20with\x20amiodarone&nbsp;is\x20responsible\x20for\x20skin\x20pigmentation.\x20<strong>Elderly\x20men</strong>\x20are\x20at\x20an\x20increased\x20risk\x20of\x20developing\x20this.&nbsp;</p>\x0a<p>Ultraviolet\x20light\x20reacts\x20with\x20amiodarone\x20and\x20its\x20metabolites\x20to\x20cause\x20local\x20vasodilatation.\x20This\x20increases\x20the\x20diffusion\x20of&nbsp;amiodarone\x20and\x20its\x20metabolites,\x20resulting\x20in\x20their\x20deposition\x20in\x20the\x20tissues,\x20causing\x20pigmentation.\x20Therefore,\x20it\x20is\x20usually\x20seen\x20in\x20<strong>sun-exposed\x20areas</strong>.</p>\x0a<p><strong>Cessation\x20</strong>of\x20amiodarone,\x20<strong>avoiding\x20</strong>exposure\x20to\x20<strong>sunlight</strong>&nbsp;using\x20<strong>sunscreen</strong>\x20cream\x20is\x20recommended.</p>\x0a<p>Amiodarone\x20is\x20an\x20iodine-containing\x20compound\x20that\x20is\x20structurally\x20related\x20to\x20thyroid\x20hormone.\x20It\x20is\x20a\x20<strong>class\x20III\x20antiarrhythmic\x20drug</strong>,\x20which\x20increases\x20the\x20duration\x20of\x20an\x20action\x20potential\x20by\x20<strong>blocking\x20potassium\x20channels.</strong>&nbsp;It\x20thereby\x20increases\x20the\x20time\x20taken\x20for\x20<strong>repolarization</strong>.\x20It\x20also\x20prolongs\x20the\x20refractory\x20period\x20and\x20suppresses\x20abnormal\x20automaticity.\x20It\x20also\x20has\x20weak\x20<strong>calcium\x20channel\x20</strong>blocking<strong>,\x20sodium\x20channel\x20</strong>blocking<strong>,</strong>\x20and\x20<strong>adrenergic\x20</strong>blocking\x20actions.</p>\x0a<p>It\x20is\x20used\x20to\x20maintain\x20normal\x20sinus\x20rhythm\x20during\x20<strong>atrial\x20fibrillation</strong>\x20and\x20prevent\x20<strong>recurrent\x20ventricular\x20tachycardia</strong>.&nbsp;</p>\x0a<p>Adverse\x20effects\x20of\x20amiodarone:</p>\x0a<ul>\x0a<li>Prolonged\x20usage\x20of\x20amiodarone\x20causes\x20interstitial\x20lung\x20disease.</li>\x0a<li>Heart\x20blocks,\x20bradycardia\x20and\x20QT\x20prolongation</li>\x0a<li>Hyperthyroidism\x20or\x20hypothyroidism</li>\x0a<li>Corneal\x20micro-deposits\x20and\x20vortex\x20keratopathy,\x20optic\x20neuropathy</li>\x0a</ul>\x0a<p>Drug\x20interactions\x20of\x20amiodarone</p>\x0a<ul>\x0a<li>Causes\x20<strong>digoxin\x20toxicity</strong>\x20by\x20decreasing\x20its\x20renal\x20clearance.</li>\x0a<li>Increases\x20concentration\x20of\x20quinidine\x20and\x20procainamide</li>\x0a<li>Potentiates\x20the\x20anticoagulant\x20effect\x20of\x20warfarin\x20when\x20given\x20simultaneously&nbsp;&nbsp;</li>\x0a</ul>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','click','exception','The\x20table\x20below\x20gives\x20the\x20AUC\x20of\x20drug\x20B\x20alone\x20and\x20that\x20of\x20drug\x20B\x20when\x20combined\x20with\x20another\x20drug\x20A.\x20If\x20the\x20\x20value\x20is\x20<0.01,\x20then\x20which\x20of\x20the\x20following\x20statements\x20is\x20true?','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','Administration\x20of\x20which\x20of\x20the\x20following\x20drugs\x20would\x20increase\x20the\x20bioavailability\x20of\x20saquinavir?','resume','TYtKZ','SkbqA','Which\x20of\x20the\x20following\x20is\x20the\x20most\x20effective\x20drug\x20in\x20smoking\x20cessation?','styZn','timed_study','4buLgdY','WnRTi','2-10\x20mcg/kg/min','Amlodipine','<p>The\x20mechanism\x20of\x20action\x20of\x20cyclosporine\x20is\x20inhibition\x20of\x20calcineurin\x20activity.</p>\x0a<p>Calcineurin\x20is\x20a\x20calcium/calmodulin-dependent\x20phosphatase\x20required\x20for\x20the\x20induction\x20of\x20T\x20cell\x20lymphokine\x20production\x20and\x20proliferation.&nbsp;<strong>Cyclosporine</strong>\x20is\x20an\x20immunomodulatory\x20drug\x20that&nbsp;<strong>inhibits\x20calcineurin\x20activity</strong>\x20by<strong>&nbsp;</strong>forming\x20a\x20complex\x20with\x20<strong>cyclophilin</strong>,\x20a\x20cytoplasmic-receptor\x20protein\x20present\x20in\x20target\x20cells,\x20to\x20form\x20a\x20<strong>cyclosporine-cyclophilin\x20complex</strong>.\x20This\x20drug-receptor\x20complex\x20specifically\x20and\x20competitively\x20binds\x20to\x20and\x20<strong>inhibits\x20calcineurin</strong>,\x20a\x20calcium\x20and\x20calmodulin-dependent\x20phosphatase.\x20This\x20in\x20turn,\x20inhibits\x20the\x20translocation\x20of\x20a\x20family\x20of\x20transcription\x20factors\x20(NF-AT),\x20leading\x20to\x20reduced\x20transcriptional\x20activation\x20of\x20cytokine\x20genes\x20for\x20interleukin\x20(IL)-2,\x20tumour\x20necrosis\x20factor\x20(TNF)-alpha,\x20IL-3,\x20IL-4,\x20CD40L,\x20granulocyte-macrophage\x20colony-stimulating\x20factor,\x20and\x20interferon-gamma.\x20Ultimately,\x20the\x20proliferation\x20of\x20T\x20lymphocytes\x20is\x20reduced,\x20resulting\x20in\x20<strong>immunomodulation.</strong></p>\x0a<p>Its\x20uses\x20are\x20:</p>\x0a<ul>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20solid\x20organ\x20transplantation,\x20to\x20treat\x20organ\x20rejection\x20in\x20kidney,\x20liver,\x20and\x20heart\x20allogeneic\x20transplants.</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20patients\x20with\x20rheumatoid\x20arthritis,\x20when\x20the\x20disease\x20has\x20not\x20adequately\x20responded\x20to\x20methotrexate.</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>It\x20is\x20approved\x20to\x20treat\x20amyotrophic\x20lateral\x20sclerosis\x20(ALS\x20or\x20Lou\x20Gehrig\x20disease)\x20and\x20its\x20variants.</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20nephrotic\x20syndrome,\x20to\x20treat\x20focal\x20segmental\x20glomerulosclerosis\x20not\x20responding\x20to\x20corticosteroids.</li>\x0a</ul>\x0a<p>Adverse\x20effects\x20of\x20cyclosporine\x20include\x20a\x20<strong>decrease</strong>\x20in\x20glomerular\x20filtration\x20rate\x20(<strong>GFR</strong>)&nbsp;and\x20<strong>metabolic\x20disturbances</strong>\x20like\x20hypomagnesemia,\x20hyperkalemia,\x20dyslipidemia,\x20gynecomastia,\x20hypertrichosis;\x20<strong>neurotoxicity</strong>\x20in\x20the\x20form\x20of\x20convulsions.&nbsp;There\x20is\x20an\x20increased\x20risk\x20of\x20developing\x20skin\x20and\x20lymphoproliferative\x20malignancies\x20in\x20cyclosporine-treated\x20psoriasis\x20patients.</p>\x0a<p>Other\x20options:<br\x20/><br\x20/>Option\x20B:&nbsp;<strong>AMP\x20kinase</strong>\x20is\x20<strong>stimulated</strong>\x20by\x20<strong>metformin,</strong>\x20a\x20first-line\x20orally\x20administered\x20drug\x20in\x20the\x20management\x20of\x20type-2\x20diabetes\x20mellitus.</p>\x0a<p>Option\x20C:&nbsp;<strong>IMP\x20dehydrogenase</strong>\x20is\x20<strong>inhibited</strong>\x20reversibly\x20by\x20the\x20drug\x20<strong>mycophenolate\x20mofetil</strong>,\x20which\x20is\x20indicated\x20in\x20the\x20prophylaxis\x20of\x20transplant\x20rejection.</p>\x0a<p>Option\x20D:&nbsp;<strong>Dihydro-orotate\x20dehydrogenase</strong>\x20is\x20<strong>inhibited</strong>\x20by\x20<strong>leflunomide,</strong>\x20a\x20pyrimidine\x20synthesis\x20inhibitor\x20indicated\x20for\x20the\x20management\x20of\x20rheumatoid\x20arthritis\x20in\x20adults.</p>','XXHRP','<p>The\x20cephalosporin\x20antibiotic\x20most\x20likely\x20to\x20have\x20caused<strong>\x20hemarthrosis</strong>\x20in\x20this\x20patient\x20on\x20warfarin\x20therapy\x20is\x20<strong>cefoperazone</strong>.</p>\x0a<p>Cephalosporins\x20containing\x20a&nbsp;methylthiotetrazole\x20(NMTT)\x20group\x20can\x20<strong>prolong</strong>\x20the\x20<strong>prothrombin\x20time.\x20</strong>This&nbsp;results\x20in\x20<strong>clinically\x20significant\x20bleeding</strong>\x20in\x20patients\x20<strong>already</strong>\x20on\x20<strong>anticoagulant\x20therapy</strong>\x20or\x20having\x20<strong>vitamin\x20K\x20deficiency</strong>.&nbsp;</p>\x0a<p>This\x20is\x20because\x20NMTT\x20cephalosporins\x20<strong>inhibit</strong>\x20the\x20enzyme\x20<strong>vitamin\x20K\x20epoxide\x20reductase</strong>\x20in\x20the\x20liver,\x20which\x20is\x20the\x20key\x20enzyme\x20for\x20<strong>vitamin\x20K-dependent\x20carboxylation</strong>,\x20a\x20posttranslational\x20modification\x20that\x20is\x20essential\x20for\x20the\x20biological\x20functions\x20of\x20coagulation\x20factors.&nbsp;<br\x20/>NMTT\x20group\x20containing\x20cephalosporins\x20include\x20latamoxef,\x20cefmenoxime,<strong>\x20cefoperazone,\x20cefotetan,\x20cefamandole</strong>.</p>\x0a<p>Vitamin\x20K\x20epoxide\x20reductase\x20is\x20also\x20the\x20target\x20of\x20<strong>anticoagulants</strong>\x20like\x20<strong>warfarin.\x20</strong>Oral\x20administration\x20of\x20vitamin\x20K\x20can\x20prevent\x20this\x20problem.</p>','<2\x20mcg/kg/min','Treatment\x20of\x20resistant\x20migraine','testModeReviewLegend','loadSource','incorrectResult','currentQuestion','cqNmj','TToEw','sSoej','Cefixime','<p><strong>Gonorrhea</strong>\x20is\x20not\x20managed\x20by\x20antimicrobial\x20combinations.\x20According\x20to\x20the\x20latest\x20<strong>CDC\x20</strong>guidelines,\u00a0<strong>single-agent\x20therapy\x20with\x20ceftriaxone</strong>\x20is\x20the\x20preferred\x20treatment\x20for\x20gonococcal\x20infections.</p>\x0a<p>Single-dose\x20of\x20500mg\x20<strong>intramuscular(IM)\x20ceftriaxon</strong>e\x20is\x20given\x20for\x20gonorrhea.\x20It\x20is\x20important\x20to\x20note\x20that\x20the\x20previous\x20guidelines\x20that\x20recommended\x20<strong>dual\x20therapy</strong>\x20with\x20<strong>ceftriaxone\x20and\x20azithromycin\x20are\x20no\x20longer\x20preferred.</strong></p>\x0a<p>Monotherapy\x20with\x20ceftriaxone\x20is\x20given\x20when\x20<strong>concurrent\x20chlamydia\x20infection\x20is\x20ruled\x20ou</strong>t\x20by\x20molecular\x20testing.\x20If\x20this\x20is\x20not\x20done\x20then\x20presumptive\x20treatment\x20for\x20chlamydia\x20should\x20be\x20given\x20along\x20with\x20the\x20treatment\x20of\x20gonorrhea.\x20According\x20to\x20CDC\x20guidelines,\x20100mg\x20doxycycline\x20twice\x20daily\x20for\x207\x20days\x20is\x20given\x20as\x20presumptive\x20treatment\x20of\x20chlamydia\x20in\x20nonpregnant\x20individuals.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Tuberculosis</strong>:\x20<strong>Multidrug\x20therapy</strong>\x20is\x20given\x20in\x20tuberculosis\x20for\x20proper\x20cure\x20and\x20to\x20prevent\x20the\x20selection\x20of\x20drug-resistant\x20mutants.\x20ATT\x20regimen\x20is\x20given\x20in\x20detail\x20in\x20the\x20pearl\x20attached.</p>\x0a<p><strong>Intraabdominal\x20infections</strong>:\x20It\x20is\x20usually<strong>\x20polymicrobial</strong>\x20and\x20can\x20result\x20in\x20an\x20intraabdominal\x20abscess\x20or\x20secondary\x20peritonitis.\x20These\x20are\x20managed\x20with\x20either\x20<strong>single-agent\x20or\x20combination\x20therapy</strong>.\x20Broad-spectrum\x20agents\x20with\x20gram-negative\x20cover\x20such\x20as\x20meropenem\x20or\x20piperacillin-tazobactam\x20can\x20be\x20used\x20alone.\x20Combination\x20therapy\x20with\x20metronidazole\x20and\x20other\x20agents\x20like\x20ciprofloxacin,\x20cefepime,\x20etc\x20are\x20used\x20as\x20empirical\x20agents\x20in\x20intraabdominal\x20infections.</p>\x0a<p><strong>Malaria</strong>:\x20It\x20is\x20also\x20treated\x20with\x20antimicrobial\x20combinations.\x20In\x20plasmodium\x20vivax\x20and\x20ovale\x20malaria,\u00a0schizontocides\x20like\x20chloroquine\x20are\x20combined\x20with\x20agents\x20that\x20attack\x20the\x20hypnozoites\x20like\x20primaquine\x20for\x20radical\x20cure.\x20Primaquine\x20is\x20also\x20given\x20in\x20combination\x20with\x20Artemisinin\x20combined\x20therapy(ACT)\x20for\x20plasmodium\x20falciparum\x20infections\x20as\x20a\x20gametocidal\x20agent.\x20Treatment\x20regimens\x20are\x20given\x20in\x20the\x20pearl\x20attached.</p>','9.8\x20hours','edrWP','gvlfv','GMZUB','AzvTq','currentMode','.option-button','performanceModal','Sqhch','optionsContainer','JbRyq','TATSQ','Paradoxical\x20bronchoconstriction\x20seen\x20with\x20ipratropium\x20bromide\x20is\x20due\x20to\x20all\x20except','ICHiq','Half-life\x20and\x20plasma\x20concentration\x20remains\x20the\x20same','map','427698zYukbB','findIndex','push','vSCXb','JLOnY','Option\x20','qQnxV','Xuafy','bRZIJ','<p>The\x20incorrect\x20statement\x20regarding\x20clomiphene\x20citrate\x20is\x20that\x20it\x20causes\x20monofollicular\x20development;\x20rather,\x20it\x20causes\x20multi\x20follicular\x20development.</p>\x0a<p>Clomiphene\x20is\x20an\x20unequal\x20mixture\x20of\x20two\x20isomers,\x20enclomiphene\x20and\x20zuclomiphene.\x20<strong>Zuclomiphene</strong>&nbsp;is\x20a\x20non-steroidal\x20compound\x20closely\x20<strong>resembling</strong>\x20an\x20<strong>estrogen</strong>,\x20<strong>blocks</strong>\x20the\x20<strong>negative</strong>\x20<strong>i</strong><strong>nhibitory\x20feedback</strong>&nbsp;of\x20<strong>estrogens</strong>\x20on\x20the\x20<strong>hypothalamus</strong>,\x20causing\x20a\x20surge\x20of\x20gonadotropins\x20(FSH,\x20LH),\x20which\x20leads\x20to\x20ovulation.\x20The\x20<strong>continued\x20flow\x20of\x20FSH</strong>\x20encourages\x20<strong>multiple\x20follicular\x20development</strong>\x20which\x20is\x20relatively\x20common.</p>\x0a<p>Being\x20an\x20anti-estrogen,\x20it\x20causes\x20<strong>thickening\x20</strong>of<strong>\x20cervical\x20mucus</strong>\x20and\x20<strong>thinning</strong>\x20of\x20the\x20<strong>endometrium</strong>.&nbsp;</p>\x0a<p><strong>Clomiphene\x20citrate\x20</strong>(CC)<strong>&nbsp;</strong>is\x20used\x20for&nbsp;the\x20treatment\x20of\x20absent\x20or\x20irregular\x20ovulation\x20due\x20to\x20hypothalamic-pituitary\x20dysfunction\x20associated\x20with\x20normal\x20levels\x20of\x20endogenous\x20estradiol;\x20the\x20patient\x20must\x20be\x20treated\x20repeatedly\x20until\x20pregnancy\x20is\x20achieved\x20since\x20the\x20normal\x20cyclic\x20ovulatory\x20function\x20does\x20not\x20usually\x20resume.\x20Clomiphene\x20citrate\x20has\x20no\x20effect\x20on\x20patients\x20with\x20ovarian\x20or\x20pituitary\x20failure.\x20Ovulation\x20induction\x20with\x20clomiphene\x20citrate\x20and\x20a\x20gonadotropin\x20like\x20FSH\x20increases\x20the\x20likelihood\x20of\x20multiple\x20concurrent\x20ovulations.</p>\x0a<p>Side\x20effects\x20of\x20CC\x20include\x20hot\x20flushes\x20and\x20some\x20nausea.\x20However,\x20it\x20is\x20usually\x20very\x20well\x20tolerated.</p>','Cotrimoxazole\x20is\x20the\x20drug\x20of\x20choice,\x20but\x20patient\x20is\x20allergic\x20to\x20sulfa\x20drugs','Ganciclovir','LQPon','ExePq','custom_quiz.html','</span><span>','lTQSd','<p><strong>Ciraparantag</strong>\x20is\x20a\x20reversal\x20agent\x20for\x20all\x20<strong>direct\x20anticoagulants</strong>\x20and\x20is\x20<strong>not\x20useful</strong>\x20with\x20<strong>fondaparinux</strong>\x20which\x20is\x20an\x20<strong>indirect\x20factor\x20Xa\x20inhibitor.</strong></p>\x0a<p>Ciraparantag,\x20andexanet\x20alfa,\x20and\x20idarucizumab\x20are\x20all\x20reversal\x20agents\x20of\x20direct\x20anticoagulants.</p>\x0a<p><strong>Ciraparantag</strong>:\x20It\x20is\x20considered\x20as\x20a\x20potential\x20<strong>reversal\x20agent\x20against\x20all\x20direct\x20anticoagulants</strong>\x20including\x20dabigatran,\x20rivaroxaban,\x20edoxaban,\x20apixaban,\x20LMWH,\x20and\x20heparin.\x20This\x20drug\x20is\x20in\x20the\x20early\x20stages\x20of\x20development.</p>\x0a<p><strong>Andexanet\x20alfa</strong>:\x20It\x20is\x20a\x20recombinant\x20analog\x20of\x20factor\x20Xa\x20and\x20is\x20proposed\x20for<strong>\x20reversal\x20of\x20oral\x20factor\x20Xa\x20inhibitors</strong>\x20like\x20rivaroxaban,\x20edoxaban,\x20and\x20apixaban.\x20It\x20rapidly\x20reverses\x20the\x20action\x20of\x20these\x20drugs\x20and\x20restores\x20thrombin\x20generation.</p>\x0a<p><strong>Idarucizumab</strong>:\x20It\x20is\x20a\x20licensed\x20monoclonal\x20antibody\x20that\x20specifically\x20acts\x20as\x20a\x20<strong>reversal\x20agent\x20for\x20dabigatran</strong>.\x20It\x20has\x20a\x20350\x20times\x20higher\x20affinity\x20for\x20dabigatran\x20than\x20thrombin.\x20Hence\x20it\x20forms\x20a\x20complex\x20with\x20dabigatran\x20and\x20is\x20excreted\x20by\x20the\x20kidneys.</p>\x0a<p>If\x20a\x20patient\x20on\x20direct\x20oral\x20anticoagulants\x20like\x20dabigatran,\x20rivaroxaban,\x20edoxaban,\x20and\x20apixaban\x20presents\x20with\x20life-threatening\x20bleeds\x20and\x20the\x20reversal\x20agents\x20are\x20not\x20available\x20then\x20other\x20options\x20are\x20the\x20administration\x20of\x20<strong>prothrombin\x20complex\x20concentrate,\x20activated&nbsp;prothrombin\x20complex\x20concentrate,\x20or\x20recombinant\x20factor\x20VII-A.\x20</strong>Hemodialysis\x20is\x20useful\x20in\x20severe\x20bleeding\x20due\x20to\x20dabigatran.&nbsp;</p>\x0a<p>Other\x20reversal\x20agents\x20for\x20anticoagulants:</p>\x0a<ul>\x0a<li><strong>Protamine\x20sulphate</strong>\x20-\x20Heparin</li>\x0a<li>Vitamin\x20K\x20-\x20Warfarin</li>\x0a</ul>\x0a<p>Note:</p>\x0a<p>Andexanet\x20alfa\x20has\x20received\x20US-FDA\x20approval\x20in\x20May\x202018\x20as\x20a\x20reversal\x20agent\x20for\x20rivaroxaban\x20and\x20apixaban.</p>\x0a<p>&nbsp;</p>','questionIndex','<p>The\x20clinical\x20features\x20and\x20the\x20CT\x20angiography\x20image\x20showing\x20diffuse\x20symmetrical\x20luminal\x20narrowing\x20of\x20the\x20lower\x20limb\x20vessels\x20are\x20suggestive\x20of<strong>\x20ergotism.</strong></p>\x0a<p>In\x20this\x20case,\x20a\x20patient\x20on\x20antiretroviral\x20therapy\x20is\x20given\x20ergotamine.\x20HIV\x20protease\x20inhibitors\x20used\x20in\x20ART\x20like\x20ritonavir,\x20lopinavir,\x20etc\x20are&nbsp;<strong>potent\x20inhibitors</strong>\x20of\x20the&nbsp;\x20<strong>CYP3A4\x20enzyme</strong>.\x20This\x20enzyme\x20is\x20responsible\x20for\x20the\x20<strong>metabolism\x20of\x20ergot</strong>\x20compounds.\x20Hence\x20inhibition\x20of\x20this\x20enzyme\x20leads\x20to\x20<strong>decreased\x20metabolism\x20of\x20ergotamine.</strong>\x20This\x20causes\x20the\x20accumulation\x20of\x20toxic\x20levels\x20of\x20ergotamine\x20in\x20the\x20patient\x20and\x20leads\x20to\x20ergotism.&nbsp;</p>\x0a<p>Ergotamine\x20is\x20a\x20partial\x20agonist\x20and\x20antagonist\x20at\x20<strong>alpha-adrenergic,\x205HT1;\x20and\x205HT2</strong>\x20receptors.\x20It\x20produces\x20sustained\x20vasoconstriction,\x20vasomotor\x20center\x20depression,\x20and\x20visceral\x20smooth\x20muscle\x20contraction.</p>\x0a<p>Adverse\x20effects:\x20Nausea,\x20vomiting,\x20and\x20abdominal\x20pain\x20may\x20be\x20seen.\x20Vasoconstriction\x20caused\x20by\x20the\x20drug\x20is\x20responsible\x20for\x20most\x20of\x20the\x20adverse\x20effects.\x20These\x20are\x20usually\x20seen\x20with\x20long-term\x20therapy\x20with\x20higher\x20doses.</p>\x0a<ul>\x0a<li>It\x20may\x20precipitate\x20or\x20aggravate\x20angina\x20pectoris\x20or\x20myocardial\x20infarction\x20due\x20to\x20coronary\x20insufficiency.</li>\x0a<li>Some\x20patients\x20develop\x20<strong>cold,\x20numb,\x20and\x20painful\x20extremities</strong>.</li>\x0a<li>Leg\x20claudication\x20may\x20be\x20seen</li>\x0a<li><strong>Gangrene</strong>\x20of\x20the\x20extremities</li>\x0a</ul>\x0a<p>&nbsp;Contraindications\x20for\x20ergotamine:&nbsp;</p>\x0a<ul>\x0a<li><strong>Peripheral\x20vascular\x20disease</strong></li>\x0a<li>Coronary\x20artery\x20disease</li>\x0a<li>Uncontrolled\x20hypertension</li>\x0a<li>Sepsis</li>\x0a<li>Pregnancy</li>\x0a<li>Liver\x20and\x20kidney\x20diseases</li>\x0a</ul>','BNxBj','oGKhs','053-pharmacology-ini-cet-2021-c9444d0f.html','addEventListener','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','BlZzU','Fenfluramine','hTYrK','includes','knJZV','table','selected','PrnXI','YQlXg','toggle','LYcZO','fSEUx','bQglA','PClSY','tGQTY','RPVtk','timeDisplay','Pulmonary\x20hypertension','tgdcw','textContent','study','question_video','open','vnqBK','gKrcr','RRLlN','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','UccHH','Prophylaxis\x20of\x20ADHD','Upregulation\x20of\x20CYP1A1','bookmarked','Not\x20Attempted','LZVyh','correctAnswers','Piperacillin-Tazobactam','hTDuf','60\x20minutes','TLyYE','36DTXVPE','erSKX','width','czAZl','solutionVideo','Causes\x20endometrial\x20thinning','Meropenem','Hemophilus\x20produces\x20beta\x20lactamase,\x20hence\x20resistant\x20to\x20ampicillin','PTSD','Eplerenone','getItem','bKJYB','MYGxY','FjlIl','not_attempted','createElement','xOBwB','TRhQB','ofLnM','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','lKLql','SGAmo','UtxRG','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','gQPrc','Oedyf','accuracyScore','FMAZl','ZszHe','<p>Drug\x20A\x20reduces\x20the\x20<strong>first-pass\x20metabolism</strong>\x20of\x20Drug\x20B<strong>.</strong></p>\x0a<p>The\x20<strong>area\x20under</strong>\x20the\x20plot\x20of\x20<strong>plasma\x20concentration</strong>\x20of\x20a\x20drug\x20versus\x20<strong>time</strong>\x20after\x20dosage\x20is\x20called\x20the&nbsp;<strong>area\x20under\x20the\x20curve&nbsp;</strong>or\x20<strong>AUC</strong>.\x20It\x20can\x20be\x20used\x20as\x20a\x20measure\x20of\x20the\x20<strong>bioavailability</strong>\x20of\x20a\x20drug\x20and\x20to\x20calculate\x20its\x20<strong>clearance\x20rate</strong>\x20from\x20the\x20body.</p>\x0a<p>Bioavailability\x20refers\x20to\x20the\x20<strong>extent</strong>\x20to\x20which\x20an\x20administered\x20dose\x20of\x20the\x20drug\x20<strong>reaches</strong>\x20its\x20<strong>site\x20of\x20action</strong>;\x20if\x20the\x20metabolic\x20and\x20excretory\x20capacity\x20of\x20the\x20intestine\x20or\x20liver\x20for\x20the\x20drug\x20is\x20large,\x20bioavailability\x20is\x20<strong>reduced\x20substantially</strong>\x20and\x20this\x20is\x20called\x20the\x20<strong>first-pass\x20metabolism</strong>\x20whereas\x20bioavailability\x20is\x20<strong>increased</strong>\x20if\x20intestinal\x20absorption\x20of\x20the\x20drug\x20is\x20increased.</p>\x0a<p>The\x20greater\x20the\x20AUC,\x20the\x20greater\x20is\x20the\x20bioavailability\x20of\x20the\x20drug.</p>\x0a<p>In\x20the\x20question,\x20is\x20observed\x20that\x20when\x20drug\x20A\x20was\x20given\x20along\x20with\x20drug\x20B,\x20the\x20total\x20AUC\x20has\x20increased\x20(820\x20seconds\x20&plusmn;\x20124\x20seconds)\x20when\x20compared\x20to\x20the\x20AUC\x20when\x20drug\x20B\x20is\x20administered\x20alone\x20(570\x20seconds\x20&plusmn;\x20127\x20seconds).</p>\x0a<p>The\x20null\x20hypothesis\x20for\x20the\x20above\x20question\x20would\x20be\x20that\x20drug\x20A\x20doesn\x27t\x20increase\x20the\x20AUC\x20for\x20drug\x20B\x20and\x20for\x20this\x20to\x20be\x20true,&nbsp;\x20value\x20should\x20be\x20&gt;0.05.</p>\x0a<p>As\x20given\x20\x20value\x20is\x20<strong>&lt;0.01</strong>,\x20it\x20is\x20significant\x20and\x20the\x20<strong>null\x20hypothesis</strong>\x20is\x20<strong>rejected</strong>,\x20which\x20means\x20that\x20drug\x20A\x20has\x20indeed\x20increased\x20the\x20AUC\x20for\x20drug\x20B.</p>\x0a<p>This\x20indicates\x20increased\x20bioavailability\x20of\x20drug\x20B\x20when\x20administered\x20with\x20drug\x20A,\x20which\x20shows\x20that\x20drug\x20A\x20has\x20either\x20<strong>increased</strong>\x20the\x20<strong>intestinal\x20absorption</strong>\x20of\x20drug\x20B\x20or\x20has\x20<strong>reduced</strong>\x20its\x20<strong>first-pass\x20metabolism</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Option\x20A</strong>:\x20If\x20drug\x20A\x20decreased\x20the\x20intestinal\x20absorption\x20of\x20drug\x20B,\x20this\x20would\x20mean\x20that\x20the\x20AUC\x20for\x20drug\x20B,\x20when\x20administered\x20with\x20drug\x20A,\x20would\x20be\x20reduced.\x20This\x20is\x20due\x20to\x20decreased\x20bioavailability\x20of\x20drug\x20B\x20when\x20given\x20with\x20drug\x20A.</p>\x0a<p><strong>Option\x20C</strong>:\x20If\x20drug\x20A\x20increases\x20the\x20metabolism\x20of\x20drug\x20B,\x20this\x20would\x20lead\x20to\x20a\x20shorter\x20t<sup>1/2&nbsp;</sup>and\x20duration\x20of\x20action\x20of\x20drug\x20B,\x20thereby\x20decreasing\x20the\x20AUC\x20for\x20when\x20drug\x20B\x20and\x20drug\x20A\x20are\x20given\x20together.</p>\x0a<p><strong>Option\x20D</strong>:\x20If\x20drug\x20A\x20increased\x20the\x20elimination\x20of\x20drug\x20B,\x20the\x20AUC\x20for\x20drug\x20B\x20when\x20given\x20with\x20drug\x20A\x20would\x20be\x20reduced\x20due\x20to\x20reduced\x20duration\x20of\x20action\x20of\x20drug\x20B.</p>','LMOQQ','quizSidebar','XszYJ','HhEmb','cSZIp','target','nav-btn-correct','padStart','iWzNo','\x22\x20data-src=\x22','DRWsl','UPmHA','questionStates','ADHnW','The\x20inhibitor\x20can\x20bind\x20with\x20any\x20site\x20resulting\x20in\x20suicidal\x20inhibition','FoLGH','Inhaled\x20Nitric\x20oxide\x20is\x20approved\x20for\x20treatment\x20of','juHqi','setItem','DzEUT','LnOLU','Fixed\x20drug\x20combination\x20is\x20preferred\x20over\x20single\x20drugs','DpIvy','Treatment\x20of\x20dementia','progressBar','MGtlP','gLEbT','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','Ceftazidime','WwDaS','log','console','brXpm','IsZdL','IdLTu','video[data-src]','fIiwd','90\x20minutes','PvCoJ','No\x20solution\x20available.','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','RFqkC','Alpha-1\x20glycoprotein','nIlJy','grtXh','mDwJp','dqRVR','RPsYF','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','yHRss','completed','Linezolid','AlWrq','oGIOF','vqzag','hQPct','answered','<p>The\x20thiazide\x20diuretic\x20that\x20can\x20be\x20used\x20as\x20an\x20antihypertensive\x20in\x20this\x20patient\x20with\x20chronic\x20kidney\x20disease\x20is\x20<strong>metolazone.</strong></p>\x0a<p>In\x20patients\x20with\x20<strong>chronic\x20renal\x20failure,</strong>\x20<strong>thiazide</strong>\x20diuretics\x20are\x20<strong>ineffective</strong>.\x20But\x20metolazone,\x20despite\x20being\x20a\x20thiazide\x20diuretic,\x20is\x20effective\x20as\x20antihypertensives\x20in\x20patients\x20with\x20chronic\x20renal\x20failure.</p>\x0a<p><strong>Metolazone</strong>\x20is\x20useful\x20even\x20in\x20<strong>severe\x20renal\x20failure\x20(GFR\x20of\x20&sim;15\x20mL/min</strong>).\x20It\x20has\x20an\x20additive\x20action\x20when\x20combined\x20with\x20loop\x20diuretics\x20like\x20furosemide.\x20It\x20also\x20has\x20an\x20additional\x20proximal\x20tubular\x20action\x20(thiazides\x20mainly\x20act\x20on\x20DCT).\x20It\x20is\x20commonly\x20used\x20for\x20edema\x20and\x20is\x20occasionally\x20used\x20as\x20an\x20antihypertensive.</p>\x0a<p>Diuretics\x20in\x20hypertension:</p>\x0a<p><strong>Thiazides</strong>&nbsp;are\x20the\x20<strong>diuretics\x20of\x20choice</strong>\x20for\x20<strong>uncomplicated\x20hypertension</strong>.</p>\x0a<p>Mechanisms\x20of\x20antihypertensive\x20action:</p>\x0a<ul>\x0a<li>Decreases\x20plasma\x20and\x20ECF\x20volume\x20by\x20diuresis\x20thereby\x20decreasing\x20cardiac\x20output</li>\x0a<li>Even\x20when\x20the\x20compensatory\x20mechanisms\x20restore\x20the\x20Na+\x20levels\x20and\x20plasma\x20volume,\x20a\x20low\x20BP\x20is\x20maintained\x20by\x20a\x20reduction\x20in\x20total\x20peripheral\x20resistance.</li>\x0a<li>This\x20reduction\x20in\x20total\x20peripheral\x20resistance\x20is\x20due\x20to\x20the\x20persistence\x20of\x20a\x20small\x20sodium\x20and\x20volume\x20deficit\x20even\x20after\x20compensation.\x20The\x20decreased\x20intracellular\x20sodium\x20is\x20responsible\x20for\x20increased\x20compliance\x20of\x20the\x20vessel\x20wall\x20and\x20a&nbsp;\x20reduced\x20response\x20to\x20constrictor\x20stimulus.</li>\x0a</ul>\x0a<p>Advantages\x20of\x20thiazide\x20as\x20an\x20antihypertensive:</p>\x0a<ul>\x0a<li>It\x20can\x20be\x20given\x20as\x20once\x20a\x20day\x20dose\x20and\x20has\x20a\x20flat\x20dose-response\x20curve.</li>\x0a<li>Decreased\x20incidence\x20of\x20postural\x20hypotension\x20and\x20relative\x20freedom\x20from\x20CNS\x20side\x20effects</li>\x0a<li>No\x20tolerance</li>\x0a<li>No\x20fluid\x20retention</li>\x0a<li>Decreased\x20risk\x20of\x20<strong>osteoporotic\x20fractures</strong>\x20due\x20to\x20its\x20<strong>hypocalciuric</strong>\x20action</li>\x0a<li>Low\x20cost</li>\x0a<li>Effectiveness\x20in\x20<strong>isolated\x20systolic\x20hypertension</strong></li>\x0a</ul>\x0a<p>Thiazides\x20are\x20ineffective\x20both\x20as\x20antihypertensive\x20and\x20diuretic\x20in\x20patients\x20with\x20chronic\x20renal\x20failure.</p>\x0a<p><strong>High\x20ceiling\x20diuretics:</strong>&nbsp;Furosemide\x20is\x20the\x20prototype\x20drug\x20in\x20this\x20class\x20and\x20it\x20is\x20a\x20<strong>weaker\x20antihypertensive</strong>\x20agent\x20than\x20thiazides.\x20They\x20are\x20given\x20in\x20hypertension\x20only\x20in\x20the\x20presence\x20of\x20the\x20following\x20complications:</p>\x0a<ul>\x0a<li>Chronic\x20renal\x20failure\x20-\x20As\x20thiazides\x20are\x20ineffective</li>\x0a<li>Coexisting\x20refractory\x20congestive\x20heart\x20failure</li>\x0a<li>Resistance\x20to\x20combination\x20regimen\x20with\x20thiazides</li>\x0a<li>Marked\x20fluid\x20retention\x20with\x20the\x20use\x20of\x20potent\x20vasodilators.</li>\x0a</ul>\x0a<p>Potassium-sparing\x20diuretics\x20-\x20They\x20are\x20only\x20used\x20in\x20combination\x20with\x20thiazides\x20to\x20prevent\x20the\x20loss\x20of\x20potassium.</p>\x0a<p>Side\x20effects\x20of\x20diuretics\x20include\x20hypokalemia,\x20carbohydrate\x20intolerance,\x20dyslipidemia,\x20and\x20hyperuricemia.</p>\x0a<p>&nbsp;</p>','Dihydro-orotate\x20dehydrogenase\x20inhibition','CDoKU','Vitamin\x20C','DhxzX','TwrYH','<p>Topiramate\x20is\x20used\x20in\x20the\x20treatment\x20of\x20Lennox-Gastuat\x20syndrome.</p>\x0a<p>Uses\x20of\x20topiramate:</p>\x0a<ul>\x0a<li>In\x20newly\x20diagnosed\x20focal\x20and\x20primary\x20generalized\x20epilepsy\x20in\x20adults\x20and\x20children&nbsp;</li>\x0a<li>As\x20monotherapy\x20for\x20refractory\x20focal\x20epilepsy\x20and\x20generalized\x20tonic-clonic\x20seizures</li>\x0a<li>Treatment\x20of&nbsp;\x20tonic-clonic\x20seizures\x20in\x20patients\x20with\x20<strong>Lennox-Gastuat\x20syndrome</strong></li>\x0a<li>It\x20is\x20also\x20used\x20in\x20the\x20<strong>prophylaxis\x20of\x20migraine(not\x20for\x20treatment)</strong></li>\x0a<li>It\x20can\x20be\x20given\x20as\x20monotherapy\x20for\x20children\x20of\x2010\x20years\x20or\x20more.\x20But\x20if\x20used\x20as\x20adjunctive\x20therapy\x20it\x20can\x20be\x20used\x20in\x20children\x20as\x20young\x20as\x202\x20years.</li>\x0a</ul>\x0a<p>Mechanism\x20of\x20action:\x20It\x20reduces\x20<strong>voltage-gated\x20sodium\x20currents</strong>\x20in\x20the\x20<strong>cerebellar\x20granule\x20cell</strong>s.\x20It\x20also\x20activates\x20a\x20hyperpolarizing\x20potassium\x20current,\x20enhances\x20GABAA\x20receptor\x20currents,\x20and\x20limits\x20the\x20activation\x20of\x20the\x20AMPA-kainate\x20subtype\x20of\x20glutamate\x20receptors.\x20It\x20also\x20produces\x20weak\x20inhibition\x20of\x20the\x20carbonic\x20anhydrase\x20enzyme.</p>\x0a<p>Pharmacokinetics:\x20Only\x2010-20%\x20is\x20bound\x20to\x20plasma\x20proteins\x20and\x20the\x20drug\x20is\x20largely\x20excreted\x20unchanged\x20in\x20the\x20urine.\x20Half-life\x20is\x20about\x201\x20day.\x20Topiramate\x20is\x20found\x20to\x20<strong>decrease</strong>\x20the\x20<strong>plasma\x20concentrations\x20of\x20oral\x20contraceptives</strong>,\x20hence\x20a\x20higher\x20dose\x20of\x20OCPs\x20should\x20be\x20given\x20along\x20with\x20topiramate.</p>\x0a<p>Adverse\x20effects:</p>\x0a<ul>\x0a<li>Somnolence,\x20weight\x20loss,\x20fatigue,\x20and\x20nervousness\x20are\x20commonly\x20seen</li>\x0a<li>It\x20can\x20precipitate\x20<strong>renal\x20calculi</strong>.\x20It\x20may\x20be\x20due\x20to\x20the\x20weak\x20carbonic\x20anhydrase\x20inhibition.</li>\x0a<li>Cognitive\x20impairment</li>\x0a</ul>','MnqxW','__proto__','JCcdh','erWXm','The\x20binding\x20of\x20the\x20enzyme\x20to\x20the\x20substrate\x20analogue\x20is\x20irreversible','IjuiV','key','Which\x20of\x20the\x20following\x20is\x20a\x20centrally\x20acting\x20opioid\x20antitussive?','Incorrect','Prejunctional\x20M2\x20receptor\x20blockade','attachMedia','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','grgHI','info','iEgqZ','opyPe','Previous\x20progress\x20cleared.','Can\x20be\x20used\x20with\x20gonadotropin','href','OlAxp','They\x20are\x20enzyme\x20specific\x20and\x20used\x20in\x20rational\x20drug\x20design','flex','oYwno','appendChild','warn','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','261eerbaq','canPlayType','name','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','<div\x20class=\x22mt-4\x22><img\x20src=\x22','Pleuropulmonary\x20blastoma','What\x20would\x20happen\x20to\x20the\x20half-life\x20and\x20plasma\x20concentration\x20of\x20a\x20drug\x20which\x20follows\x20first-order\x20kinetics,\x20\x20if\x20the\x20dose\x20is\x20doubled?','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','wXJno','Progress\x20loaded.','hSIyE','floor','QEbzq','bHwmh','Easier\x20to\x20administer\x20IV\x20ceftriaxone\x20than\x20IV\x20ampicillin','return\x20(function()\x20','Medulloblastoma','efSMl','nPHju','qTkQZ','PYQ','-600\x20text-white\x22>','vCoxV','xGmFX','YAeks','mFelv','gLngG','Bipolar\x20disorder','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','userHistory','modeModal','nav-btn-current','bfnHx','ffeOe','timeSpent','OEabE','lvqxd','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','none','toISOString','Which\x20of\x20the\x20following\x20is\x20a\x20novel\x20anti-depressant?','NxlXF','getAttribute','OMgSh','GGLbr','kgtMp','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','aUbQA','dIiBa','BcJcr','Metolazone','uDzCV','IMP\x20dehydrogenase\x20inhibition','Stop\x20the\x20drug','stringify','Metoprolol','border-green-500','totalAttempted','gKerb','fYOqY','3052208cXJYrS','gZxus','No\x20question\x20text\x20available','.m3u8','<p><span\x20class=\x22notion-enable-hover\x22\x20data-token-index=\x220\x22\x20data-reactroot=\x22\x22>The\x20preferred\x20diuretic\x20for\x20this\x20patient\x20with\x20cirrhosis\x20presenting\x20with\x20abdominal\x20distension\x20and\x20lower\x20limb\x20swelling\x20is\x20<strong>eplerenone</strong>.</span></p>\x0a<p>Eplerenone\x20is\x20a\x20<strong>mineralocorticoid\x20receptor/aldosterone\x20antagonist</strong>.\x20High\x20doses\x20of\x20mineralocorticoid\x20receptor/aldosterone\x20antagonists&nbsp;decrease\x20total\x20body\x20sodium&nbsp;in\x20cirrhotic\x20patients\x20with\x20ascites&nbsp;by&nbsp;natriuresis.&nbsp;</p>\x0a<p>Patients\x20with\x20liver\x20cirrhosis\x20have\x20a\x20decreased\x20effective\x20arterial\x20blood\x20volume\x20because\x20of\x20splanchnic\x20vasodilatation.\x20This\x20stimulates\x20the\x20renin-angiotensin-aldosterone\x20system\x20and\x20results\x20in\x20hyperaldosteronism.\x20This\x20causes\x20increased\x20sodium\x20and\x20water\x20retention\x20and\x20leads\x20to\x20the\x20development\x20of\x20ascites.\x20This\x20also&nbsp;contributes\x20to\x20resistance\x20to\x20loop\x20diuretics.&nbsp;</p>\x0a<p>Normally<strong>,\x20aldosterone</strong>\x20(<strong>AL</strong>)\x20enters\x20the\x20cells\x20of\x20the\x20<strong>late\x20distal\x20tubule</strong>\x20and\x20<strong>collecting\x20ducts</strong>\x20by\x20diffusion\x20and\x20binds\x20to\x20a\x20specific\x20<strong>mineralocorticoid\x20receptor</strong>\x20(<strong>MR</strong>)\x20in\x20the\x20cytoplasm.\x20This\x20AL-MR\x20complex\x20mediates\x20Na<sup>+</sup>\x20reabsorption,\x20which\x20drives\x20the\x20secretion\x20of\x20K<sup>+</sup>\x20and\x20H<sup>+</sup>into\x20the\x20tubules.</p>\x0a<p>Eplerenone\x20<strong>competitively\x20blocks</strong>&nbsp;this<strong>\x20MR</strong>,\x20preventing\x20it\x20from\x20binding\x20with\x20aldosterone.\x20The\x20net\x20effect\x20is&nbsp;<strong>sodium\x20diuresis</strong>\x20and\x20<strong>potassium\x20retention</strong>.\x20It\x20is\x20a\x20potassium-sparing\x20diuretic.\x20Other\x20mineralocorticoid\x20receptor\x20antagonists\x20include&nbsp;<strong>spironolactone</strong>,\x20<strong>canrenone</strong>,\x20<strong>potassium\x20canrenoate</strong>.</p>\x0a<p>Some\x20clinical\x20uses\x20of\x20MR\x20antagonists\x20are\x20-&nbsp;</p>\x0a<ul>\x0a<li>Hypertension\x20due\x20to\x20primary\x20hyperaldosteronism&nbsp;</li>\x0a<li>Edema\x20associated\x20with\x20liver\x20cirrhosis,\x20congestive\x20cardiac\x20failure,\x20chronic\x20kidney\x20disease</li>\x0a<li>They\x20may\x20reduce\x20mortality\x20in\x20patients\x20with\x20myocardial\x20infarction</li>\x0a</ul>\x0a<p><strong>Hyperkalemia</strong>\x20is\x20the\x20major\x20side\x20effect\x20of\x20MR\x20antagonists,\x20the\x20risk\x20being\x20greater\x20in\x20patients\x20with\x20<strong>renal\x20disease</strong>\x20or\x20those\x20already\x20<strong>taking\x20ACE\x20inhibitors</strong>.\x20Other\x20important\x20side\x20effects\x20are\x20<strong>gynecomastia</strong>\x20and\x20<strong>decreased\x20libido</strong>\x20due\x20to\x20the&nbsp;<strong>anti-androgenic\x20effect</strong>\x20of\x20spironolactone\x20but\x20eplerenone\x20does\x20not\x20cause\x20gynecomastia\x20and\x20decreased\x20libido.</p>\x0a<p>Other\x20options\x20:&nbsp;</p>\x0a<p>Option\x20A-&nbsp;<strong>Triamterene</strong>&nbsp;directly\x20<strong>inhibits</strong>\x20renal\x20<strong>epithelial</strong>\x20<strong>sodium\x20channels\x20</strong>(ENaC)\x20in\x20the\x20<strong>late\x20distal\x20tubule</strong>\x20and\x20<strong>collecting\x20duct.</strong>&nbsp;It\x20is\x20a\x20potassium-sparing\x20diuretic\x20and\x20is\x20generally\x20used\x20along\x20with\x20other\x20diuretics\x20in\x20the\x20treatment\x20of\x20hypertension\x20and\x20edema.\x20Triamterene\x20is\x20metabolized\x20in\x20the\x20liver,\x20hence\x20triamterene\x20toxicity\x20may\x20be\x20enhanced\x20in\x20patients\x20with\x20hepatic\x20disease.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>Liddle\x20syndrome.</strong></p>\x0a<p>Option\x20C-&nbsp;<strong>Chlorthalidone\x20</strong>is\x20a\x20thiazide-like\x20diuretic.\x20It<span\x20style=\x22font-weight:\x20400;\x22><span\x20style=\x22font-weight:\x20400;\x22>&nbsp;<strong>inhibits\x20Na<sup>+</sup>-Cl<sup>-</sup>\x20symporter</strong>&nbsp;in\x20the&nbsp;<strong>early\x20distal\x20tubule</strong>\x20and\x20increases\x20the\x20excretion\x20of\x20sodium\x20and\x20chloride.&nbsp;</span></span>Thiazide\x20diuretics\x20may\x20be\x20used\x20for\x20the\x20treatment\x20of\x20hypertension,\x20heart\x20failure,\x20nephrolithiasis\x20due\x20to\x20idiopathic\x20hypercalciuria,\x20and\x20nephrogenic\x20diabetes\x20insipidus.</p>\x0a<p>Option\x20D-<strong>\x20Furosemide</strong>\x20is\x20a\x20<strong>loop\x20diuretic</strong>.\x20It\x20acts\x20by\x20<strong>inhibiting</strong>\x20the\x20<strong>Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup></strong>\x20symporter\x20in\x20the\x20<strong>thick\x20ascending\x20limb</strong>\x20of\x20the&nbsp;<strong>loop</strong>\x20<strong>of\x20Henle</strong>\x20resulting\x20in\x20increased\x20excretion\x20of\x20sodium\x20and\x20chloride.\x20It\x20also\x20has\x20mild\x20carbonic\x20anhydrase\x20inhibitory\x20activity\x20and\x20also\x20increases\x20urinary\x20excretion\x20of\x20bicarbonate\x20and\x20phosphate.\x20Cirrhotic\x20patients\x20are\x20often\x20resistant\x20to\x20loop\x20diuretics\x20due\x20to&nbsp;<strong>decreased\x20secretion</strong>\x20of\x20the\x20drug\x20into\x20<strong>tubular\x20fluid</strong>\x20and\x20high\x20aldosterone\x20levels.\x20Furosemide\x20may\x20be\x20given\x20along\x20with\x20eplerenone,\x20but\x20the\x20best\x20answer\x20here\x20is\x20eplerenone\x20since\x20<strong>aldosterone\x20antagonists</strong>\x20are\x20the\x20<strong>main\x20therapy</strong>\x20for\x20cirrhotic\x20edema.</p>','EwMTj','totalQuestionsResult','ALnaP','className','cZuVj','zNSXX','A\x20patient\x20is\x20on\x20phenytoin\x20for\x20a\x20seizure\x20disorder.\x20He\x20was\x20prescribed\x20sucralfate\x204\x20times\x20a\x20day\x20for\x20peptic\x20ulcers.\x20What\x20should\x20be\x20the\x20minimum\x20duration\x20of\x20time\x20between\x20consumption\x20of\x20these\x20drugs?','PLVOH','Downregulation\x20of\x20CYP2E1','incorrectCount','wNwIp','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','vQwzJ','endsWith','toLowerCase','pathname','A\x2034-year-old\x20man\x20with\x20hypertension\x20is\x20diagnosed\x20with\x20stage\x204\x20chronic\x20kidney\x20disease,\x20with\x20eGFR\x20of\x20<30.\x20His\x20doctor\x20wants\x20to\x20prescribe\x20a\x20thiazide\x20diuretic.\x20Which\x20of\x20the\x20following\x20can\x20be\x20given?','Ckvwv','join','notAttemptedResult','reduce','jbSaU','Which\x20of\x20the\x20following\x20is\x20not\x20an\x20off-label\x20use\x20of\x20risperidone?','button','<p>Vancomycin\x20acts\x20on\x20<strong>step\x204</strong>&nbsp;in\x20the\x20given\x20image.</p>\x0a<p>Mechanism\x20of\x20action\x20of\x20vancomycin:\x20It\x20is\x20a\x20<strong>cell\x20wall\x20synthesis\x20inhibitor</strong>.\x20It\x20binds\x20to\x20the\x20<strong>D-Ala-D-Ala\x20terminus</strong>\x20of\x20the\x20newly\x20formed\x20peptidoglycan\x20pentapeptide\x20and\x20<strong>inhibits\x20the&nbsp;transglycosylase</strong>\x20enzyme.\x20This\x20would\x20<strong>prevent\x20further\x20elongation</strong>\x20of\x20<strong>the\x20peptidoglycan</strong>\x20and\x20its\x20cross-linking.</p>\x0a<p>Vancomycin\x20is\x20a\x20bactericidal\x20agent\x20for\x20<strong>gram-positive</strong>\x20organisms.\x20It\x20is\x20also\x20active\x20against\x20many\x20gram-positive\x20anaerobes\x20like\x20<strong>Clostridium\x20difficile</strong>.&nbsp;Resistance\x20against\x20vancomycin\x20in\x20enterococci\x20is\x20due\x20to\x20the\x20alternation\x20in\x20its\x20binding\x20site\x20where\x20D-Ala\x20is\x20replaced\x20by\x20D-Lactate.</p>\x0a<p><strong>Clinical\x20uses:</strong></p>\x0a<ul>\x0a<li>Parenteral\x20vancomycin\x20is\x20given\x20for\x20bloodstream\x20infections\x20and\x20<strong>endocarditis\x20caused\x20by\x20MRSA</strong>.</li>\x0a<li>Vancomycin\x20plus\x20gentamicin\x20is\x20given\x20as\x20an\x20alternative\x20regimen\x20for\x20enterococcal\x20endocarditis\x20with\x20penicillin\x20allergy.</li>\x0a<li>In\x20combination\x20with\x20other\x20agents\x20for\x20suspected\x20meningitis\x20or\x20<strong>meningitis\x20due\x20to\x20penicillin-resistant\x20pneumococcus</strong>.</li>\x0a<li><strong>Oral\x20vancomycin</strong>\x20is\x20given\x20for\x20<strong>Clostridium\x20difficile\x20colitis.</strong></li>\x0a</ul>\x0a<p>Adverse\x20effects:</p>\x0a<ul>\x0a<li>Injection\x20site\x20phlebitis</li>\x0a<li>Nephrotoxicity</li>\x0a<li><strong>\x22Redman\x22\x20syndrome</strong>\x20due\x20to\x20histamine\x20release\x20following\x20infusion</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p><strong>Fosfomycin</strong>\x20inhibits\x20<strong>step\x201</strong>\x20in\x20the\x20image.\x20It\x20acts\x20at\x20a\x20very\x20early\x20stage\x20in\x20cell\x20wall\x20synthesis\x20and\x20inhibits\x20the\x20cytoplasmic\x20enzyme<strong>&nbsp;enol\x20pyruvate\x20transferase</strong>.\x20This\x20would\x20block\x20the&nbsp;addition\x20of\x20phosphoenolpyruvate\x20to\x20UDP-N-acetylglucosamine.\x20This\x20<strong>prevents\x20the\x20formation\x20of&nbsp;UDP-N-acetylmuramic\x20acid</strong>\x20which\x20is\x20the\x20precursor&nbsp;N-acetylmuramic\x20acid.\x20N-acetylmuramic\x20acid\x20is\x20a\x20component\x20of\x20the\x20bacterial\x20cell\x20wall\x20and\x20hence\x20cell\x20wall\x20synthesis\x20is\x20inhibited.</p>\x0a<p><strong>Cycloserine</strong>\x20inhibits\x20<strong>step\x202</strong>\x20in\x20the\x20image.\x20It\x20is\x20a\x20structural\x20analog\x20of\x20D-alanine\x20and\x20inhibits\x20the\x20enzymes\x20<strong>alanine\x20racemase</strong>\x20that&nbsp;converts\x20L-alanine\x20to\x20D-alanine\x20and\x20<strong>d-alanyl-d-alanine\x20ligase</strong>.\x20This\x20would\x20thereby\x20inhibit\x20the\x20incorporation\x20of\x20D-alanine\x20into\x20the\x20peptidoglycan\x20pentapeptide.\x20It\x20is\x20mainly\x20used\x20in\x20the\x20management\x20of\x20tuberculosis\x20where\x20there\x20is\x20resistance\x20to\x20the\x20first-line\x20agents.</p>\x0a<p><strong>Bacitracin</strong>\x20inhibits\x20<strong>step\x203</strong>\x20in\x20the\x20image.\x20It\x20is\x20a\x20cell\x20wall\x20synthesis\x20inhibitor\x20that\x20interferes\x20with&nbsp;<strong>dephosphorylation</strong>\x20in\x20the\x20cycling\x20of\x20the\x20<strong>lipid\x20carrier</strong>\x20which\x20transfers&nbsp;peptidoglycan\x20subunits\x20to\x20the\x20growing\x20cell\x20wall.\x20It\x20is\x20only\x20given\x20for\x20topical\x20application\x20because\x20of\x20its\x20severe\x20nephrotoxicity\x20when\x20given\x20systemically.</p>\x0a<p>Note:</p>\x0a<p><strong>Beta-lactam</strong>\x20antibiotics\x20prevent\x20cross-linking\x20by\x20inhibiting\x20the<strong>\x20transpeptidases</strong>.\x20(Last\x20step\x20in\x20the\x20images)</p>','border-red-500','RdqHx','55880RQUTtD','A\x2014-month-old\x20boy\x20was\x20diagnosed\x20with\x20Hemophilus\x20influenza\x20meningitis.\x20The\x20initial\x20treatment\x20plan\x20was\x20to\x20start\x20on\x20ampicillin\x20but\x20later\x20was\x20shifted\x20to\x20ceftriaxone.\x20What\x20could\x20be\x20the\x20probable\x20reason?','nGAnc','882yoAetV','zbIMs','<p>The\x20<strong>anti-epileptic\x20drugs</strong>\x20which\x20can\x20also\x20be\x20used\x20for\x20<strong>neuropathic\x20pain</strong>\x20are\x20<strong>1</strong>,\x20<strong>2</strong>,\x20and\x20<strong>4</strong>&nbsp;which\x20are\x20pregabalin,\x20carbamazepine\x20and\x20gabapentin\x20respectively.</p>\x0a<p><strong>Pregabalin</strong>\x20is\x20an\x20anti-epileptic\x20drug\x20that\x20acts\x20by\x20binding\x20to\x20&alpha;2&delta;,\x20a\x20protein\x20that\x20is\x20a\x20subunit\x20of\x20voltage-gated\x20calcium\x20channels\x20and\x20causes\x20a\x20decrease\x20in\x20glutamate\x20release\x20at\x20excitatory\x20synapses.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20neuropathic\x20pain\x20associated\x20with\x20<strong>diabetic\x20peripheral\x20neuropathy</strong>,\x20<strong>spinal\x20cord\x20injury</strong>\x20or\x20<strong>postherpetic\x20neuralgia</strong>.</p>\x0a<p><strong>Gabapentin</strong>\x20is\x20an\x20anti-epileptic\x20drug\x20that,&nbsp;like\x20pregabalin,\x20acts\x20by\x20binding\x20to\x20&alpha;2&delta;\x20protein.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20neuropathic\x20pain\x20due\x20to\x20<strong>postherpetic\x20neuralgia</strong>\x20in\x20adults.</p>\x0a<p>The\x20binding\x20of\x20gabapentin\x20and\x20pregabalin,\x20also\x20called\x20\x22gabapentinoids\x22\x20due\x20to\x20their\x20structural\x20similarity\x20to\x20GABA,\x20to&nbsp;<strong>calcium\x20channel\x20subunit\x20a2&delta;&nbsp;</strong>protein,\x20is&nbsp;considered\x20to\x20mediate\x20the\x20anti-convulsant\x20effects\x20of\x20gabapentin\x20and\x20pregabalin.\x20They\x20are\x20used\x20in\x20focal\x20onset\x20seizures\x20with\x20or\x20without\x20progression\x20to\x20bilateral\x20tonic-clonic\x20seizures\x20when\x20used\x20in\x20addition\x20to\x20other\x20anti-epileptic\x20drugs.</p>\x0a<p><strong>Carbamazepine</strong>\x20is\x20an\x20iminostilbine\x20derivative.\x20It\x20blocks&nbsp;<strong>voltage-activated</strong>\x20<strong>sodium\x20channels,&nbsp;</strong>slowing\x20their\x20rate\x20of\x20recovery&nbsp;and\x20limiting\x20the\x20repetitive\x20firing\x20of\x20action\x20potentials.&nbsp;It\x20is\x20used\x20in\x20the\x20treatment\x20of:</p>\x0a<ul>\x0a<li>Generalized,\x20focal-to-bilateral\x20and\x20idiopathic\x20<strong>tonic-clonic\x20seizures</strong></li>\x0a<li><strong>Focal\x20seizures</strong></li>\x0a<li>Neuropathic\x20pain\x20associated\x20with\x20<strong>trigeminal</strong>\x20and\x20<strong>glossopharyngeal\x20neuralgias</strong>.</li>\x0a</ul>\x0a<p><strong>Lamotrigine</strong>\x20is\x20an\x20anti-folate\x20agent\x20whose\x20mechanism\x20of\x20action\x20is\x20similar\x20to\x20that\x20of\x20carbamazepine\x20i.e.\x20it\x20<strong>delays</strong>\x20the\x20recovery\x20from\x20inactivation\x20of\x20recombinant\x20<strong>sodium\x20channels.\x20</strong>It\x20also&nbsp;<strong>inhibits</strong>\x20the\x20<strong>release</strong>\x20of\x20<strong>glutamate</strong>\x20by\x20acting\x20directly\x20on\x20the\x20sodium\x20channels.\x20Therefore,\x20when\x20used\x20concurrently\x20with\x20carbamazepine,\x20is\x20associated\x20with\x20toxicity\x20in\x20some\x20patients\x20due\x20to\x20increase\x20in\x2010,11-\x20epoxide\x20of\x20carbamazepine.\x20It\x20is\x20useful\x20in\x20the\x20management\x20of:</p>\x0a<ul>\x0a<li>Focal\x20and\x20secondarily\x20generalized\x20<strong>tonic-clonic\x20seizures</strong>\x20in\x20adults</li>\x0a<li><strong>Lennox-Gastaut\x20syndrome\x20</strong>-&nbsp;a\x20childhood\x20disorder\x20characterized\x20by\x20multiple\x20type\x20seizures,\x20mental\x20retardation,\x20and\x20refractoriness\x20to\x20anti-seizure\x20medication.</li>\x0a</ul>\x0a<p>&nbsp;</p>','markedForReview','nlCOO','NjdRz','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','qDigP','https://cdn1.dailyrounds.org/uploads/e5f470b5d0ef4785a0a3eaba9c8dfafa.JPEG','The\x20elimination\x20rate\x20constant\x20of\x20a\x20drug\x20is\x200.05/hr.\x20What\x20is\x20its\x20half-life?','FNRmM','UyMqc','UfzJO'];_0x13ef=function(){return _0x9dccc3;};return _0x13ef();}function updateMarkReviewButton(){const _0x48a85a=_0x21a98a,_0x22bd52={'cmVfK':_0x48a85a(0x3d3),'jwnSA':'markReviewText','duvWX':_0x48a85a(0x36f),'lTSfC':_0x48a85a(0x21d),'oKJys':_0x48a85a(0x385),'LYcZO':'Mark\x20for\x20Review'},_0x113a6f=document[_0x48a85a(0x137)](_0x22bd52['cmVfK']),_0x537abe=document[_0x48a85a(0x137)](_0x22bd52[_0x48a85a(0x345)]),_0x36d3c6=questionStates[currentQuestionIndex][_0x48a85a(0x28e)];_0x113a6f['className']=_0x36d3c6?_0x22bd52['duvWX']:_0x22bd52['lTSfC'],_0x537abe[_0x48a85a(0x1a0)]=_0x36d3c6?_0x22bd52[_0x48a85a(0x29a)]:_0x22bd52[_0x48a85a(0x197)];}function previousQuestion(){const _0x76bedc=_0x21a98a,_0x179a82={'FQMub':function(_0xce40a0,_0x137994){return _0xce40a0===_0x137994;},'qWVEH':_0x76bedc(0x39b),'DqNsb':'incorrectCount','FQnqU':_0x76bedc(0x265),'fmWAm':function(_0x2ec596,_0x264576){return _0x2ec596>_0x264576;},'zeVJK':function(_0x1bc774,_0x5ace2c){return _0x1bc774*_0x5ace2c;},'wZfcK':function(_0x433379,_0x11c665){return _0x433379/_0x11c665;},'jJPgG':_0x76bedc(0x31b),'OsAFV':function(_0x388948,_0x4514d3){return _0x388948+_0x4514d3;},'zuPSP':function(_0x2546f3,_0x2107b9){return _0x2546f3/_0x2107b9;},'kgtMp':function(_0x45a6a9,_0x5563cd){return _0x45a6a9%_0x5563cd;},'SxFcI':function(_0x57cb82,_0x210f61){return _0x57cb82>_0x210f61;},'YLJbY':_0x76bedc(0x180),'fYOqY':function(_0x443b30,_0x532d05){return _0x443b30-_0x532d05;},'bRZIJ':function(_0x33d444){return _0x33d444();}};if(_0x179a82[_0x76bedc(0x2d5)](currentQuestionIndex,0x0)){if(_0x179a82[_0x76bedc(0x340)](_0x179a82[_0x76bedc(0x391)],_0x179a82['YLJbY']))questionStartTime&&(questionStates[currentQuestionIndex][_0x76bedc(0x24e)]+=_0x179a82[_0x76bedc(0x267)](Date[_0x76bedc(0x2c5)](),questionStartTime)),currentQuestionIndex--,_0x179a82[_0x76bedc(0x17c)](displayQuestion),saveProgress();else{if(_0x43f115===_0x76bedc(0x1a1)||_0x179a82[_0x76bedc(0x340)](_0x39e2f0,_0x76bedc(0x151))){_0x2f9cbd[_0x76bedc(0x137)](_0x179a82['qWVEH'])['textContent']=_0x18c997[_0x76bedc(0x1af)],_0x4743dc[_0x76bedc(0x137)](_0x179a82['DqNsb'])[_0x76bedc(0x1a0)]=_0x63bec['incorrectAnswers'],_0x55e615['getElementById'](_0x179a82[_0x76bedc(0x2a5)])[_0x76bedc(0x1a0)]=_0x2e5fb3['totalAttempted'];const _0x193dc3=_0x179a82[_0x76bedc(0x2aa)](_0x36941e['totalAttempted'],0x0)?_0x18fa9e[_0x76bedc(0x3b7)](_0x179a82['zeVJK'](_0x179a82[_0x76bedc(0x3ac)](_0x5a6bd4[_0x76bedc(0x1af)],_0x137a24['totalAttempted']),0x64)):0x0;_0x238c8d[_0x76bedc(0x137)](_0x179a82['jJPgG'])[_0x76bedc(0x1a0)]=_0x179a82[_0x76bedc(0x2cc)](_0x193dc3,'%'),_0x4b2791[_0x76bedc(0x2b7)]=_0x5e3776[_0x76bedc(0x281)]((_0x572a4a,_0x3bc277)=>_0x572a4a+_0x3bc277['timeSpent'],0x0);const _0x5dc1a2=_0x22b55f[_0x76bedc(0x237)](_0x179a82[_0x76bedc(0x324)](_0x7c4f44[_0x76bedc(0x2b7)],0x3e8)),_0x151c52=_0x5db76c[_0x76bedc(0x237)](_0x179a82['zuPSP'](_0x5dc1a2,0x3c)),_0x15f209=_0x179a82[_0x76bedc(0x259)](_0x5dc1a2,0x3c);_0x4b094a['getElementById'](_0x76bedc(0x24e))[_0x76bedc(0x1a0)]=_0x179a82[_0x76bedc(0x2cc)](_0x151c52+':',_0x15f209['toString']()['padStart'](0x2,'0'));}}}}function nextQuestion(){const _0x4a61a2=_0x21a98a,_0x401928={'SKNin':'selected','nKdzW':function(_0x2b4042,_0x3f6559){return _0x2b4042===_0x3f6559;},'LQzYc':_0x4a61a2(0x320),'LhEVC':_0x4a61a2(0x3bf),'sByEe':function(_0x31dad0,_0x157577){return _0x31dad0-_0x157577;},'lvqxd':'kiGDW','eQkLA':_0x4a61a2(0x309),'GMZUB':function(_0x19b226,_0x2f26b6){return _0x19b226<_0x2f26b6;},'dqRVR':function(_0x687462){return _0x687462();},'wmlfv':function(_0x25bd69){return _0x25bd69();},'qnLje':function(_0xa10ffa,_0x4a111d){return _0xa10ffa===_0x4a111d;},'ashvH':function(_0x47b8da,_0x1b9f7c){return _0x47b8da===_0x1b9f7c;},'XszYJ':_0x4a61a2(0x2d3),'LnOLU':function(_0x5f2b2b,_0xea402d){return _0x5f2b2b(_0xea402d);},'gJzcj':'You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','xIvTY':_0x4a61a2(0x177),'VPXHC':_0x4a61a2(0x277),'AfeBh':_0x4a61a2(0x3b0),'FNRmM':_0x4a61a2(0x1f8),'gUfdy':'fwmse','RPsYF':function(_0x3daff2){return _0x3daff2();}};if(questionStartTime){if(_0x401928[_0x4a61a2(0x37e)](_0x401928[_0x4a61a2(0x250)],_0x401928['eQkLA'])){_0x3e3e21[_0x4a61a2(0x364)][_0x4a61a2(0x12b)](_0x401928[_0x4a61a2(0x34e)]);if(_0x401928['nKdzW'](_0x2f9a11,_0xfb568b))_0x30e225['classList'][_0x4a61a2(0x338)](_0x401928[_0x4a61a2(0x35a)]);else{if(_0x401928[_0x4a61a2(0x37e)](_0x1b9a38,_0x3459a3)&&!_0x23f267)_0x5be434[_0x4a61a2(0x364)][_0x4a61a2(0x338)](_0x401928[_0x4a61a2(0x3d5)]);}}else questionStates[currentQuestionIndex]['timeSpent']+=_0x401928[_0x4a61a2(0x13c)](Date[_0x4a61a2(0x2c5)](),questionStartTime);}_0x401928[_0x4a61a2(0x167)](currentQuestionIndex,_0x401928[_0x4a61a2(0x13c)](questionsData[_0x4a61a2(0x376)],0x1))?(currentQuestionIndex++,_0x401928[_0x4a61a2(0x200)](displayQuestion),_0x401928[_0x4a61a2(0x3cf)](saveProgress)):_0x401928[_0x4a61a2(0x2ac)](currentMode,_0x4a61a2(0x3e2))||_0x401928['ashvH'](currentMode,_0x401928[_0x4a61a2(0x1d4)])?_0x401928[_0x4a61a2(0x1e6)](confirm,_0x401928[_0x4a61a2(0x373)])&&submitQuiz():_0x401928[_0x4a61a2(0x2ac)](_0x401928['xIvTY'],_0x401928['VPXHC'])?_0x985512[_0x2d862d][_0x4a61a2(0x24e)]+=_0x401928[_0x4a61a2(0x13c)](_0x41ebf1['now'](),_0x191462):confirm(_0x401928[_0x4a61a2(0x318)])&&(_0x401928[_0x4a61a2(0x295)]===_0x401928['gUfdy']?_0x528685[_0x10919d][_0x4a61a2(0x24e)]+=_0x401928['sByEe'](_0x4357fb[_0x4a61a2(0x2c5)](),_0x53217d):(currentQuestionIndex=0x0,displayQuestion(),_0x401928[_0x4a61a2(0x201)](saveProgress)));}function startTimer(){const _0x17d672=_0x21a98a,_0x1e3f6e={'WFvZn':function(_0x21df28,_0x292fef){return _0x21df28===_0x292fef;},'tGQTY':_0x17d672(0x2d3),'lKLql':function(_0x3a24f0){return _0x3a24f0();},'itJjM':function(_0x2694ba,_0xe74993){return _0x2694ba(_0xe74993);},'FzNOE':function(_0x2520e1){return _0x2520e1();},'gKerb':function(_0xb21cac,_0x3c20a3,_0x41443e){return _0xb21cac(_0x3c20a3,_0x41443e);}};if(timer)_0x1e3f6e[_0x17d672(0x2d7)](clearInterval,timer);timeRemaining=0x78,_0x1e3f6e[_0x17d672(0x11b)](updateTimerDisplay),timer=_0x1e3f6e[_0x17d672(0x266)](setInterval,()=>{const _0x2a418c=_0x17d672;timeRemaining--,updateTimerDisplay(),timeRemaining<=0x0&&(clearInterval(timer),_0x1e3f6e[_0x2a418c(0x3e3)](currentMode,_0x1e3f6e[_0x2a418c(0x19b)])?submitQuiz():_0x1e3f6e[_0x2a418c(0x1c8)](nextQuestion));},0x3e8);}function updateTimerDisplay(){const _0x4e9bea=_0x21a98a,_0x1d42ed={'cCuid':function(_0x4ecc2e,_0x2f3758){return _0x4ecc2e/_0x2f3758;},'gLEbT':_0x4e9bea(0x19d),'Opdty':function(_0x4cea54,_0x14451c){return _0x4cea54+_0x14451c;}},_0x39196a=Math[_0x4e9bea(0x237)](_0x1d42ed[_0x4e9bea(0x2ae)](timeRemaining,0x3c)),_0x278326=timeRemaining%0x3c;document[_0x4e9bea(0x137)](_0x1d42ed[_0x4e9bea(0x1ec)])[_0x4e9bea(0x1a0)]=_0x1d42ed[_0x4e9bea(0x129)](_0x1d42ed[_0x4e9bea(0x129)](_0x39196a,':'),_0x278326[_0x4e9bea(0x13b)]()[_0x4e9bea(0x1d9)](0x2,'0'));}function toggleSidebar(){const _0x10efa0=_0x21a98a,_0x280dc7={'FMAZl':_0x10efa0(0x1d3)};document[_0x10efa0(0x137)](_0x280dc7[_0x10efa0(0x1cf)])[_0x10efa0(0x364)][_0x10efa0(0x196)](_0x10efa0(0x1a3));}document[_0x21a98a(0x18b)]('DOMContentLoaded',()=>{const _0x34e74e=_0x21a98a,_0x2918f2={'CDoKU':_0x34e74e(0x233),'NOLlx':function(_0x4a9708){return _0x4a9708();},'AqEVj':function(_0x2f07ee,_0xf6714f){return _0x2f07ee===_0xf6714f;},'UdnPg':'ONrKO','vnqBK':_0x34e74e(0x24a),'iWzNo':function(_0x5423e6){return _0x5423e6();},'OEabE':function(_0x4d9749,_0x2b6ed3){return _0x4d9749!==_0x2b6ed3;},'beQLj':'jFrwL','DhxzX':_0x34e74e(0x1d2),'vQwzJ':_0x34e74e(0x227),'fymRM':_0x34e74e(0x182)};if(resume){if(_0x2918f2[_0x34e74e(0x38a)](loadProgress)){if(_0x2918f2[_0x34e74e(0x3b1)](_0x34e74e(0x166),_0x2918f2['UdnPg'])){const _0x344bfb=_0x41e8ab['createElement'](_0x34e74e(0x284));_0x344bfb[_0x34e74e(0x1a0)]=_0xe55750+0x1,_0x344bfb['className']=_0x2918f2[_0x34e74e(0x20d)],_0x344bfb['onclick']=()=>_0x153f75(_0x493bb4),_0x344bfb['id']=_0x34e74e(0x30e)+_0x376afe,_0xe540ec['appendChild'](_0x344bfb);}else document[_0x34e74e(0x137)](_0x2918f2[_0x34e74e(0x1a4)])['style'][_0x34e74e(0x2a4)]=_0x34e74e(0x252),_0x2918f2[_0x34e74e(0x1da)](initializeQuiz);}else _0x2918f2[_0x34e74e(0x24f)](_0x2918f2['beQLj'],_0x2918f2[_0x34e74e(0x20f)])?(_0x2918f2[_0x34e74e(0x38a)](clearProgress),document[_0x34e74e(0x137)](_0x2918f2[_0x34e74e(0x1a4)])[_0x34e74e(0x13d)][_0x34e74e(0x2a4)]=_0x2918f2[_0x34e74e(0x279)]):_0x5043d9['explanation_images'][_0x34e74e(0x301)](_0x170850=>{const _0x3ae6a5=_0x34e74e;if(_0x170850)_0x3b9ace[_0x3ae6a5(0x2a9)]+=_0x3ae6a5(0x230)+_0x170850+_0x3ae6a5(0x251);});}else!window[_0x34e74e(0x307)][_0x34e74e(0x27c)]['endsWith'](_0x2918f2[_0x34e74e(0x35e)])?(clearProgress(),document[_0x34e74e(0x137)](_0x34e74e(0x24a))[_0x34e74e(0x13d)][_0x34e74e(0x2a4)]=_0x2918f2[_0x34e74e(0x279)]):initializeQuiz();}),document['addEventListener'](_0x21a98a(0x3b5),function(_0x53273d){const _0x58d05d=_0x21a98a,_0x63b286={'WswmD':function(_0x1003a4,_0x21a264){return _0x1003a4/_0x21a264;},'CrwsZ':function(_0xd7ea1a,_0x5d3734){return _0xd7ea1a%_0x5d3734;},'OlAxp':function(_0x40868d,_0x294989){return _0x40868d+_0x294989;},'hTDuf':_0x58d05d(0x38c),'oGKhs':_0x58d05d(0x3d4),'CVTcD':function(_0x1944ff,_0x575d90){return _0x1944ff<_0x575d90;},'LPKGE':function(_0x39b415,_0x464716){return _0x39b415!==_0x464716;},'zYAUl':_0x58d05d(0x24a),'RPVtk':function(_0x5abb29,_0x528fba){return _0x5abb29===_0x528fba;},'eMtZy':function(_0x37f3e0,_0x88dcbf){return _0x37f3e0>=_0x88dcbf;},'MGtlP':function(_0x3412cd,_0x4cae0f){return _0x3412cd===_0x4cae0f;},'HRLFC':_0x58d05d(0x1b7),'AxONV':function(_0x2aa725,_0x591a10){return _0x2aa725-_0x591a10;},'wtLvf':function(_0x51f95d,_0xdebdde){return _0x51f95d(_0xdebdde);},'gZxus':_0x58d05d(0x16a),'Xobre':function(_0x3d7de1,_0x371dc8){return _0x3d7de1<_0x371dc8;},'uDzCV':function(_0x16feda,_0x7dd027){return _0x16feda(_0x7dd027);},'MvHpB':_0x58d05d(0x1b3),'DzEUT':function(_0x313b8e){return _0x313b8e();},'xqsFY':'ArrowRight','RlfLu':function(_0x47a723,_0x38c5e3){return _0x47a723===_0x38c5e3;},'gQPrc':'OQmrO','gKrcr':function(_0x5031c7,_0x33b14a){return _0x5031c7===_0x33b14a;},'fBAfD':function(_0x48e2d8,_0x15d372){return _0x48e2d8===_0x15d372;},'FgtvO':_0x58d05d(0x1a1),'OzEZA':function(_0x3aa25e,_0x36af4d){return _0x3aa25e===_0x36af4d;},'hvPqE':_0x58d05d(0x374),'lmCTu':function(_0x28c0b9,_0xbb8c2f){return _0x28c0b9===_0xbb8c2f;},'gwXDf':_0x58d05d(0x3e2),'BZDCk':_0x58d05d(0x2d3),'uvwar':function(_0x574cd2){return _0x574cd2();},'MYGxY':function(_0x26c42b,_0x133036){return _0x26c42b===_0x133036;},'UyMqc':function(_0x1441c5,_0x2135b7){return _0x1441c5===_0x2135b7;}};if(_0x63b286[_0x58d05d(0x33e)](document[_0x58d05d(0x137)](_0x63b286[_0x58d05d(0x35b)])['style'][_0x58d05d(0x2a4)],_0x58d05d(0x252)))return;if(_0x63b286[_0x58d05d(0x19c)](document['getElementById']('performanceModal')[_0x58d05d(0x364)][_0x58d05d(0x2c8)](_0x63b286[_0x58d05d(0x189)]),![]))return;if(_0x63b286[_0x58d05d(0x2ca)](_0x53273d['key'],'1')&&_0x53273d[_0x58d05d(0x218)]<='4'){if(_0x63b286[_0x58d05d(0x1eb)](_0x63b286[_0x58d05d(0x2bf)],_0x63b286[_0x58d05d(0x2bf)])){const _0x4699df=_0x63b286[_0x58d05d(0x2d0)](_0x63b286['wtLvf'](parseInt,_0x53273d['key']),0x1),_0x588c48=document['querySelectorAll'](_0x63b286[_0x58d05d(0x269)]);if(_0x63b286[_0x58d05d(0x354)](_0x4699df,_0x588c48[_0x58d05d(0x376)]))_0x63b286[_0x58d05d(0x25f)](selectOption,_0x4699df);}else{const _0x1ee470=_0x390184[_0x58d05d(0x237)](_0x63b286['WswmD'](_0x2d56b5,0x3c)),_0x56c692=_0x63b286[_0x58d05d(0x2ea)](_0x528cff,0x3c);_0x423189[_0x58d05d(0x137)](_0x58d05d(0x19d))[_0x58d05d(0x1a0)]=_0x63b286[_0x58d05d(0x225)](_0x63b286[_0x58d05d(0x225)](_0x1ee470,':'),_0x56c692[_0x58d05d(0x13b)]()[_0x58d05d(0x1d9)](0x2,'0'));}}else{if(_0x53273d['key']===_0x58d05d(0x3de))_0x63b286[_0x58d05d(0x33e)](_0x63b286[_0x58d05d(0x378)],_0x63b286[_0x58d05d(0x378)])?_0x5ed17a[_0x58d05d(0x137)](_0x63b286[_0x58d05d(0x1b1)])['classList']['remove'](_0x63b286['oGKhs']):_0x63b286[_0x58d05d(0x1e5)](previousQuestion);else{if(_0x53273d[_0x58d05d(0x218)]===_0x63b286[_0x58d05d(0x2b9)]||_0x63b286[_0x58d05d(0x1eb)](_0x53273d[_0x58d05d(0x218)],'\x20'))_0x63b286[_0x58d05d(0x330)](_0x63b286[_0x58d05d(0x1cc)],_0x63b286[_0x58d05d(0x1cc)])?(_0x53273d['preventDefault'](),nextQuestion()):_0x31bd8d[_0x58d05d(0x2b3)][_0x58d05d(0x190)](_0x305ce5[_0x58d05d(0x27b)]()[_0x58d05d(0x131)](/ /g,'-'))&&(_0x63b286[_0x58d05d(0x321)](_0x24bf6a['questionIndex'],_0x3b035d[_0x58d05d(0x376)])&&(_0x294bdc[_0xc7a9fd['questionIndex']][_0x58d05d(0x1ac)]=!![]));else{if(_0x63b286['gKrcr'](_0x53273d[_0x58d05d(0x218)]['toLowerCase'](),'b')&&(_0x63b286[_0x58d05d(0x363)](currentMode,_0x63b286['FgtvO'])||currentMode===_0x58d05d(0x151)))_0x63b286['OzEZA'](_0x58d05d(0x2e3),_0x63b286['hvPqE'])?_0x45bec9=_0x13a54e:toggleBookmark();else{if(_0x63b286['lmCTu'](_0x53273d[_0x58d05d(0x218)][_0x58d05d(0x27b)](),'m')&&(_0x63b286[_0x58d05d(0x1a5)](currentMode,_0x63b286[_0x58d05d(0x3df)])||currentMode===_0x63b286[_0x58d05d(0x334)]))_0x63b286['uvwar'](toggleMarkForReview);else _0x63b286[_0x58d05d(0x1c0)](_0x53273d[_0x58d05d(0x218)][_0x58d05d(0x27b)](),'s')&&(currentMode===_0x63b286[_0x58d05d(0x3df)]||_0x63b286[_0x58d05d(0x296)](currentMode,_0x63b286[_0x58d05d(0x334)]))&&_0x63b286[_0x58d05d(0x1e5)](submitQuiz);}}}}});</script>

</body></html>